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Abstract 
Binding molecules recognizing their target molecules with high affinity and specificity are 
important tools for many biotechnological and pharmaceutical applications. Especially in 
targeted tumor therapy, where specific recognition of cancer cells via their particular oncogenes 
is used as starting point for the selective treatment of these cells, such binding molecules are 
indispensable. 
The development of new generations of binding molecules within the last years has 
fostered novel strategies and approaches of targeted tumor therapy. One example of such 
alternative binders are Designed Ankyrin Repeat Proteins (DARPins). The focus of this thesis lies 
on the exploration of DARPins binding the oncogene HER2 (human epidermal growth factor 
receptor 2) for tumor targeting approaches.  
Since HER2 functions via dimerization, and since HER2-overexpressing cancer cells – so 
called HER2-addicted cells – are dependent on the pro-proliferative signals that are elicited by HER2-
dimerization, the overall idea pusued in this project was to use HER2-binding DARPins to prevent 
HER2-dimerization. 
In the first part of this project, screening via cell proliferation assays with monovalent HER2-
binding DARPins previously selected by ribosome or phage display identified one DARPin with an 
anti-proliferative effect on the HER2-overexpressing cell line BT474. 
The second part of the project then focussed on the development of bivalent and bispecific 
DARPin-formats which elicit stronger anti-proliferative, in the best case even cytotoxic effects on 
such cells. 
The mechanism of action by which the developed bispecific constructs cause their cytotoxic 
effects can be described, mainly with the aid of three crystal structures of DARPin-target complexes 
that were solved in this work. 
In conclusion, this work describes the development of new tumor targeting reagents which act 
via a so far undescribed mechanism. We envision that the generic structure of the presented binding 
reagents might allow to apply the drawn conclusions onto other oncogenes that act via dimerization. 
  XVII 
 
Zusammenfassung 
Bindemoleküle, die Zielmoleküle mit hoher Affinität und Spezifität erkennen, sind wichtige 
Werkzeuge für viele biotechnologische und pharmazeutische Anwendungen. Speziell in der 
tumorgerichteten Therapie, in der die spezifische Erkennung von Krebszellen anhand spezieller 
Onkogene als Dreh- und Angelpunkt für die selektive Behandlung dieser Zellen genutzt wird, 
sind solche Bindemoleküle unverzichtbar. 
Die Entwicklung neuer Generationen von Bindemolekülen innerhalb der letzten Jahre 
hat zu neuen Strategien und Ansätzen der tumorgerichteten Therapie geführt. Ein Beispiel für 
solche alternativen Binder sind Designed Ankyrin Repeat Proteins (DARPins). Der Fokus dieser 
Doktorarbeit liegt in der Erkundung von DARPins gegen das Onkogen HER2 (humaner 
epidermaler Wachstumsfaktor Rezeptor 2) für die gerichtete Tumortherapie. 
Da HER2 via Dimerisierung aktiviert wird, und da HER2-überexprimierende Krebszellen 
– so genannte HER2-abhängige Zellen – abhängig von den wachstumsfördernden Signalen sind, 
die durch die HER2-Dimerisierung ausgelöst werden, lag die übergreifende Idee des Projekts 
darin, HER2-bindende DARPins zur Verhinderung der HER2-Dimerisierung einzusetzen. 
Im ersten Teil des Projekts wurde mittels Zellwachstum-basiertem Screening mit 
DARPins aus ribosome und phage display Selektionen ein monovalentes DARPin identifiziert, das 
einen wachstumshemmenden Effekt auf die HER2-überexprimierende Zelllinie BT474 hat. 
Der zweite Teil des Projekts richtete sich auf die Entwicklung von bivalenten und 
bispezifischen DARPin-Formaten, mit stärkeren wachstumshemmenden Effekten. 
Der Wirkungsmechanismus, durch den die entwickelten bispezifischen Konstrukte ihre 
zytotoxischen Effekte auslösen, kann hauptsächlich mithilfe dreier Kristallstrukturen von Komplexen 
aus DARPin und Zielmolekül beschrieben werden, die in dieser Arbeit gelöst wurden. 
Schlussendlich beschreibt diese Arbeit die Entwicklung eines neuen gerichteten 
Krebsmedikaments, das durch einen bislang unbeschriebenen Mechanismus wirkt. Wir erhoffen uns, 
dass die generische Struktur der präsentierten Reagenzien es ermöglichen wird, die gezogenen 
Schlussfolgerungen auf andere durch Dimerisierung wirkende Onkogene zu übertragen. 
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1 General Introduction 
According to the US-american National Institutes of Health (NIH), cancer is the leading cause of 
death in developed countries and the second leading cause of death in developing countries. 
Besides the rather traditional methods of surgery, chemo- and radiation therapy, progress in 
oncological treatment has also been made with other, more contemporary methods which make 
use of the increased understanding of the biological and biochemical properties of cancer cells. 
Unraveling of pathways and characteristics of different tumor entities like the description of 
tumor-associated proteins has led to new possibilities in tumor therapy. Since the overall aim of 
cancer therapy is to kill all tumor cells without interfering with any healthy cells, targeted tumor 
therapy has raised hope towards a better, because more directed, therapy. 
 
1.1 Targeted tumor therapy 
„Targeted tumor therapy“ also known as “Molecularly targeted therapy” encompasses a wide 
variety of different medication strategies to block the growth of cancer cells by interfering with 
tumor specific molecules (called “targets”) that constitute tumor growth. One way to classify the 
different approaches of targeted therapy is to divide them into “direct” and “indirect” 
approaches (Schrama et al. (2006)). 
“Direct approaches” function through sole binding, meaning that the binding molecules 
achieve effects on tumor cells without being conjugated to e.g. a cytotoxic moietiy. The main 
category of molecules that belong to such direct approaches are the so called “small molecule 
drugs”. The largest subgroup within the group of “small molecule drugs” are kinase inhibitors 
(which is not surprising, as kinases are the biggest group of enzymes important for cell 
proliferation), but the “small molecule drugs” comprise furthermore molecules acting on other – 
normally intracellular – targets, like inhibitors of the proteasome (e.g. Bortezomib (Teicher et al. 
(1999))), estrogen receptor modulators (e.g. tamoxifen (Jordan and Koerner (1976))), binders 
to apoptosis regulator proteins (e.g. obatoclax binding Bcl-2 (Shore and Viallet (2005))) or PARP 
inhibitors (e.g. iniparib (Mendeleyev et al. (1995))). 
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“Indirect approaches” generally use the tumor-associated proteins expressed on the cell 
surface as a target device for fusion proteins containing different kinds of effector molecules. 
Here the possibilities for targeting are manifold. Delivery of conjugated cytokines to the tumor 
can, for example, activate the immune system or induce apoptosis. Specific degradation of tumor 
cells by induction of apoptosis can furthermore be achieved through conjugation of targeting 
molecules with toxins like cytotoxic drugs or radionuclides (Milenic et al. (2004)). In the case of 
antibody-directed enzyme prodrug therapy (ADEPT), an enzyme is targeted to the tumor cell 
and converts a subsequently injected non-toxic prodrug into its active cytotoxic form, effecting 
only the targeted tumor cells (Bagshawe (2006)). 
The idea to use tumor-associated proteins – so-called tumor markers – in order to 
deliver a cytostatic or even cytotoxic effect depends on both the presence of such tumor markers 
on the cancer cell to treat and molecules specifically binding to this tumor marker. 
The most prominent targeting binders are monoclonal antibodies (mAbs) and smaller 
versions of antibodies, such as single-chain scFv portion monomers (and their genetically linked 
dimers, trimers or tetramers). However, the arsenal of the targeting binders used nowadays is 
not restricted to the immunoglobulin fold but comprises furthermore so called engineered 
binders derived from other protein scaffolds like protein A, the lipocalins, a fibronectin domain, 
an ankyrin consensus repeat domain and thioredoxin (Skerra (2007)). Furthermore, the specific 
binding of the “target” might – at least in principle – of course be accomplished by non-protein 
molecules like e.g. DNA-aptamers.  
The prominent tumor marker used in the here presented work is the receptor tyrosin 
kinase ErbB2, also refered to as Human Epidermal growth factor Receptor 2 (HER2).  
The following introductory sections are aimed to introduce both the target and the 
targeting molecules used in this work. 
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1.2 ErbB receptors: architecture and mode of action 
The four members of the family of human epidermal growth factor receptor tyrosine kinases 
(ErbB receptors, also known as HERs) are important mediators of cell growth, differentiation, 
migration and survival (Citri and Yarden (2006)). They have been shown to be overexpressed 
and involved in aberrant signaling in many cancers (Yarden (2001)) and are therefore often 
considered as target in tumor targeting approaches. In humans, there are four different 
homologous ErbB-receptors: epidermal growth factor receptor (EGFR, also refered to as HER1), 
HER2 (also known as ErbB2/neu), HER3 (ErbB3) and HER4 (ErbB4). These transmembrane 
receptors consist of a single polypeptide chain of about 1200 aa (e.g. 1186 aa for EGFR, 
equivalent to a Mr of 170 kDa (Carpenter and Cohen (1990))) and can be found in different 
concentrations and mixtures on the surface of the majority of somatic cells.  
The receptor architecture can be divided into three regions, the extracellular ligand- 
binding region, the intracellular region with tyrosine kinase activity and a transmembrane 
region with a single hydrophobic anchor sequence by which the receptor traverses the cell 
membrane a single time. The extracellular aminoterminal end can be divided into four domains 
(termed extracellular domains (ECDs) I to IV (ECD_I to ECD_IV). 
All members of the EGFR family belong to subclass I of receptor tyrosine kinases (Yarden 
and Ullrich (1988)) which generally means that receptor activation occurs by binding of 
monomeric ligands to the active site on the extracellular region of monomeric receptor 
molecules.  
According to the present opinion, all ErbB-receptors except HER2 persist until activation 
through ligand-binding in a “closed” or “tethered” conformation with the dimerization arm in 
ECD_II interacting with modules 5 and 6 of ECD_IV (Figure 1.1). This ECD-conformation 
autoinhibits the receptor from dimerization, as the interacting regions on domains II and IV (the 
“dimerization arm” on ECD_II and the “tethering arm” on ECD_IV) are needed to form 
intermolecular contacts with the corresponding domains of the dimerization partner once two 
receptors dimerize (Figure 1.2)(Cho and Leahy (2002); Ferguson et al. (2003)). 
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Figure 1.1: Schematic drawing of the four homologous ErbB receptors. The ErbB family contains 
four members (EGFR, ErbB2, ErbB3 and ErbB4) with similar topologies. Each receptor is 
composed of three functional modules: an extracellular domain (which can in turn be subdivided 
into 4 different subdomains), an α-helical transmembrane segment and an intracellular tyrosine 
kinase domain that also contains motifs that mediate interactions with intracellular signaling 
molecules. EGFR, ErbB3 and ErbB4 exist in a tethered (“closed”) conformation in which the 
dimerization domain is not available to interact with partner ErbB receptors in the absence of 
ligand. There is no known natural ligand for ErbB2, this receptor exists in an active extended 
(“open”) conformation and is permanently available for dimerization. Figure adapted from 
Baselga and Swain (2009). 
 
 
 
Figure 1.2:Conceptualization of the conformational change of the extracellular domain of EGFR, 
ErbB3 or ErbB4 induced by ligand binding to subdomains I and III. In the ligand-induced open 
conformation, the dimerization domain (the “dimerization arm”) on subdomain II becomes 
exposed. Intermolecular interactions between subdomains II and IV of two receptors constitute 
dimerization. The kinase domain interaction is asymmetric, with the amino-terminal lobe of one 
tyrosine kinase interacting with the carboxy-terminal lobe of the other. Figure adapted from 
Baselga et al. (2009). 
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In the ligand-bound “open” or “non-tethered” state the dimerization arm on domain II 
protrudes out from the rest of the molecule and is therefore able to interact with residues from 
ECD II of the dimerization partner, which can be any other activated receptor (Ogiso et al. 
(2002)) leading to the formation of either homo- or heterodimers. 
As a consequence of dimerization the kinase domains of the dimerization partners, that 
were in the inactive conformation in the monomeric receptors, transactivate each other (or to be 
more precise: one kinase activates the other): The close proximity of the two kinases allows the 
C lobe of one partner to bind to the N lobe of the other, resulting in the αC helix of the latter 
rotating to the position required for kinase activity (Zhang et al. (2006)). The activated kinase 
subsequently transphosphorylates tyrosine-residues within the intracellular part of the 
dimerization partner, especially within the very C-terminal “tail”.  
The thereby phosphorylated residues serve as docking sites for the recruitment and 
phosphorylation of a number of intracellular substrates that activate pro-proliferative and anti-
apoptotic pathways.  
Signalling is terminated partly through endocytosis and lysosomal degradation of the 
activated receptor/ligand complex (whereas the receptor may be recycled to the plasma 
membrane (French et al. (1994))), and partly by dephosphorylation. 
 
1.3 Peculiarities of ErbB receptor family members 
Within the ErbB receptor family, the two EGFR-homologues HER2 and HER3 carry interesting 
peculiarities:  
HER2 does not bind to any of the 12 natural ligands known so far and is most likely to 
not have a natural ligand (Alvarado et al. (2009)). Its extracellular domains are supposed to be 
always in the open conformation due to the absence of the domain II-IV interaction (in detail 
discussed in (Hynes and Lane (2005)) which may explain why HER2 is the preferred 
dimerization partner for the other three receptor family members (Li et al. (2012)). In such 
heterodimers the affinity of HER2’s dimerization partners for their ligands is enhanced by 
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slowing down the rate of ligand-receptor complex dissociation. In accordance with publications 
based on computer simulations, HER2 molecules might permanently be homodimerized when 
overexpressed on the cell surface (Fleishman et al. (2002); Garnier et al. (2003)). This model 
proposes an equilibrium between two states of the receptor dimer, one active and one inactive. 
The amount of active receptor dimers signalling for cell proliferation and -survival would 
therefore be related to the amount of HER2 molecules on the cell. At higher concentrations more 
and more receptor dimers would exist in the active state, driving cancerous growth. This 
concept aligns well with growth-data from HER2-overexpressing cells. 
HER3 is a special family member as its kinase domain is catalytically inactive or only 
weakly active (Telesco et al. (2011)). However, HER3 plays an important role, especially in 
oncogenic HER3 signaling, as its intracellular part appears to readily serve both as activator and 
as substrate.  
 
1.4 ErbB receptors and cancer 
Although expressed as well in nonmalignant cells, the EGFR-family members, especially HER2, 
are highly expressed in a variety of tumors (Yarden and Sliwkowski (2001)) and their 
expression correlates with poor response to treatment, fast disease progression and poor 
survival (Baselga (2002)). ErbB receptor signaling impacts on many aspects of tumor biology 
including the promotion of proliferation, angiogenesis, invasion/metastasis and inhibition of 
apoptosis. Major routes for ErbB-related signalling are the Ras-Raf-mitogen-activated protein 
(MAP) kinase pathway, mainly responsible for proproliferative signaling (Alroy and Yarden 
(1997)) and the phosphatidylinositol 3-kinase and Akt (PI3K/Akt) pathway, which constitutes 
general tumor-cell survival (Burgering and Coffer (1995)). 
However, the respective mechanisms affecting ErbB signaling differ in each particular 
tumor. Transformation might occur by mutation, overexpression or coexpression of different 
EGFR-family members with one or more of their ligands resulting in an autocrine loop leading to 
uncontrolled cell growth (Voldborg et al. (1997)). In order to employ ErbB-signalling for cancer 
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therapy by molecular targeted agents, one can generally treat the pathway at different stages 
(like ligand binding, receptor-dimerisation or downstream-signaling). The most promising arms 
and their respective drugs can be divided into two main groups, presented in the following 
section. 
 
1.5 Different routes of ErbB tumor targeting 
Tyrosine kinase inhibtors (TKIs) (also termed 'small-molecule inhibitors') have been 
developed to block the catalytic ability of protein tyrosine kinases. TKIs act by competing with 
ATP for binding to the kinase's active site. Unfortunately, low response rates have been reported 
from clinical trials (Gadgeel et al. (2007)) which might be explained by mutations in the ErbB 
genes that seem to impair TKI effects, leading to TKI resistance (Toschi and Cappuzzo (2007)). 
Monoclonal antibodies (mAbs), mostly in the IgG-format, are used as experimental 
therapy in humans since the beginning of the 1980s (Houghton and Scheinberg (1986)). In 
selective anticancer therapy of ErbB-driven tumors, therapeutic mAbs work via manifold 
mechanisms: 
Disruption of ErbB signaling can be archieved either through binding the ligand in order 
to prevent it from activating the receptor, binding the receptor in order to prevent it from being 
bound by the ligand (e.g. mAb cetuximab binding EGFR) or binding the receptor in order to 
prevent it from dimerization (e.g. mAb pertuzumab (Perjetta) binding HER2).  
In general, binding of mAbs is furthermore able to induce antibody dependent cellular 
cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). A big advantage of mAbs is 
their long serum half-life, which has been shown to be in the range of days (Müller et al. (2007)). 
 
1.6 Trastuzumab – the first mAb FDA approved for α-HER2 tumor targeting 
Trastuzumab, better known under its tradename 'Herceptin', has been shown to effectively 
inhibit the growth of HER2-overexpressing cells in vitro and in vivo through binding to an 
epitope on HER2_IV (Cho et al. (2003)). Herceptin received FDA approval in 1998. It is indicated 
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for the treatment of patients with metastatic breast cancer whose tumors do overexpress HER2 
(20-30% of all patients suffering from breast cancer) and clinically active in patients that have 
received prior anti-cancer therapy (Baselga et al. (1996)). The majority of HER2-positive tumors 
have nevertheless been found to be non-responding to the antibody therapy, e.g. 15% objective 
response rate in extensively pretreated patients, 26% of previously untreated patients, and 45% 
overall response rate for antibody- with chemotherapy vs. 29% after chemotherapy alone 
(Baselga (2001); Slamon et al. (2001)). Besides treatment of patients with HER2-overexpressing 
metastatic breast cancers, Herceptin is approved in combination with chemotherapy for use in 
patients with HER2-positive metastatic gastric cancer. Although Herceptin was the first FDA-
approved HER2-targeting mAb, its mode of action gives still rise for discussion (cf. next section). 
 
1.7 Modes of action of trastuzumab 
Besides CDC and especially ADCC, which are by far the most important mechanisms of action in 
vivo and in the patient, the following effects of trastuzumab are discussed: 
Binding of trastuzumab (in contrast to binding of cetuximab or pertuzumab) to HER2 has 
been shown to sterically block proteinases like matrix metalloproteinases (MMPs) from cleaving 
the extracellular parts of receptor dimers (Molina et al. (2001)). In the absence of trastuzumab, 
this 'receptor-shedding' leads to truncated but still dimerized receptors that stay as 
phosphorylated specimens in the membrane. Whether these truncated dimers, consisting of the 
phosphorylated intracellular domains, escape dephosphorylation or internalization or if the pro-
proliferative signalling is maintained through other effects is not understood. 
HER2 overexpression leads to ligand-independent HER2/HER3 interaction and HER3 
phosphorylation. Trastuzumab sterically disrupts this ligand-independent interaction of HER2 
with HER3 (Junttila et al. (2009)).  
Another originally suggested mode of action, that trastuzumab induces some of its effect 
by down-regulation of HER2, leading to disruption of receptor dimerization and signaling, could 
be excluded by Austin et al. (2004). 
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When discussing trastuzumab’s modes of action, one will always have to take care to not 
confuse the overall (phenotypic) effect caused by trastuzumab with the direct mode of action of 
trastuzumab.  
For instance, it has clearly been shown that “trastuzumab triggers the accumulation of 
the cyclin-dependent kinase inhibitor p27Kip1 in the nucleus and therefore initiates cell cycle 
arrest” (Le et al. (2005)). However, this accumulation of p27 in the nucleus is not more than one 
of the effects caused by trastuzumab binding through a long signaling cascade, but might not 
really be named direct “mode of action”, as it just describes an effect that follows several steps 
from the initial mode of action. 
 
1.8 New models of ErbB receptor activation 
Besides the so called canonical receptor dimers schematically depicted in Figure 1.2, more 
recent publications have focused on alternative models of ErbB receptor activation.  
One of such additional modes of ErbB receptor activation are “ligand-independent ErbB 
receptor interactions” that appear as a result of receptor overexpression. HER2 overexpression, 
for instance, leads to HER3 phosphorylation, that could be shown to be a result of ligand-
independent HER2/HER3 interactions (Junttila et al. (2009)) that not necessarily resemble 
canonical receptor dimers. 
Besides canonical dimers and ligand-independent receptor-interactions, there have also 
been reports on ligand-induced transient tetramers composed of side-by-side oriented canonical 
dimers (Clayton et al. (2008); Zhang et al. (2012)).  
How exactly all those alternative models look like is by far not entirely solved. In 
principle, each way of bringing two ErbB-kinases in close proximity, could allow allosteric 
activation with all consequences discussed in Chapter 2. 
The description of new models for ErbB receptor activation implies the possibility to 
search for new ErbB targeting binders, employing new mechanisms of action in ErbB tumor 
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targeting. This is a promising development, as, in the end, tumor targeting strategies employing 
HER2 and its relatives need to be as versatile as possible. 
 
1.9 New therapeutic modalities 
Monoclonal antibodies (mAbs), the assumed most potent molecular targeting agents for 
selective anticancer therapy, face several disadvantages. For instance, antibodies are 
comparatively diffcult and expensive to produce. Furthermore the huge size of an 
immunglobulin G (IgG) of approximately 150 kDa is rather large for therapeutic applications 
that require efficient tissue penetration (Binz et al. (2005)). As the in vitro mechanisms of action 
of e.g. cetuximab, pertuzumab and trastuzumab are caused by steric effects like blockage of 
ligand binding (cetuximab), inhibition of receptor dimerization (pertuzumab, trastuzumab) or 
prevention of receptor shedding (trastzumab), the question arises, if biological activity in terms 
of cytostatic effects can't just be achieved by specific binding through other molecules than 
mAbs.  
For example, so called peptidomimetics, small protein-like amino acid sequences 
designed to mimic structural features of the antibody complementarity determining regions 
(CDRs), appear to have similar inhibitory properties as mAbs in experimental models (Pal and 
Pegram (2006)). Although peptidomimetics are attractive – because simple – candidates for 
stabilizing or disrupting protein-protein interactions, their efficacy as in vivo-reagents is 
severely compromised by their loss of secondary structure, susceptibility to proteolytic 
degradation and low serum half life. 
During the last years several alternative binding proteins have been developed (for a 
review see (Binz et al. (2005))) including camelid antibodies (“Nanobodies” (Muyldermans and 
Lauwereys (1999))), protein scaffolds derived from protein A domains (“Affibodies” (Hansson et 
al. (1999))), fibronectin-domain based “Monobodies” (also known as “Adnectins” (Batori et al. 
(2002))), genetically engineered lipocalins (“Anticalins” (Schlehuber and Skerra (2005))), A-
domains of several receptors (“Avimers” (Jeong et al. (2005))), PDZ domains (Kurakin et al. 
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(2007)), ubiquitin based scaffolds (“Affilins” (Ebersbach et al. (2007))), knottins (Smith et al. 
(1998)) or DARPins (recently reviewed in (Boersma and Plückthun (2011))).  
These alternatives to antibodies have a completely different protein topology, associated 
with advantages like small size (for good tissue penetration) and single-chain buildup (allowing 
easy manufacturing and subsequent construction of fusion proteins). Furthermore the small 
single-chain character facilitates the application of powerful selection technologies like Phage 
Display (PD) and Ribosome Display (RD). 
 
1.10 Designed Ankyrin Repeat Proteins (DARPins) 
Repeat proteins can be found in all phyla mediating numerous key protein-protein interactions 
(Bork (1993)). They are characterized by consecutive homologous structural units ('repeats'), 
which stack to form an elongated protein domain with a continuous hydrophobic core (Kobe and 
Kajava (2000)).  
The natural function of repeat proteins to assure specific binding to substrates like 
proteins and nucleic acids suggests using repeat proteins as binding molecules for diagnostic 
and therapeutic applications. The strategy of designing binding molecules that employ the 
modular nature of repeat proteins was evaluated on leucine-rich- (Stumpp et al. (2003)) and 
ankyrin repeat proteins (Binz et al. (2003)). The latter was named Designed Ankyrin Repeat 
Proteins ('DARPins'). In a combined approach of structure and sequence analysis a consensus 
repeat module of 33 amino acids with fixed framework residues and randomized positions as 
potential interaction surface was designed. Using this consensus design strategy, combinatorial 
libraries of ankyrin repeat proteins with varying repeat numbers and diversified binding 
surfaces were generated (Binz et al. (2004)). 
DARPins are designed single-chain proteins that consist of varying numbers of repeat 
modules, held together in a fixed tertiary structure by a self-assembling hydrophobic core 
(Figure 1.3). Each repeat forms a structural unit consisting of a β-turn followed by two 
antiparallel α-helices. Addition of an N- and C-terminal module ('cap') shields the hydrophobic 
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areas of the first and the last repeat module and assures favorable behavior in solution. High 
expression level in E. coli, thermodynamic stability and the absence of disulfide bonds or free 
cysteins provide advantages in comparison to other novel frameworks. 
 
 
 
 
Figure 1.3: Architecture of Designed Ankyrin Repeat Proteins (DARPins). (A) Primary 
sequences of the N-terminal capping ankyrin repeat (AR), the internal designed AR module and 
the C-terminal capping AR. The secondary structure elements are indicated above the 
sequences. Each designed AR module consists of 26 defined framework residues, six randomized 
potential interaction residues (red x, any of the 20 natural amino acids except cysteine, glycine 
or proline) and one randomized framework residue (z, any of the amino acids asparagine, 
histidine or tyrosine). (B) Assembly of DARPins from N- and C-terminal capping repeats (green 
and cyan, respectively) and varying numbers of internal designed AR modules (blue) (side 
chains of the randomized residues are shown in stick mode in red). (C, D) Two perpendicular 
views of the crystal structure of the complex of DARPin off7 bound to MBP. MBP is on the left 
(blue), off7 on the right (ochre). The interaction residues are highlighted in stick-mode in red 
(off7) and blue (MBP), respectively. Figure adapted from (Binz et al. (2004)).  
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2 The Project 
The initial question of my PhD-project had already been posed as initial question of my diploma 
project: Is it possible to use HER2-binding-DARPins – without cytotoxic fusions – to obtain anti-
proliferative effects on HER2-overexpressing cells? 
This question appears consequent when taking into consideration that the efficacy of the two 
most prominent non small molecule drugs engaged in tumor targeting of HER2-overexpressing 
cancer cells – trastuzumab (hu4D5, Herceptin) and pertuzumab (hu2C4, Omnitarg) – relies at 
least partially on the mere binding to the receptor.  
After having screened and characterized DARPins binding to the extracellular part of 
HER2 during my diploma thesis, first screenings for effects on cell-proliferation and viability of 
BT474-cells had identified one DARPin – termed “H14” (H_14 in (Steiner et al. (2008))) – which 
displayed antitumor activity on this cell line.  
In my PhD thesis, the developments to improve the antitumor activity of this DARPin are 
described. The main improvements during this development were achieved by switching from 
the monovalent to the bivalent format. Various DARPin-constructs ranging from simple 
monovalent up to hexavalent binders have been engineered, expressed, characterized and finally 
screened for their potential antitumor activity on different cancer cell lines. The majority of the 
constructs did not exhibit antitumor activity. However, several engineered binders could be 
shown to affect proliferation and viability of cancer cells with diverse gain in activity as 
compared to the initially identified monovalent H14. The exhibited mode of action ranges from 
cytostatic up to cytotoxic effects.  
In the course of the project it became evident that knowledge on the epitopes of the 
HER2-binding DARPins would be essential to understand and explain the main achievements 
obtained in improving their tumoricidal activity.  
This knowledge, at least for three of the most interesting binders, has finally been gained 
at atomic resolution by resolving crystal structures of the DARPins in complex with their target. 
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Therefore, the initial question, if DARPins binding the extracellular part of HER2 can be 
used to cause anti-proliferative effects on HER2-overexpressing cancer cells, is not only 
affirmed, but has been extended towards improving the observed effects. Furthermore, the 
answer given has even been extended: The knowledge gained on the DARPins’ epitopes and the 
orientation of binding can be used as a blueprint for the construction of any HER2-binding 
reagent with anti-proliferative effects on HER2-dependent cancer cells.  
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1 Abstract  
 
The human epidermal growth factor receptor 2 (hErbB2, HER2) is implicated in the malignant 
growth of tumors from various human cancers, including an aggressive form of breast cancer. 
This high potential of HER2 to become an oncogene is explained by the mode of action of this cell 
surface protein: Receptor dimerization leads to trans-phosphorylation events at the intracellular 
part of the receptor that in turn serve as starting points for pro-proliferative and anti-apoptotic 
signaling cascades. HER2 overexpression therefore leads to transformation into malignant cells, 
but can be used as point of attack for diverse approaches of molecular tumor targeting as well. 
The prevention of HER2-dimerization in HER2 overexpressing tumor cells that have become 
addicted to the receptor might induce anti-proliferative effects in such cells. Such inhibition 
might be caused sterically through binding to the extracellular domain of HER2. Designed 
Ankyrin Repeat Proteins (DARPins) have been previously selected as high-affinity binders of 
HER2, so far being employed as reporters in diagnostic approaches or as targeting domains for 
gene vector delivery. We now aimed to engage our anti-HER2-DARPins to inhibit the in vitro 
growth of HER2 addicted cancer cells. Screening 22 monovalent anti-HER2 DARPins in cell 
proliferation assays on BT474 cells yielded one DARPin that exhibits an anti-proliferative effect 
through binding to the extracellular subdomain IV of HER2 (HER2_IV). Bivalent fusions of this 
DARPin, in which the two DARPin paratopes are held at a distance by an inert rigid linker 
DARPin, could be found to have pronounced cytostatic effects. Interestingly, the antiproliferative 
effects caused by the bivalent DARPins are comparable to those caused by the therapeutic 
antibody trastuzumab. Furthermore, the bivalent rigid linker format can be transferred to 
another DARPin binding another epitope on HER2_IV. We conclude that the observed effect on 
cell proliferation is a result of the “trapping” of HER2 monomers by the DARPin-constructs. The 
HER2 molecules are kept apart from each other by the intermolecular DARPin binding and 
thereby contribute to a lesser extent to the HER2 signaling than non-bound HER2 molecules that 
are free to undergo homo- and heterodimerization.  
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2 Introduction 
The human epidermal growth factor receptor 2 (HER2, hErbB2) is an important and very well 
studied model system for the role that a receptor tyrosine kinase might play in oncogenesis. In 
the same manner as all other receptor tyrosine kinases, HER2 acts via homodimerization with 
other HER2-molecules and especially via heterodimerization with the homologous receptors 
EGFR, HER3 and HER4 (Sundaresan et al. (1999)). The so formed receptor dimers contribute to 
important signal transduction pathways, mainly by signaling onto the PI3K/Akt and the 
mitogen-activated protein (MAP) kinase cascades, leading to cell survival and proliferation, 
respectively (Craven et al. (2003)). 
The amplified expression of a member of the EGFR-family therefore promotes 
tumorigenesis (Yarden and Sliwkowski (2001)). Especially amplification of HER2 is a hallmark 
of a number of different tumors, as HER2 is special in the sense that it does not require ligand 
binding for dimerization (reviewed in (Brennan et al. (2000))).  
As HER2-overexpression is characteristic to many different types of cancer, it has 
provoked the development of molecular targeting reagents that specifically target this receptor. 
The monoclonal antibodies trastuzumab (Herceptin®) (Genentech, San Francisco, CA) and 
pertuzumab (Perjeta®) (Roche), humanized versions of the murine antibodies 4D5 and 2C4, are 
FDA-approved drugs that bind the extracellular part of HER2 (HER2_ECD or p110) and thereby 
mark HER2-overexpressing cells for the attack of cytotoxic T-cells. However, this antibody-
dependent cellular cytotoxicity (ADCC) and the closely related complement-dependent 
cytotoxicity (CDC), that do mainly account for the antibodies’ efficacy in vivo (Yan et al. (2008)), 
do not comprise the antibodies’ whole mechanism of action. Both antibodies also have anti-
proliferative effects on the growth of HER2-overexpressing cancer cell lines grown in vitro, 
where no immune- or complement system are present. It can be therefore concluded that a 
certain part of the anti-proliferative effect caused by HER2-binding proteins on HER2-
overexpressing cancer cells is attributed to sole binding. 
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 This steric effect can be explained in view of the epitopes on HER2_ECD that are bound 
by pertuzumab and trastuzumab. Both epitopes cover parts of the ECD that come close to the 
partnering receptor during dimerization. Pertuzumab blocks the receptor dimerization through 
binding its epitope next to the dimerization arm on subdomain II of HER2, while the epitope of 
trastuzumab is located on a region of subdomain IV. Both subdomain II and IV make contact 
with the corresponding subdomains of the dimerization partner in a receptor dimer. This is why 
binding to epitopes on subdomains II and IV that are facing the dimerization partner can 
sterically prevent dimerization.  
A similar steric effect on HER2 dimerization potential obtained through binding to the 
ECD was reported by Chen et al. (2003). In this study, a biologically inert binder, the aptamer 
A30 binding to the ECD of HER3, was found to have an inhibitory effect on ligand-induced in 
vitro growth of MCF7 cells. Interestingly, the epitope of A30 is not located within the dimer 
interaction surface, but laterally situated on subdomain III (HER3_III).  This epitope location, 
taken together with the observation that A30 inhibits HER2- but not HER3-phosphorylation, led 
to a model in which A30 disrupts ligand-induced transient tetramers composed of side-by-side 
oriented canonical dimers (Zhang et al. (2012)) that had already been proposed for EGFR in an 
earlier studies by Clayton and coworkers (Clayton et al. (2008)).  
The described anti-proliferative in vitro effects on HER2-overexpressing cancer cell lines of both 
the HER2-binding monoclonal antibodies trastuzumab and pertuzumab, and the aptamer A30 
binding to HER3, depict the potential that ECD-binding agents may have for disrupting HER2 
dimerization. 
One new class of such binding agents are designed ankyrin repeat proteins (DARPins) 
that have been recently developed in our lab. DARPins are binding scaffolds that can be selected 
to bind virtually any target-protein with high specificity and affinity (Binz et al. (2004)). 
Previously, DARPins binding the soluble recombinant ectodomain of HER2 (HER2_ECD) were 
selected by ribosome display (Zahnd et al. (2007)) or phage display (Steiner et al. (2008)). These 
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DARPins all show monomeric behavior in size exclusion chromatography and have 
(sub)nanomolar affinities.  
Using the HER2-addicted BT474 cell line, a widely used model system for testing anti-
HER2 activity, we investigated the biological activities of these monovalent DARPins and 
compared them to that of trastuzumab. We could identify one monovalent DARPin that elicits an 
anti-proliferative effect on BT474 cells. Interestingly, this DARPin competes with trastuzumab 
for binding and has a biological activity that is comparable to the anti-proliferative effect caused 
by the scFv 4D5, which is the scFv of trastuzumab. 
In the course of our screening for biologically active DARPins, we further made use of an 
advantage that DARPins offer in comparison to other binding scaffolds: The facile generation of 
bivalent constructs by genetical fusion allowed us to engineer bivalent constructs with rigid 
protein linkers in between the two DARPin paratopes. This led to DARPins composed of two 
HER2_IV-binding DARPins per molecule, fused via a third non-binding DARPin as rigid linker 
moiety. The best rigid bivalent constructs were found to inhibit the in vitro growth of BT474 
cells equally to trastuzumab, both in terms of concentration and efficacy.  Notably, the effect is 
obtained by binding only and seems to rely on arresting HER2 molecules in fixed distances from 
each other. Our knowledge on the epitopes of the HER2-binding DARPins allows us to describe 
the molecular mechanism by which the rigid bivalent DARPin constructs cause their effect. 
 
3 Results and Discussion 
3.1 Screening HER2-binding DARPins for antitumor activity 
In order to screen DARPins for antitumor activity on HER2-overexpressing cells, we choose 22 
candidates that had previously been selected by ribosome display (Zahnd et al. (2007)) or phage 
display (Steiner et al. (2008)) to bind the recombinant ectodomain of HER2. The binders were 
chosen judging on exclusive monomeric running behavior in size exclusion chromatography and 
affinities to be at least in the nanomolar range. Screening 1 µM dilutions of all 22 candidates in 
cell-proliferation assays (XTT) identified one DARPin to have anti-proliferative activity: BT474 
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cells that had been grown for four days in presence of DARPin H14 showed a concentration-
dependent decrease in cell viability of 25% compared to cells that had been grown without 
treatment, while treatment with trastuzumab decreased cell viability by 45% (Figure 2.1). It has 
to be noted that the indicated decreases in cell viability are calculated in comparison to the 
untreated control which grows over the four days. Since our XTT-assays were performed as 
endpoint measurement after four days of growth, and since the cell count of untreated cells 
doubles during this time, a signal decrease of ~50% after four days (comparing signals from 
treated cells with the signals from untreated control) equals the signal at the beginning of the 
assay. Therefore a decrease in cell viability of about 50% (like observed for trastuzumab) 
indicates a cytostatic effect. 
 
3.2 Epitope-mapping of DARPin H14 
As described previously, DARPin H14 had been originally selected using an epitope masking 
strategy employing high-affinity DARPin G3 to mask an epitope on HER2_IV that had proven to 
be very dominant in earlier selections on HER2_ECD (Steiner et al. (2008)). Already in the initial 
characterization, binder H14 had attracted our interest due to its exceptionally high binding 
signal in ELISA. Further analysis by surface plasmon resonance (SPR) revealed binder H14 to 
show an affinity in the picomolar range (Figure 2.2). Interestingly, besides its high affinity 
already after three rounds of selection, H14 proved to compete with DARPin G3 for binding, both 
in ELISA on recombinant target protein and in flow cytometry using BT474 cells (Jost et al., 
submitted, Chapter 3). Apparently, the epitope masking strategy had not resulted in directing 
the binder to another epitope, but to select for a binder targeting a similar epitope with 
comparably high affinity as DARPin G3, which underwent ten rounds of selection including 
affinity maturation steps (Zahnd et al. (2006); Zahnd et al. (2007)) to reach that affinity. 
Furthermore, the overlapping epitopes for binders G3 and H14 again highlight the fact that this 
particular region on HER2_ECD seems to be well suited for DARPin-binding.  
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3.3 Competition with trastuzumab and evaluation of ectodomain-shedding 
To further characterize the epitope of the biologically active DARPin H14, we set up competition 
assays with trastuzumab. In analogy to DARPin G3, preincubation with trastuzumab competed 
binding of DARPin H14 in flow cytometry using BT474 cells (Figure 2.3). DARPin H14 therefore 
shares parts of its epitope with both DARPin G3 and the antibody trastuzumab. Both of these 
binders, DARPin G3 and antibody trastuzumab, do however not compete for binding among each 
other (Jost et al., cf. Chapter 3).  
As trastuzumab had previously been shown to inhibit HER2 ectodomain-shedding 
(Molina et al. (2001)) and given the fact that our biologically active DARPin H14 shares an 
overlapping epitope with trastuzumab, we were interested to investigate HER2 ectodomain-
shedding in presence of H14. Proteins from BT474-supernatants after 48 hours of growth were 
therefore extracted by methanol/chloroform precipitation (Wessel and Flügge (1984)) and 
applied to anti-HER2 immunoblotting, detecting the N-terminus of HER2. Our results confirm 
the inhibitory effect of trastuzumab on ectodomain-shedding, but do not indicate any 
comparable effect of the DARPins H14 nor G3 (Figure 2.4). 
 
3.4 Importance of epitope and bivalent binding for antitumor activity 
To investigate the significance of bivalent binding for antitumor activity, we used further XTT-
cell-proliferation assays comparing dilution series of trastuzumab, scFv 4D5 and DARPin H14. 
Interestingly, we found that the scFv 4D5 was only half as effective as trastuzumab in its anti-
proliferative activity. This is striking, especially because the potential of H14 was found to be 
comparable to the one of scFv 4D5 both in terms of activity and concentration (Figure 2.5). The 
two monovalent binders to similar epitopes on HER2_IV – a scFv and a DARPin – showed 
comparable anti-proliferative activity, while the respective antibody trastuzumab was clearly 
more potent than the monovalent binders in inhibiting the cell proliferation of BT474 cells in 
vitro. 
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3.5 H14 in flexibly linked bivalent format promotes BT474 cell proliferation 
Since biological activities of DARPin and scFv were comparable and since both proteins were 
able to achieve half the effect of the respective bivalent antibody format, it appeared reasonable 
to test bivalent constructs built up of H14 moieties linked by various protein-linkers. The first 
bivalent binders were constructed with flexible icosa-peptide linkers ((G4S)4). Testing of this 
bivalent DARPin construct, termed H_20_H, concerning its potential effects on cell viability in 
XTT assays on BT474 cells revealed, very much to our surprise, an increased cell proliferation as 
a result of H_20_H-treatment (Figure 2.6). The agonistic activity found for H14_20_H14 is 
however similar to the agonistic activity of a monospecific F(ab’)2-like trastuzumab isomer 
reported by Scheer et al. (2012). 
 
3.6 Engineering of H14-constructs for improved antitumor activity 
The finding that the flexible fusion of H14 into bivalent constructs had turned the anti-
proliferative effect of monovalent H14 into a pro-proliferative effect highlights the above-
mentioned significance of bivalent binding to the HER2 ectodomain for achieving an effect on 
cellproliferation. However, flexible bivalent binding of HER2_ECD – at least when making use of 
binder H14 – did not prove to be beneficial and on the contrary could enhance cellular growth. 
In order to improve the anti-tumor effect of H14, we reasoned that an inflexible linker 
connecting the H14 moieties might strengthen the anti-proliferative effect of DARPin H14.  
Inflexibly linked bivalent H14-constructs were obtained by replacing the flexible icosa-
peptide linker in H_20_H through consensus DARPins of various sizes, ranging from one to ten 
internal repeat modules (see Chapter 5 for vector design and construction of NXC-consensus-
DARPins). A certain degree of flexibility between the HER2-binding H14-moieties and the linker-
DARPin was ensured by introducing short tri-peptides (GGS) at the two boundaries. The 
resulting six inflexibly linked bivalent H14-constructs (with 3, 4, 6, 7, 8 or 10 consensus repeat 
modules in the linker-DARPin) were all tested regarding their potential effects on cell viability in 
XTT assays on BT474 cells. In contrast to the flexibly linked H_20_H, all tested inflexibly linked 
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bivalent H14-constructs showed anti-proliferative effects that exceeded the effect of monovalent 
H14 (Figure 2.7). The inhibitory effects slightly increased in strength with increasing linker 
length from N3C to N6C, whereas further linker elongation to N8C or N10C did not further 
improve the constructs’ anti-proliferative potential. Notably, the most potent inflexible construct 
H_N6C_H proved to be comparable to trastuzumab both in terms of activity and EC50. 
 
3.7 Transfering the inflexible linker format to DARPin G3 
Since our approach of engineering inflexible bivalent H14-constructs had resulted in H14-
derivatives with clearly improved efficacy as compared to monovalent H14, we next wanted to 
address the importance of the targeted HER2-epitope for the bivalent targeting format. For this 
purpose, we chose DARPin G3 to be combined with the N6C-linker to form G3_N6C_G3 
(“G_N6C_G”). Though sharing an overlapping epitope with DARPin H14 on HER2_IV, monovalent 
DARPin G3 had proven to show no effect on BT474 cell proliferation by itself (Jost et al. 
submitted). Interestingly, however, the inflexible bivalent construct G_N6C_G could be shown to 
inhibit cell proliferation comparable to H_N6C_H in terms of activity and EC50 (Figure 2.8). 
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4 Materials and Methods 
4.1 Cell culture 
BT-474 cells were obtained from the American Type Culture Collection (ATCC HTB-20). Cells 
were grown in complete RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% (v/v) 
heat-inactivated FCS (PAA GmbH, Pasching, Austria) and 100 U/ml penicillin/streptomycin 
(Sigma) in a humidified incubator with 5% CO2. 
 
4.2 Cell-proliferation assays (XTT assays) 
BT474 cells were seeded at a density of 10,000 cells/cm2 in 96-well-plates (Nunc). After 24 h, 
DARPins (or trastuzumab as control) were added and cells were incubated for another 72 h. 
Cells were then incubated with 50 µl/well 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT; Roche) for 4h at 37°C. Absorbance was measured at 450 nm 
and expressed as percentage of the untreated controls. 
 
4.3 Cloning, Expression and Purification of DARPins 
DARPin H14 is derived from H_14 (Steiner et al. (2008)) with a Cys→Arg mutation 
(C31R). DARPin G3 was originally termed H10-2-G3 (Zahnd et al. (2007)). 
All DARPins were purified essentially as described previously (Zahnd et al. (2010)). Briefly, 
proteins were overexpressed in E. coli XL1-Blue and purified via their N-terminal MRGSH6 tag 
with nickel-nitrilotriacetic acid superflow resin (Qiagen, Hilden, Germany). For cloning of 
bivalent constructs, the DARPin ORFs were digested with BamHI and HindIII (New England 
Biolabs, Ipswich, Massachusetts) and ligated into compatible expression vectors pQiBi,  coding 
for an flexible (G4S)5 linker or various inflexible NxC linkers (see Supplementary Material for 
vector design and construction of NXC-consensus-DARPins).  
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4.4 ELISA 
HER2-domains (200 nM in PBS, 100 μl/well) were immobilized on MaxiSorp plates (Thermo 
Scientific) by overnight incubation at 4°C. For ELISAs, wells were blocked with 300 μl of PBSTB 
(PBS, 0.1% Tween-20, 0.2% BSA) for 1 h at room temperature. 50 nM of purified DARPins were 
incubated with the target domains for 1 h at room temperature followed by three washing steps 
with 300 μl of PBSTB. For detection of bound DARPins, an anti RGS-His IgG1 mouse antibody 
(Qiagen) was added (1:5,000 in PBSTB, 1 h at RT) which recognizes the N-terminal MRGS-His6 
tag of the DARPins and wells were washed as described above. After incubation with a 
secondary anti mouse-IgG antibody alkaline phosphatase conjugate (Sigma-Aldrich) (1:10,000 in 
PBSTB, 1 h at RT), pNPP substrate (Fluka) was added to measure alkaline phosphatase activity. 
 
4.5 Surface Plasmon Resonance (SPR, Biacore) 
SRP measurements were performed using a Biacore 3000 system (GE Healtcare). Biotinylated 
HER2_ECD was immobilized on Sensor Chips SA, that had been conditioned with three 
consecutive 1-minute injections of 1 M NaCl in 50 mM NaOH. One flow cell was left without 
immobilized ligand as reference flow cell. For interaction analysis and determination of kinetic 
data, the analyte (DARPin H14) was exchanged into HBS_T running buffer (20 mM HEPES, pH 
7.4; 150 mM NaCl; 3 mM EDTA; 0.005% Tween20) via NAP5 columns (GE Healthcare). The 
concentrations of the rebuffered protein stock solution was determined by a spectrophotometer 
and diluted to different concentrations ranging from 1 nM to 40 nM for measuring on- and off-
rates. Kinetic measurements were performed with a flow of 50 µl/min as follows: five minutes 
initial buffer blow, followed by a 2 min injection of DARPin at different concentrations. In 
between each single measurement the surfaces of the flow cells were regenerated with three 
10 µl injections of 10 mM glycine-HCl, pH 3, as tested in preliminary studies. The signal of the 
uncoated reference cell and buffer response was always subtracted from the sonsograms 
(double referencing). Data were analysed with a global fit using “Scrubber-2” (BioLogic 
Software Ltd.).  
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4.6 Epitope characterization via flow cytometry competition 
For flow cytometry competition assays, 1 × 105 BT474 cells were incubated with the respective 
AlexaFluor488-labeled binders binding at 100 nM in 100 µl PBS_BA (PBS, 0.2% NaN3, 1% BSA) 
either alone or after preincubation with unlabeled binder at 1 µM to be tested for competition. 
After incubation, cells were harvested by centrifugation (800 × g, 30 sec, 4°C) and washed twice 
using 1 ml PBS_BA, each. Flow cytometry was performed on a Cyflow space system (Partec, 
Germany). Recorded events were gated for FSC/SSC of single viable cells. Fluorescence data 
were analyzed using FlowJo software. 
 
4.7 Receptor Shedding assays 
 BT474 cells were grown in 6-well plates with 200,000 cells/cm2 for 48 hours in presence or 
absence of the HER2 binders to be tested for inhibition of receptor shedding. After 48 hours of 
incubation, proteins from cell-supernatants were extracted by methanol/chloroform 
precipitation Wessel and Flügge (1984) and applied to anti-HER2 immunoblotting detecting the 
N-terminus of HER2 using primary antibody L87 (Thermo Scientific).  
 
4.8 Receptor recycling assay via flow cytometry 
For receptor recycling assays, aliquots of 1 × 105 cells in 100 µl DMEM were incubated with 
100 nM of the respective AlexaFluor-488-labeled binder for 2 hours at 37°C in a thermal shaker 
to allow internalization. The cells were then washed twice with cold PBS and incubated with 100 
nM anti-Alexa-488 quenching antibody (Invitrogen) and 1 µM unlabeled DARPin (chasing 
DARPin). The cells were put back to 37°C for 20, 40, 60 or 80 min to allow recycling. For each 
time point, receptor recycling was stopped by adding NaN3 (0.1% final concentration) and 
putting the respective aliquots on ice. Prior to the detection of the remaining fluorescent signal 
by flow cytometry, cells were washed with cold PBS_BA. The percentage of unchased signal 
corresponding to non-recycled DARPins was calculated by comparison to aliquots of cells with 
internalized DARPins which had not been allowed to recycle. 
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4.9 Expression and purification of scFv 4D5 
The scFv 4D5 was expressed and purified as described before (Willuda et al. (2001)). In brief, 
expression was performed in the periplasm of E. coli strain SB536. Freshly transformed cells 
grown overnight in 50 ml of 2YT medium containing 50 µg/ml ampicillin (2YT/Amp) were used 
to inoculate 1 litre of culture, shaking in baffled 5 l flasks. At an OD600 of 0.7, expression was 
induced with 1 mM IPTG (final concentration) and continued for 8 hours at 20°C. Cells were 
harvested by centrifugation (4000 g, 15min, 4°C) and lysed with an Emulsiflex-C5 homogenizer 
(Avestin, Canada). The scFv was purified via IMAC. 
 
5 Conclusions 
The screening of 22 monovalent DARPins binding to different extracellular HER2-epitopes led to 
the discovery of one DARPin, termed H14, which exhibits antiproliferative effects on the in vitro 
growth of BT474 cells. These antiproliferative effects are comparable, both in terms of activity 
and EC50, with those caused by scFv 4D5, which is the monovalent single-chain fragment of the 
therapeutic antibody trastuzumab. Interestingly, DARPin H14 and scFv 4D5 bind to overlapping 
epitopes on HER2_IV, as could be concluded from competition experiments. Different than 
trastuzumab, DARPin H14 does not affect the receptor shedding of HER2.  
Since both monovalent binders, DARPin H14 and scFv 4D5, cause their antiproliferative 
effect in vitro, where mechanisms like ADCC or CDC are excluded, and since alternative 
mechanisms of action like a putative effect on receptor shedding have been excluded, this 
antiproliferative effect seems to be of steric nature. 
This hypothesis that binding of DARPin H14 and scFv 4D5 sterically interferes with 
HER2 homo- or heterodimerization is in line with previous reports, which named residues in the 
homologous region of EGFR_IV as being important for intermolecular contacts between 
dimerization partners (Adak et al. (2011)). In the publication by Adak et al. it was suggested that 
the tethering arm on EGFR_IV (residues 561-585), that is highly conserved among ErbB family 
receptors, contributes to intersubunit interactions within receptor homo- and heterodimers. 
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Interestingly, the region on HER2_IV that is homologous to the tether region of EGFR is part of 
the epitope bound by scFv 4D5, and thereby most likely part of the epitope of DARPin H14 as 
well. It is therefore very likely that binding to that particular epitope on HER2_IV, both by 
DARPin H14 or scFv 4D5, reduces the receptor’s potential to undergo canonical dimerization.  
In an attempt to improve the antiproliferative effect of DARPin H14 and inspired by the 
example of trastuzumab, which connects two monovalent 4D5 moieties to one bivalent IgG 
molecule, we engineered bivalent DARPin constructs which are composed of two H14 moieties, 
connected via inflexible, inert DARPin-linkers with various lengths (“H14_NxC_H14” with x being 
3, 4, 6, 7, 8 or 10 internal repeat modules). In analogy to the immunoglobulin formats scFv 4D5 
and IgG trastuzumab, these bivalent DARPins could be shown to have improved antiproliferative 
activity, with N6C (or longer) linkers being most effective. 
In contrast to the monovalent format, where DARPin H14 was the only DARPin found to 
exhibit an effect on cell growth, the bivalent format could be applied to DARPin G3, another anti-
HER2 DARPin binding subdomain IV, which lacks biological activity in the monovalent format. 
Testing the rigid linker format with different anti-HER2 DARPins binding subdomain I (HER2_I) 
yielded bivalent constructs that had only weak antiproliferative effects or completely lacked any 
effect on cell growth of HER2 overexpressing cells. 
In summary, our investigations with monovalent and bivalent HER2 binding DARPins 
offer two new ways how to affect the cell proliferation of HER2-addicted cancer cells with 
protein binders to the extracellular part of the receptor. On the one hand, we identified an 
epitope region within the dimer interaction surface on HER2_IV, which seems to play a role for 
the HER2 dimerization potential, as binding of DARPin H14 or scFv 4D5 affect cell proliferation 
of cells that are dependent on HER2 dimerization. On the other hand, we have demonstrated 
another way to efficiently inhibit HER2’s pro-proliferative influence in such cells: the inhibitory 
constructs act by keeping pairs of HER2 molecules in a fixed distance by bivalent binding of rigid 
DARPin constructs. As the receptor positioning induced by our rigid DARPin constructs leads to 
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strong anti-proliferative effects on HER2-addicted cancer cells, we propose that the bound 
receptor molecules are inhibited from contributing to HER2 signaling.  
Interestingly, bivalent binding to the same epitope with flexible constructs led to an 
increased cell proliferation. This finding might propose a role of HER2 homodimers for cell 
proliferation. It is tempting to speculate that pairs of HER2, that are flexibly kept in close 
proximity by flexible bivalent binders, are prone to transphosphorylate each other and 
contribute thereby to proproliferative signaling. 
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Figure 2.1: Cell proliferation assay with 1 µM concentrations of DARPins on BT474 cells. Cells 
were seeded with 10’000 cells × cm-2 and allowed to attach for 24 hours. Cell viability after 
additional four days of growth with or without treatment (Ctrl) was measured by XTT-assays 
(indicated as OD450). Cells treated with 10 nM trastuzumab (Herceptin) served as positive 
control. 
 
 
 
 
                
Figure 2.2: Quantitative affinity measurements (SPR) with DARPin H14. Measurements were 
performed in HBS-T buffer at a flow rate of 50 µl/min with increasing concentrations of H14 
(nM 1, 2.5, 5, 7.5, 10, 15, 25, 40). 
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Figure 2.3: Epitope characterization of HER2-binding DARPins. Flow cytometry experiments 
with AlexaFluor488-labeled trastuzumab binding to BT474 cells at 100 nM either alone 
(continuous lines) or after preincubation with unlabeled DARPins to be tested at 1 µM for 
competition (dotted lines). 
 
 
 
 
 
 
 
Figure 2.4: Effect of HER2 binders on receptor shedding. Proteins from BT474-cell supernatants 
after 48 hours of growth in the presence or absence (Ctrl) of HER2 binders were extracted by 
methanol/chloroform precipitation and applied to anti-HER2 immunoblotting, detecting the N-
terminus of HER2. Each condition was performed in duplicates. 
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Figure 2.5: Cell proliferation assay with dilution series of different HER2-targeting proteins on 
BT474 cells. Cells were seeded with 10,000 cells × cm-2 and allowed to attach for 24 hours. Cell 
viability after an additional four days of growth with or without treatment (Ctrl) was measured 
by XTT-assays (indicated as OD450). 
 
 
 
 
 
Figure 2.6: Cell proliferation assay with dilution series of DARPin H14 in monovalent (H14) or 
flexible bivalent (H14_20_H14) format. Cells were seeded with 10’000 cells × cm-2 and allowed 
to attach for 24 hours. Cell viability after additional four days of growth with or without 
treatment (Ctrl) was measured by XTT-assays (indicated as OD450). Cells treated with 100 nM of 
trastuzumab or scFv 4D5 served as controls. Data points were recorded in triplicates. 
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Figure 2.7: Cell proliferation assay with dilution series of inflexibly linked bivalent H14 
constructs. Cells treated with 100 nM of trastuzumab or untreated cells (Ctrl) served as controls. 
Data points were recorded in triplicates. 
 
 
 
 
 
 
Figure 2.8: Cell proliferation assay with dilution series of inflexibly linked bivalent DARPin 
constructs composed of DARPin G3 (G_N6C_G) or H14 (H_N6C_H). Cells treated with 100 nM of 
trastuzumab or untreated cells (Ctrl) served as controls. Data points were recorded in 
triplicates. 
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1 Summary 
Human epidermal growth factor receptor-2 (HER2) is a receptor tyrosine kinase directly linked 
to the growth of malignancies from various origins and a validated target for monoclonal 
antibodies and kinase inhibitors. Utilizing a new approach with Designed Ankyrin Repeat 
Proteins (DARPins) as alternative binders, we show that binding of two DARPins connected by a 
short linker, one targeting extracellular subdomain I, the other subdomain IV, causes much 
stronger cytotoxic effects on the HER2-addicted breast cancer cell line BT474, surpassing the 
therapeutic antibody trastuzumab. We determined crystal structures of these DARPins in 
complex with the respective subdomains. Detailed models of the full-length receptor, 
constrained by its rigid domain structures and its membrane anchoring, explain how the 
bispecific DARPins connect two membrane-bound HER2 molecules, distorting them such that 
they cannot form signaling-competent dimers with any EGFR family member, preventing any 
kinase dimerization, and thus leading to a complete loss of signaling. 
 
2 Highlights 
- Particular Bispecific DARPins binding to the HER2 extracellular domain are cytotoxic 
- Crystal structures of the DARPin:target complexes reveal mechanism of action 
- Bivalent binding crosslinks HER2-monomeres in a signaling-incompetent state  
- Bispecific DARPin-bound state prevents HER2 kinases from forming any complex 
 
3 Introduction 
The human epidermal growth factor receptor 2 (HER2, hErbB2) is a receptor tyrosine kinase 
expressed on the cell surface of nearly every cell in the human body. HER2 contributes to 
multiple signal transduction pathways, but mainly stimulates the HER3/PI3K/Akt pathway and 
the mitogen-activated protein (MAP) kinase cascades, leading to cell survival and proliferation 
(Craven et al. (2003); Yarden and Sliwkowski (2001)). HER2 amplification promotes 
tumorigenesis (Faber et al. (2010)), and human tumors and various tumor cell lines rely on 
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HER2-signaling for their survival. Such cancer cells are often referred to as “HER2-addicted” 
(Moasser (2007)).  
Trastuzumab (Herceptin®, Genentech, San Francisco, CA), a humanized monoclonal 
antibody binding to the extracellular subdomain IV of HER2 (HER2_IV), is effectively used in the 
clinic to treat patients with HER2-overexpressing breast cancers (Cobleigh et al. (1999); Finn 
and Slamon (2003)). Besides exerting cytotoxic effects in vivo through antibody-dependent 
cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), trastuzumab mainly 
acts as a cytostatic agent inducing a G1 phase cell cycle arrest in HER2-amplified cancer cells 
(Sliwkowski et al. (1999)). Inhibition of HER2 homodimerization (Ghosh et al. (2011)) and of 
HER2/HER3 heterodimerization (Junttila et al. (2009)) is thought to be responsible for this anti-
proliferative effect. Pertuzumab (Perjeta®, Genentech, San Francisco, CA), a humanized 
monoclonal antibody binding next to the dimerization arm on subdomain II of HER2, shows only 
moderate anti-tumor effects in vitro on HER2 overexpressing breast cancer cell lines (shown for 
SkBr-3 cells (Schaefer et al. (1997))). However, for cell lines with normal HER2 expression levels 
that are grown in the presence of the HER3-activating ligand Heregulin, which efficiently 
stimulates HER2/HER3 heterodimer formation (Sliwkowski et al. (1994)), the effect of 
pertuzumab exceeds the effect of trastuzumab (Schaefer et al. (1997)). This finding can be 
explained in that pertuzumab, bound next to the HER2 dimerization arm, sterically blocks the 
formation of back-to-back heterodimers that are induced by ligand stimulation of HER3 
(Franklin et al. (2004)). 
Recently, Trastuzumab emtansine (T-DM1) (Kadcyla®), a maytansinoid conjugate 
(Burris et al. (2011); Verma et al. (2012)), has become FDA-approved. It is thought to be 
endocytosed with the slow internalization and recycling rates intrinsic to ErbB2 and thus to 
release the toxin. These encouraging data stimulate the search for novel mechanisms of action, 
which may pave the way for agents not requiring a conjugated toxin. 
Recent studies on the regulation of the homologous receptor EGFR have shown that 
receptor dimerization is required, but may not be sufficient for full receptor activation 
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(Arkhipov et al. (2013); Endres et al. (2013)). Dimerization of ECD, TM-helices and, as a 
consequence, the kinase domains have to take place in a well ordered mechanism, requiring, e.g., 
pairing the N- but not the C-terminal parts of the two TM-helices for functional dimerization of 
the kinase domains. Additional factors modifying the coupling between dimerization of the 
extracellular domain to the dimerization and activation of the kinase domain may contribute to 
the subtle regulation of receptor activity (Arkhipov et al. (2013); Endres et al. (2013)).  
Tumor cells becoming refractory to trastuzumab treatment present a major clinical 
problem. This is not only caused by down-regulation or loss of HER2 expression, but also by 
various mutations bypassing the blocked HER2-signaling, including constitutive activation of the 
PI3K-signaling pathway, accumulation of a constitutively active HER2-kinase, and crosstalk of 
HER2 with other growth factor receptors (Sergina et al. (2007); Xia et al. (2004)). Acquisition of 
trastuzumab resistance might be promoted by the cytostatic effect of trastuzumab, which allows 
the tumor to undergo a directed evolution to escape treatment. Thus, an optimal drug against 
HER2-overexpressing cancer cells would have to be cytotoxic instead of cytostatic, but the 
cytotoxicity should not broadly aim at all HER2-expressing cells, but rather specifically target 
cancer cells that are dependent on HER2.  
The concept that HER2 remains the active oncogenic driver in many cancer cells, e.g. by 
signaling through HER2-HER3-heterodimers, motivates further research for alternative 
molecular therapies targeting HER2 (Gajria and Chandarlapaty (2011)). To expand and 
complement existing anti-HER2 therapies beyond pertuzumab and trastuzumab or any toxin 
conjugates, such as T-DM1 (Burris et al. (2011)), further HER2-binders that employ alternative 
mechanisms should thus be developed for abolishing HER2-dependent signaling.  
Designed ankyrin repeat proteins (DARPins) are binding scaffolds that have recently 
been developed to expand the range of formats and applications beyond what is possible with 
immunoglobulin-based proteins (Binz et al. (2004); Boersma and Plückthun (2011)). Because of 
their small size, high stability and efficient folding, DARPins can easily be fused to each other in 
different orientation and geometries and to different protein domains, to generate multivalent 
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or multispecific constructs or to provide targeting specificity to effector proteins. They are 
highly suitable for site-specific chemical modification (Simon et al. (2012)), e.g. coupling to 
polyethylene glycol (PEGylation) to increase the hydrodynamic radius and thus serum half-life 
and thereby promote tumor uptake (Zahnd et al. (2010)) or conjugation of toxins. While they 
have been used for targeting toxins to a tumor (Martin-Killias et al. (2011)), it is of interest to 
investigate whether they can also exert a biological function by themselves. Thus, they appear 
predestined as binding moieties for novel approaches in targeted therapy. DARPins recognizing 
the soluble recombinant ectodomain of HER2 (HER2-ECD) with sub-nanomolar to low 
nanomolar affinities were selected by ribosome display (Zahnd et al. (2007)) and phage display 
(Steiner et al. (2008)). These HER2-specific DARPins have been used for histochemical staining 
(Theurillat et al. (2010)), for tumor targeting of toxins (Zahnd et al. (2010)) and for targeting 
adenoviral (Dreier et al. (2013)) and lentiviral vectors (Münch et al. (2011); cf. Appendix 1) to 
HER2-overexpressing cells.  
In this paper, we demonstrate the cytotoxic activity of bispecific DARPin constructs 
against the HER2-addicted cell line BT474, a widely used model system for testing anti-HER2 
activity in vitro. The bispecific DARPins do not only induce a cytostatic effect like trastuzumab, 
but rather act as specific cytotoxic agents. This cytotoxic effect does not rely on any conjugated 
toxin, but is intrinsic to the binding mechanism.  
The results were confirmed on a broad panel of breast tumor cell lines and tumor models 
by (Tamaskovic et al. (2013), cf. Chapter 4), who proceeded to characterize in great detail the 
influence of these constructs on various aspects of downstream signaling, such as 
phosphorylation pattern, downstream kinase activity and apoptotic markers. They showed that 
the most potent of the bispecific DARPins cause a persistent inhibition of both the phosphatidyl-
inositol-3-kinase (PI3K-AKT/PKB) and the RAS-RAF-MAPK pathway, leading to a strong 
apoptotic response. Based on the X-ray structures of three DARPins in complex with the cognate 
HER2-ECD subdomain we have determined here, we propose a model of how such a complete 
shutdown of HER2-dependent signaling is achieved. 
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4 Results 
4.1 Epitope-mapping of HER2-binding DARPins 
DARPins that had been selected by phage display (Steiner et al. (2008)) or ribosome display 
(Zahnd et al. (2007)) to target the full-length ectodomain of HER2 without showing any cross-
specificity against other EGFR-family members were characterized concerning which of the four 
HER2-subdomains forms the epitope. Since DARPins typically recognize conformational 
epitopes, we expressed subdomains alone and in combination in insect cells using a baculovirus 
system (Supplementary Text, SI Text). To minimize glycosylation for subsequent crystallization, 
we replaced the Asn residues in predicted N-linked glycosylation sites by Asp. ELISAs on these 
proteins showed that the epitopes recognized by DARPins 9_26 and 9_29 are located on HER2-I, 
while DARPin G3 bound to HER2-IV (Supplementary Fig. S1A). Competition for binding to 
HER2-overexpressing cells measured by flow cytometry revealed that DARPins 9_26 and 9_29 
compete for the same epitope (Fig. S1B). DARPin G3, which binds to HER2 subdomain IV, did 
not compete with trastuzumab but competed with a different HER2-specific DARPin, H.14, 
which in turn competed with trastuzumab.  
 
4.2 Construction of bispecific binders targeting different epitopes  
Various bivalent and bispecific constructs were generated by genetically fusing two DARPins by 
(G4S)n linkers of different lengths. To target two non-overlapping epitopes with a single 
molecule, DARPins 9_29 or 9_26 were connected to DARPin G3 by a 20 amino acid linker, with 
either an ECD-I binder at the N-terminal end and the ECD-IV binder at the C-terminus or in 
opposite orientation. The four different bispecific binders (e.g., 9_26-(G4S)4-G3, abbreviated 
“6_20_G” for the two DARPins and the linker length of 20 amino acids) were tested regarding 
their binding to HER2-overexpressing cells. G3 with a KD of 90 pM (Zahnd et al. (2007)) has the 
highest affinity of the three HER2-binders used in this study, compared to a KD of 1 nM for 9_26 
and 1 nM for 9_29 (Steiner et al. (2008)). Kinetic experiments on cells in the presence of a 
competing DARPin (to prevent rebinding) revealed that the off-rates of the bispecific binders 
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were 10 times lower than the off-rates of monovalent G3 (Fig. 1A, Table S1). The slower off-rate 
and higher KD of the bispecific constructs, compared to their monovalent building blocks, can be 
attributed to an avidity effect and indicates bispecific binding to HER2 on the cell.  
 
4.3 Effects of mono- and bivalent constructs on cell proliferation and cell death 
We tested the influence of the different DARPin constructs on cell proliferation and cell survival 
in XTT assays, using BT474 cells as an example of a HER2-addicted cell line. MCF7-cells, which 
express HER2 at much lower levels than BT474 cells, were used as a control. Calibration 
experiments showed that a signal decrease by 60%, compared to untreated cells, corresponded 
to lack of cell proliferation over the 4 days of cell growth before the XTT assay — a larger 
decrease indicated cell death.  
None of the monovalent DARPins characterized in this study affected the number of 
viable cells measured by the XTT assay (Fig. 1B). Mixtures of two different DARPins proved to 
be equally inert, as did control constructs in which one of the two DARPins in the bispecific 
molecule had been replaced by a non-HER2-binding DARPin (DARPin off7, targeting maltose-
binding-protein (Binz et al. (2004))) (Fig. 1C). A monospecific bivalent DARPin G_20_G even 
stimulated cell proliferation (Fig. 1C).  
Bispecific constructs composed of a subdomain I binder at the N- and the subdomain IV 
binder at the C-terminus (6_20_G or 9_20_G) showed a concentration-dependent decrease of cell 
viability by up to 75%, while treatment with trastuzumab decreased viability by ~50% 
(Fig. 1D). The constructs with reverse orientation (G_20_9) either lacked any effect on cell-
growth (G_20_6) or even slightly promoted cell growth. Similar to trastuzumab, bispecific 
constructs did not affect the cell-proliferation of MCF7-cells (Fig. 1E), suggesting the restriction 
of the observed effects to HER2-addicted cells. Comparison of constructs with 5, 10, 20, 30 and 
40 amino acid linkers showed that for 9_x_G constructs, specific activity and potency decreases 
with increasing linker length. The most potent constructs proved to be 6_5_G and 9_5_G, with 
(G4S)-linkers of only five amino acids. They decreased the cell viability in XTT-assays after four 
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days of growth by more than 80% as compared to untreated cells, and showed a half-maximal 
effect already at a concentration of less than 100 pM compared to ca. 1 nM for 6_20_G and 
9_20_G. Conversely, increasing the linker length to forty amino acids, as in 6_40_G and 9_40_G, 
decreased the biological activity (growth reduction of only 40%) (Fig. 1F). The constructs with 
inverse orientation, G_x_6 and G_x_9, inactive or even stimulatory at a linker length of 20 amino 
acids, gained anti-proliferative activity at short linker lengths, but the best construct was found 
to be only as active as trastuzumab (Fig. 1G). Neither the single DARPins nor the bispecific 
constructs affected internalization or degradation of HER2, as determined by flow cytometry 
(Tamaskovic et al. (2013), cf. Chapter 4).  
 
4.4 X-Ray Crystal Structures of complexes HER2_I:9_29, HER2_I:9_26 and HER2_IV:G3 
The structures of the complexes of HER2_I with DARPin 9_29 and with 9_26 were determined at 
2.55 Å and 3.2 Å resolution, respectively, the structure of HER2_IV in complex with G3 at 2.65 Å 
resolution. A summary of data collection statistics and refinement results is listed in Table S2. 
Unliganded 9_26 was solved to 2.9 Å (unpublished result), unliganded G3 (PDB ID: 2JAB) (Zahnd 
et al. (2007)) to 1.7 Å. G3 and unliganded 9_26 contain the original DARPin C-cap, which by NMR 
had been shown, to some percentage, to show some transient unfolding in solution (Wetzel et al. 
(2010)). For crystallization in complex with HER2_I, this C-cap was replaced by an optimized C-
cap (Mut5) (Interlandi et al. (2008)) in DARPins 9_29 and 9_26, which does not give any sign of 
transient unfolding. 
The asymmetric unit of HER2_I:9_29 contains one heterodimeric complex with 7 
intermolecular hydrogen bonds (Table S3), and a buried surface area of 784 Å2 (Fig. 2 A-C). In 
the asymmetric unit of HER2_I:9_26, two heterodimers are present. Due to the limiting quality of 
the HER2_I:9_26 data set, slight differences are visible between the two complexes and parts of 
the complex are not resolved. Most of our analyses are therefore concentrated on the 
HER2_I:9_29 complex. The asymmetric unit of the HER2_IV:G3 structure contains two 
heterodimeric complexes with 7 and 5 intermolecular hydrogen bonds between DARPin G3 and 
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HER2_IV (Table S4), respectively, and a buried surface area of 818 Å2 (complexes A/D, Fig. 2D-
F) or 759 Å2 (complex B/C).  
The conformation of HER2_I and HER2_IV is essentially the same as that of the respective 
subdomain in structures of the whole extracellular domain of HER2 (Bostrom et al. (2009); Cho 
et al. (2003); Fisher et al. (2010); Franklin et al. (2004); Garrett et al. (2003)), with rmsd values 
for the Cα-backbone around 0.49 to 0.81 Å for HER2_I and 0.24 to 0.68 for HER2_IV (Table S5, 
Fig. S2 A,B), underlining the rigidity of the HER2 domains.  
A comparison of the epitopes recognized by various HER2 binders in the Protein Data 
Bank (Fig. 3) shows that the regions recognized by the three DARPins do not overlap with 
epitopes recognized by any of the other binders: scFv A21 binding to domain I (Zhou et al. 
(2011)), therapeutic antibody pertuzumab recognizing subdomain II (Franklin et al. (2004)), Z-
domain-derived affibody zHER2 (Eigenbrot et al. (2010)), recognizing the same epitope on 
domain III as Fab37 (Fisher et al. (2010)), and trastuzumab (Cho et al. (2003)) and its 
HER2/VEGF dual specific variant bH1 (Bostrom et al. (2009)) binding to subdomain IV.  
DARPins 9_29 and 9_26 bind to the same epitope on HER2_I, involving residues from the 
N-cap and the first two internal repeats (Fig. 4). The third repeat and the C-cap make no 
contacts. The DARPin contacts two adjacent strands of HER2_I at the edge of this domain, 
including further interactions down the side perpendicular to the β-helix axis of domain I, which 
is a member of the L-domain family. The high-affinity binding of DARPin 9_29 to HER2_I is 
governed by six hydrogen bonds, pi-stacking and extended hydrophobic interactions described 
in detail in the SI Text (Table S3). Epitope and paratope residues are highlighted in the 
sequence alignments shown in Fig. S3. Comparison of the sequence differences between the two 
DARPins to this contact map shows that 14 out of 19 contact residues are conserved.  
Construct HER2-IV spans residues 509-604 of the HER2-ECD, omitting the last two 
disulfide bonds. Residues 581-604 are disordered in the structure. DARPin G3 binds to an 
epitope on the N-terminal half of subdomain IV (residues 513-564). The structure of G3 in the 
complex is well maintained compared to its uncomplexed structure (rmsd 0.65 or 0.55 Å, 
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Fig. S2 C), demonstrating that the DARPin:HER2 complexes can, in a first approximation, be 
considered as rigid body interactions. The paratope comprises both internal repeats and the C-
cap of the DARPin (Fig. 2, Fig. S3). The long axis of the DARPin is at nearly a right angle to the 
long axis of HER2_IV, the DARPin β-turns facing towards the membrane. The DARPin wraps 
around the rod shaped Cys-rich domain IV, its slight curvature is fitting the target shape very 
well, explaining the high affinity of 90 pM. It contacts two protrusions, formed by the loop 
spanned by Cys 523 and 539 and the adjacent pair of interlocked disulfide bond. Two of the four 
mutations introduced during affinity maturation are directly involved in binding interaction. Of 
the 14 randomized residues, 9 are involved in specific contacts, as are several framework 
residues. Six hydrogen bonds and extended hydrophobic interactions, altogether contributed by 
13 residues (SI Text), are responsible for the picomolar affinity of G3. The atomic interactions 
are summarized in Table S4. Thus, although G3 possesses only two internal repeats, the 
perfectly matching hydrophobic and hydrogen bonding interactions, contributed by adapted 
curvature as a result of directed evolution (Zahnd et al. (2007)), account for its high affinity. 
 
4.5 Molecular modeling of full HER2 and DARPin-inhibited states 
Since the HER2 domains are very rigid, and their structure did not change between the DARPin 
complexes and the whole ECD, we could easily place the DARPins on the full HER2_ECD 
(residues 1-620). We also built models of putative HER2_ECD homo-and heterodimers (see 
SI Text for a detailed description of the modeling procedure), taking into account all available 
ErbB-family structures to make the models as realistic as possible. The DARPins bound to 
HER2_I and HER2_IV could be added to the HER2 monomer and dimer models without any 
clashes (Fig. 5 A-D).  
To build a model of the whole receptor, the HER2-ECD model were combined with the 
NMR structures of transmembrane helices (PDB entry 2JWA (Bocharov et al. (2008))) and the X-
ray structures of the kinase domains (PDB ID: 3PP0 for the active kinase dimer (Aertgeerts et al. 
(2011)), 3RCD for the inactive kinase (Ishikawa et al. (2011))), taking the EM-based models of 
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Mi et al. (2011) as a guide. Seven residues between the last disulfide bridge of ECD domain IV 
and the start of the transmembrane helix and 30 residues between TM domain and kinase were 
treated as flexible to connect the domains. The resulting models assume that initially both 
monomer and dimer stand upright on the membrane, and that the HER2-ECD is as rigid as 
suggested by Cho et al. (2003) and Dawson et al. (2007).  
The distance between the C-term of the domain-I-binding DARPin and the N-term of the 
domain-IV-binding DARPin is 130 Å on the same HER2 molecule (Fig. 5A). For intramolecular 
binding to a HER2_ECD monomer in this orientation, 9_x_G, the linker would have to be even 
longer, as it needs to wrap around the monomer. However, the most active of our constructs has 
a linker length of a mere five amino acids, spanning no more than 17 Å, which thus excludes 
intramolecular binding (Fig. S4).  
To connect two DARPins on the same side of the HER2 homodimer (Fig. 5 C,D), the 
linker would have to span at least 80 Å for the 9_x_G construct, and to connect DARPins on two 
independent monomers, the linker would have to span at least the difference in height above the 
membrane of the two termini, more than 50 Å. It follows that with the most active of our 
constructs, with a 17 Å linker, linking two HER2 molecules in either of these upright 
conformation is not possible, either. 
Since the observed biological activity and increased binding avidity of the short-linkered 
constructs prove that the bispecific constructs do bind bivalently on cells, it follows that the 
HER2 molecules must arrange to accommodate this. For bivalent binding of 9-5-G to occur, the 
9_29 epitope of HER2_I has to move closer to the membrane, and this requires either a major 
conformational change within the HER2_ECD (which is unlikely, as explained below), or a major 
change in the orientation of the HER2-ECD relative to the membrane.  
Comparison of extracellular domain conformations in various different ErbB family 
crystal structures indicates that there are very few possibilities for major conformational 
changes within the HER2_ECD. The connection between subdomains I and II and between III and 
IV is quite rigid: the side chain of conserved Trp 183 of subdomain II inserting into the core of 
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subdomain I and the side chain of Trp 499 of subdomain IV inserting into the core of domain III 
severely limit the flexibility of these interfaces. Major conformational changes within ErbB 
receptor extracellular domains appear to be limited to a rigid-body movement of the domain I–II 
pair relative to the domain III–IV pair around a pivot between domains II and III (Cho et al. 
(2003)). EGFR/HER1, HER3 and HER4 occur in two conformational states: In the presence of an 
activating ligand, their extracellular domain assumes an “open” conformation, similar to the 
default conformation of the HER2_ECD (Liu et al. (2012); Ogiso et al. (2002)), while their default 
conformation in the absence of a ligand and/or dimerization partner is a “tethered” 
conformation (Bouyain et al. (2005); Cho and Leahy (2002); Ferguson et al. (2003)), which has 
so far not been observed for HER2. The HER2_ECD constitutively assumes an “open” 
conformation (Garrett et al. (2003)). 
However, a rigid HER2_ECD could easily tilt relative to the membrane (Fig. 6 D, G). This 
would require flexibility in the short peptide segment between the last disulfide-bridged 
cysteine of the extracellular domain and the start of the transmembrane helix. Indeed, these 
residues are disordered in reported structures of the HER2 extracellular domain and in NMR 
structures of the transmembrane helix. Based on single-molecule Förster resonance energy 
transfer (FRET) analysis and fluorescence lifetime imaging microscopy, this region in EGFR has 
been proposed to be sufficiently flexible to allow the EGFR_ECD to equilibrate between an 
upright position and one lying flat on the membrane (Webb et al. (2008)). Thus, tilting the ECD 
in such a way that the dimerization loop points towards the membrane (Fig. 6 D, G) would 
lower the C-terminus of 9_29/9_26 and raise the N-terminus of G3 in such a way that the two 
can be connected by a short linker.  
Alternatively, a hypothetical pseudo-tethered conformation of HER2, for which there is 
currently no direct evidence, would bring the 9_29 epitope into an ideal position relative to the 
G3 epitope of a second HER2 monomer for intermolecular crosslinking with short-linkered 
constructs (Fig. 6 C, F), while intra-molecular crosslinking within a tethered monomer would 
still require a 70 Å (G_x_9) to 80 Å (9_x_G) linker. Such a conformation would not interfere with 
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DARPin binding, but would prevent the formation of back-to-back HER2 homo- and 
heterodimers.  
The most important deduction from these models is that linking domain I of one HER2 
molecule to domain IV of another by a short linker, the transmembrane domains of the two 
HER2 are forced apart. This conclusion is independent of the pivot point utilized. The 
consequence of this movement is that it prevents the assembly of active kinase dimers. 
 
5 Discussion 
The results presented in this paper and the associated models of the induced inhibited states of 
HER2 allow us to propose a mechanism of the induction of cytotoxicity within the framework of 
activation and inhibition of the ErbB receptor family. We present the X-ray structures of three 
DARPin:target complexes, with DARPins 9_29 and 9_26 binding to the same epitope on 
subdomain I of HER2, and DARPin G3 recognizing subdomain IV. The structures of the DARPins 
in complex with the cognate receptor domain can be superimposed on the structure of the full-
length HER2 extracellular domain without any evidence for conformational changes in the 
individual domain beyond some very small local flexibility, already apparent from the 
comparison of the various structures of HER2_ECD in the Protein Data Bank. Thus, the 
superposition of the DARPins on the whole HER2 ECD is unambiguous.  
 
5.1 Monomeric DARPins do not interfere with HER2 signaling 
All tested monovalent DARPins that were used for the construction of the bispecific binders, 
individually or as a mixture, have no effect on the cell survival and proliferation of cultured 
BT474 cells, indicating that the monovalent DARPins do not interfere with HER2 signaling in this 
HER2-addicted cell line. Models of the putative HER2 “back-to-back” homodimer (Fig. 6B) or of 
canonical heterodimers with EGFR or HER3 (not shown), which are generally thought to 
represent the active state of HER2, indicate indeed that the binding of unlinked, i.e. monovalent, 
DARPins should not interfere with homo- or heterodimerization, consistent with the 
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observation that the monovalent DARPins are not biologically active. Since the monovalent 
DARPins cover both sides of the dimer, they should interfere with the lateral association of 
receptor dimers to produce tetramers or higher oligomers formed by stacking the planes 
defined by domains I, II and III, as recently proposed (Zhang et al. (2012)). However, since the 
unlinked DARPins do not interfere with HER2 activity, higher oligomers associating in this 
specific manner cannot be required for the activity of HER2 measured in our assays. 
 
5.2 Activity depends on linker length 
When connected by short flexible linkers, the two DARPins 9_29 and G3 acquire biological 
activity: While monospecific bivalent constructs, in particular G_20_G, activate HER2 signaling 
and have a pro-proliferative effect on BT474 cells, presumably by stabilizing HER2-HER2 
homodimers, the bispecific bivalent constructs described here inhibit HER2 signaling and 
decrease cell viability, without affecting the number of receptors displayed on the cell surface 
(Tamaskovic et al. (2013), cf. Chapter 4). Their activity is dependent on linker length and on 
domain orientation: Constructs with shorter linkers show higher activity than constructs with 
longer linkers, and constructs with N-terminal DARPin 9_29 and C-terminal DARPin G3 (9_x_G) 
show significantly higher activity than G_x_9 of the same linker length. While for the G_x_9 
conformation the inhibitory activity already disappears with a linker length of 20 amino acids, in 
the 9_x_G orientation, even the construct equipped with a 40 amino acid linker shows some 
activity.  
Constructs in which one of the DARPins has been replaced by the non-binding DARPin 
off7 are biologically inactive, demonstrating the need for bivalency. Therefore, we have to 
conclude that the biological activity of the bispecific constructs is indeed due to crosslinking of 
HER2 molecules and not to simple direct steric hindrance of HER2 homo- or heterodimerization 
by the DARPins. 
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5.3 The linker length is too short for both DARPins to bind to the same HER2 monomer 
or dimer 
The linkers of the shortest and most potent of the bispecific constructs tested, 9_5_G, 9_10_G and 
9_20_G, are too short to connect the C-terminus of 9_29 to the N-terminus of G3 bound to the 
same HER2 molecule, in either the open conformation seen in all crystal structures of the HER2 
ectodomain (Bostrom et al. (2009); Cho et al. (2003); Eigenbrot et al. (2010); Fisher et al. 
(2010); Franklin et al. (2004)) or in a hypothetical pseudo-tethered conformation modeled in 
analogy to the tethered conformations of other members of the ErbB family (Bouyain et al. 
(2005); Cho and Leahy (2002); Ferguson et al. (2003); Hollmen et al. (2012); Li et al. (2005); Liu 
et al. (2012); Ramamurthy et al. (2012)). The linkers are also too short to connect DARPins 
bound to the two HER2 monomers in a putative “back-to-back” HER2 homodimer. The observed 
bivalent binding, therefore, can only be explained by crosslinking of two independent HER2 
monomers, at least one of which has to bend down (see below).  
 
5.4 Orientation of HER2 on the cell surface 
On the surface of intact cells, the transmembrane domain of the receptor is constrained to the 
plane of the membrane, restricting translational and rotational freedom of the receptors. 
Conventionally, receptors of the ErbB2 family are depicted as standing upright on the cell 
surface, with their main axis about perpendicular to the plane of the membrane. However, it has 
been proposed that a small percentage of EGFR, providing high-affinity EGF sites, can lie flat on 
the surface (Webb et al. (2008)), underlining the flexibility of the few residues between the 
receptor ectodomain and the TM helices to allow this. Therefore, a tilting of the whole 
ectodomain of HER2 with a pivot close to the membrane has some precedent.  
Nonetheless, a completely flat orientation of HER2 dimers is inconsistent with binding of 
DARPins, as in the bound state they would prevent a flat orientation, since DARPin epitopes 
would be located between receptor and membrane. Also, since the majority of receptors is 
standing upright in EGFR (Webb et al. (2008)), there must be a dynamic equilibrium, and any 
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bound DARPin will shift this equilibrium away from any flat orientation. Considering the data on 
EGFR, it follows for HER2 that a tilted orientation of HER2 molecules in the DARPin-linked state 
is possible, but not a completely flat one. This flat orientation, which we can exclude, would be 
the only one in which the TM helices would be able to come close enough for the kinases to form 
an active dimer. 
 
5.5 Conformational flexibility of the HER2 extracellular domain 
Our experiments show that even the shortest linker, spanning less than 17 Å in extended 
conformation, allows bivalent binding of the bispecific DARPins. Since such bivalent binding is 
not possible for the open, fully erect conformation of the extracellular domain, something has to 
bend. The interfaces between domain I and II and between domain III and IV are rigid: The side 
chain of Trp 183 in cysteine-rich domain II is buried in the core of domain I, and the side chain of 
Trp 499 of cysteine-rich domain IV is buried in the core of domain III, allowing only very limited 
flexibility. HER2_I_II and HER2_III_IV can therefore be regarded as structurally rigid units. Only 
two positions in the extracellular domain have the potential to act as a pivot for allowing large-
scale conformational changes: Either a hinge motion around the boundary residue between 
domain II and III (a Lys in EGFR, HER3 and HER4, corresponding to Arg 317 in HER2), which 
relates the open to the tethered conformation in other ErbB family members (Fig. 6 C, F), or – 
more likely regarding the probable constitutively open confirmation of HER2_ECD – a tilting of 
the whole ECD relative to the membrane, relying on the flexibility of the residues between the 
last cysteine of domain IV and the transmembrane helix (Fig. 6 D, G). 
 
5.6 Interference with HER2 dimerization and activation 
Either of the two discussed conformational changes captured by the bispecific DARPins leads to 
a situation where the “back-to-back” dimerization interface of HER2 is obstructed. In a pseudo-
tethered conformation, this obstruction is intramolecular, in the tilted conformation it is due to 
the enforced proximity of the dimerization interface to the membrane. Either model would 
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result in bringing the C-terminus of DARPin 9_29 closer to the N-terminus of DARPin G3. As the 
transmembrane helices cannot be pulled out of the plane of the membrane, this enforces the 
membrane insertion points, and therefore the transmembrane and intracellular kinase domains 
apart, independent of the pivot point.  
For maximal inhibition, formation of larger oligomers formed by daisy-chaining may be 
required, where every receptor monomer is bound to two bispecific DARPins and both DARPin 
epitopes on HER2 are occupied. For linker lengths >> 20 amino acids, alternative, intramolecular 
binding modes may start to compete with the intermolecular binding modes enforced by the 
short linker, explaining their overall lower biological activity.  
 
6 Conclusions 
The contrast between the biological inertness of the monovalent DARPins alone or in 
combination, the stimulation of HER2 signaling by monospecific bivalent DARPin construct 
G_20_G and, on the other hand, the potent inhibition of HER2 signaling by bispecific DARPin 
constructs connected by a minimal linker is intriguing. Trivial explanations for the inhibitory 
activity of the bispecific constructs, such as receptor downregulation or direct steric hindrance 
of receptor dimerization could be excluded (Tamaskovic et al. (2013), cf. Chapter 4), leaving a 
model where the steric constraints imposed by the membrane anchoring of the receptors play 
an important role in forcing apart the transmembrane helices of two HER2 monomers connected 
by the bispecific DARPin constructs.  
The large fraction of the HER2 dimer surface covered by the biologically inert 
monovalent DARPins challenges models which postulate a need for lateral tightly packed HER2-
oligomers for certain aspects of HER2 signalling in the cell line described here. The strong 
inhibitory effect of the bispecific DARPin constructs makes them an interesting starting point for 
future tumor targeting constructs directed against HER2-addicted cancer cells. A detailed 
analysis of their effects on different aspects of downstream signaling is presented in a separate 
publication (Tamaskovic et al. (2013), cf. Chapter 4).  
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In summary, the engineering of binding molecules that bispecifically target HER2 at 
domains I and IV, connected by a linker not commensurate with intramolecular binding or 
binding to back-to-back complexes, has proven to be a very promising way to expand the arsenal 
of molecular targeting of cancer cells that are addicted to this receptor. In this context, DARPins 
might be particularly promising, as they can be easily engineered in a variety of molecular 
orientations, and equipped for prolonged systemic circulation in order to extend their 
outstanding in vitro potency for in vivo studies (Tamaskovic et al. (2013), cf. Chapter 4). 
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7 Experimental Procedures 
7.1 Cloning, Expression and Purification of DARPins 
All DARPins were purified essentially as described previously (Zahnd et al. (2010)). Proteins 
were overexpressed in E. coli XL1-Blue and purified via their N-terminal MRGSH6 tag with 
nickel-nitrilotriacetic acid superflow resin (Qiagen, Hilden, Germany). For cloning of bispecific 
constructs, the DARPin ORFs were digested with BamHI and HindIII (New England Biolabs) and 
ligated into compatible expression vectors pQiBi, coding for different flexible (G4S)n linkers. This 
results in the connecting sequence …AEILQKL(G4S)nRSDLGKKLL…, where the first underlined 
sequence is from the C-cap of the N-terminal DARPin, the second underlined sequence is from 
the N-cap of the C-terminal DARPin and n indicates the number of pentapeptides present in the 
flexible linker. 
 
7.2 Cell culture 
BT-474 cells were obtained from the American Type Culture Collection (ATCC HTB-20). Cells 
were grown in complete RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% (v/v) 
heat-inactivated FCS (PAA GmbH, Pasching, Austria) and 100 U/ml penicillin/streptomycin 
(Sigma) in a humidified incubator with 5% CO2. 
 
7.3 Flow cytometry 
Per assay, 1 × 106 cells were incubated with the respective fluorescently labeled DARPins at the 
indicated concentrations in 100 µl PBS_BA (PBS, 0.2% NaN3, 1% BSA). After incubation, cells 
were harvested by centrifugation (800 g, 30 sec, 4°C) and washed twice using 1 ml PBS_BA, each. 
Flow cytometry was performed on a Cyflow space system (Partec, Germany). Recorded events 
were gated for FSC/SSC of single viable cells. Fluorescence data were analyzed using the FlowJo 
software. 
Dissociation experiments were performed as described (Tamaskovic et al. (2012)). In 
brief, aliquots of 1 × 106 cells were preincubated with DARPin-AlexaFluor488-conjugates at 100 
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nM in PBS_BA for 1 h at room temperature. Cells were washed twice as described above and 
dissociation was allowed to proceed in the presence of unlabeled DARPin for the times indicated 
shaking at room temperature, followed by washes and flow cytometry measurements as 
described above. 
 
7.4 Cell viability assays (XTT assays) 
BT474 cells were seeded at a density of 10,000 cells/cm2 in 96-well-plates (Nunc). After 24 h, 
DARPins (or trastuzumab as control) were added and cells were incubated for another 72 h. 
Cells were then incubated with 50 µl/well 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT; Roche) for 4h at 37°C. Absorbance was measured at 450 nm 
and expressed as percentage of the untreated controls. 
 
7.5 Expression in insect cells 
Recombinant HER2-ectodomains carrying an N-terminal melittin signal sequence and an N-
terminal His6 tag were expressed in Spodoptera frugiperda (Sf9) cells. Baculoviruses for 
infection of Sf9 cells were generated using the Multibac system as described (Fitzgerald et al. 
(2006)). Sf9 cells were grown to a density of 4  106 cells/mL and co-infected with the 
respective virus at a MOI of 1. 72 h post infection, cells were harvested by centrifugation 
(30 min, 5000 g, 4°C) and the cleared medium was subjected to immobilized metal ion affinity 
chromatography (IMAC) purification with Ni-NTA Superflow (Qiagen) purification resin.  
 
7.6 X-ray crystallography 
HER2_I and HER2_IV were expressed and purified as described above. After preincubation with 
DARPins 9_26_Mut5, 9_29_Mut5 or G3 at equimolar concentrations, complexes were purified via 
size exclusion chromatography on a Superdex 200 HiLoad 16/60 column equilibrated with 
TBS150 (PBS, 150 mM NaCl). Eluted protein was concentrated to 14 (9_26/HER2_I), 8 
(9_29/HER2_I) or 9 (G3/HER2_IV) mg/ml using centrifugal concentrators (Millipore). Crystals 
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of the complexes formed in sitting drops mixed with two parts protein solution and one part 
mother liquor. The mother liquor contained 0.2 M NaCl, 0.1 M phosphate citrate (pH 4.2) and 
20% PEG 8000 for 9_26/HER2_I; 0.2 M ammonium acetate (pH 5.6), 0.1 M sodium citrate, 30% 
(w/v) PEG 4000 for 9_29/HER2_I or 0.05 M succinic acid and 29% ammonium sulfate (pH 4.0) 
for G3/HER2_IV, respectively. Crystals grew within three days (9_29/HER2_I), three weeks 
(9_26/HER2_I) or four weeks (G3/HER2_IV), respectively. They were then transferred to a cryo-
protectant solution containing 20% glycerol. Data were collected using the PILATUS 2 M 
detector system on the PXIII beam line at the Swiss Light Source (Paul Scherrer Institute, 
Villigen, Switzerland) and processed using the program XDS (Kabsch (2010)). The structures 
were solved by molecular replacement using PHASER MR (McCoy et al. (2007)) from within the 
CCP4 package (CCP4 (1994)). Model building was carried out by using the program 
COOT(Emsley et al. (2010)). The structures were refined using PHENIX (Adams et al. (2010)). 
Stereochemical properties were analyzed with MOLPROBITY (Davis et al. (2007)) and structure 
figures were generated in PYMOL (http://pymol.org). 
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Figure 1: Biological activity of DARPin constructs  
(A) Dissociation of monovalent and bispecific DARPins from the surface of BT474 cells. Median 
fluorescence intensities (MFI) of fluorescently labeled DARPins bound to the BT474 cell surface 
are plotted as a function of dissociation time. See Table S1 for fitted off-rates, Fig. S1A for ELISA 
epitope mapping and Fig. S2B for binding competition on intact cells. (B-G) Inhibition of cell 
proliferation was determined by XTT assays with HER2-addicted BT474 cells. Cells grew for 
72 h in the presence of different concentrations of DARPins. Bispecific DARPins 6_20_G and 
9_20_G decreased the cell viability, whereas the reversely oriented constructs G_20_6 and 
G_20_9 did not. Cells that grew in the presence of 100 nM trastuzumab and cells growing 
without treatment served as control (CTRL). (B) Biological effects of monovalent DARPins. 
(C) Bispecific DARPins containing a non-binding DARPin. Off7 is a control DARPin recognizing 
maltose binding protein. G_20_G is homobivalent and contains twice the DARPin G3. 
(D) Biological effects of bispecific anti-HER2-DARPins on HER2-addicted BT474 cells and (E) on 
non-overexpressing MCF7 cells. (F) Effect of linker length on biological activity of bispecific 
DARPins in 9_x_G orientation or (G) in G_x_9  orientation. 
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Figure 2: Structures of  
DARPin:HER2 complexes: 
 DARPins 9.29 (red) and G3 (orange) 
in complex with HER2 subdomain I 
and IV, respectively (blue). HER2 
residues having at least one non-
hydrogen atom within 5.0 Å of a 
non-hydrogen atom of the DARPin 
(i.e., epitope residues) are shown in 
yellow, those with atoms within 5.0 
Å of the DARPin (solvent excluding 
contacts) in orange, and those with 
atoms within 3.6 Å (Van-der-Waals 
contacts) in red. (A, B, C) DARPin 
9_29 in complex with HER2_I.  
(D, E, F) DARPin G3 in complex with 
HER2_IV. (C, F) Close-up of epitope 
and paratope: side chains of 
residues having at least one non-
hydrogen atom within 5.0 Å of a 
non-hydrogen atom of HER2 
(paratope residues) are shown in 
stick representation. See Fig. S2 for 
superpositions of the HER2 
subdomains on the full-length 
HER2_ECD, Table S5 for rmsd-
values. 
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Figure 3: Superposition of HER2 complexes on the full-length HER2 ECD:  
DARPin 9_29 (PDB ID: 4HRL, red) is binding to subdomain I, DARPin G3 (PDB ID: 4HRN, orange) 
to subdomain IV. In addition, Fab fragments of the therapeutic antibody trastuzumab 
(Herceptin®, PDB ID 1N8Z, pale green), its derived HER2/VEGF dual specific variant bH1 (PDB 
ID: 3BE1, forest green) and pertuzumab (Perjeta®, PDB ID: 1S78, lime) are shown, as well as 
Fab 37 (PDB ID: 3N85, pale yellow), scFv chA21 (PDB ID: 3H3B, sand) and Z-domain affibody 
zHER2 (PDB ID: 3MZW). 
 
 
Figure 4: Comparison of DARPin 9_26 and 9_29 complexes with HER2-I: 
(A) Superposition of the HER2_I:DARPin 9_29 complex structure (HER2_I: dark blue, 9_29: 
purple) onto the HER2_I:DARPin 9_26 complex structure (HER2_I: pale blue, 9_26: magenta). 
The two structures were superimposed by a least-squares fit of the Cα positions of HER2_I 
residues 21-96 and 116-152 (rmsd 0.53 Å). Unliganded DARPin 9_26 (2.9 Å resolution, pale 
pink) was superimposed on the DARPin in the HER2_I:9_26 complex. A one residue deletion in 
the second loop of DARPin 9_29 is indicated by (*). (B) Sequence differences between DARPins 
9_29 (dark blue) and 9_26 (pale blue). DARPin 9_26 was superimposed on DARPin 9_29 in the 
HER2_I:DARPin 9_29 complex structure. Side chains of conserved paratope residues (blue) and 
divergent DARPin residues (9_29, red; 9_26, orange) are shown in stick representations. (See 
Fig. S3 for a sequence alignment) 
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Figure 5: Distances between DARPin N- and C-termini  
(A) For bivalent binding to a HER2 monomer, the linker in a 9_x_G construct would need to span 
a distance of 130 Å (solid line), with enough slack added to wrap around HER2. In a G-x-9 
constructs, the two termini would need to span 90 Å (broken line). (B) To bind to a HER2 
monomer in a pseudo-tethered conformation, 70 Å (9_x_G construct) or 95 Å (G_x_9 construct) 
would have to be bridged. (C, D) To connect two DARPins bound to the same side of a HER2 
dimer, 80 Å would have to be bridged by a 9_x_G construct, 70 Å by a G_x_9 construct. (C) and 
(D) show the same dimer, rotated by 90° around the y-axis. Linker lengths in the various 
bispecific DARPins vary from 16.5 Å (9_5_G) to 132 Å (9_40_G). assuming a fully extended 
conformation (Fig. S4). 
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Figure 6: Models of full-length HER2 complexed by monovalent or bispecific DARPins.  
A model of the complete structure of HER2 in complex with the two DARPins 9_29 and G3 was 
generated as described in the SI Text. (A, B, E): Unlinked DARPins 9_29 (red) and G3 (orange) 
are modeled to bind to putative HER2 homo- and heterodimers and are predicted to not 
interfere with receptor dimerization. (C,D,F,G): Bispecific DARPins with short linkers can only 
crosslink two HER2 molecules if domain I is brought closer to the membrane through binding of 
the DARPin. (D, G): Domain I is brought closer to the membrane by pivoting the rigid 
extracellular domain (ECD) around a point in a short flexible peptide between the last disulfide 
bridge in domain IV and the start of the transmembrane helix. This would allow bispecific 
DARPin 9_5_G to bind two HER2 molecules with ECDs in the open conformation found in all 
structures. (C,F): Alternatively, a rotation around the pivot point utilized in the transition 
between open and tethered conformation (Arg 317) of other ErbB members would yield a 
pseudo-tethered conformation that brings domain I closer to the membrane and allows 
bispecific DARPin 9_5_G to crosslink two HER2 molecules with ECDs in (putative) tethered 
conformation. Both models (B/F and C/G) enforce a large distance between the kinase domains, 
and both prevent further dimerization by the strong tilt of dimerization interfaces and/or 
making the dimerization loop inaccessible. Both models would also be compatible with daisy-
chaining, forming higher order oligomers. 
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(subsequent page) Fig. S1: Sequence and binding specificity of DARPins 
(A) ELISA of HER2 binding DARPins 9_26, 9_29 and G3. The respective DARPins were tested for 
binding to the immobilized target proteins HER2_I-IV, HER2_I or HER2_IV, respectively. 
(B) Sequence of ELISA targets. HER2_I-IV contains the entire extracellular part of HER2, 
whereas HER2_I and HER2_IV denote the respective single domains, and the sequences are given 
underneath. The N-glycosylation sites (highlighted in red) were mutated (N→D) for 
crystallization. (C, D) Competition experiments using flow cytometry with AlexaFluor488-
conjugated HER2-binders. BT474 cells were incubated with the respective fluorescently labeled 
HER2 binder at 100 nM concentration, either without (solid lines) or with (dotted lines) prior 
preincubation of the cells with the indicated non-labeled competitor at 1 µM concentration. 
(C) DARPins, (D) trastuzumab control. 
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(subsequent page) Fig. S3: Sequence comparisons of ErbB domains and of DARPins 
(A, B) Sequences of HER2_I and HER2_IV constructs in comparison to the sequences of HER1, 
HER3 and HER4. Residues that are identical to the HER2 sequence are shown in black on white 
background, sequence differences as white letters on black background, the cysteine residues on 
yellow background. HER2_I includes the first two interlocked disulfide bonds of the Cys-rich 
HER2_II. HER2 residues having at least one non-hydrogen atom within 5.0 Å of a non-hydrogen 
atom of the DARPin are considered part of the epitope and highlighted by a red background. 
(C) Sequences of DARPins G3, 9_26 and 9_29. DARPin residues having at least one non-hydrogen 
atom within 5.0 Å of a non-hydrogen atom of HER2 are considered part of the paratope and 
highlighted by a red background. Sequence differences between 9_26 and 9_29 are shown in 
white on blue background. "r" indicates positions randomized in the DARPin libraries, "m" 
mutations acquired by G3 during affinity maturation, improving the KD from 270 nM to 0.09 nM 
(Zahnd et al. (2007)) and "x" the mutations introduced into the C-cap to improve stability. 
Fig. S2: Conservation of HER2 
domain structures 
(A) Overlay of the HER2_I-chains 
from the two DARPin-complex 
structures (chain A from 
HER2_I:9_29 in dark blue; chain A 
and C from HER2_I:9_26 in cyan 
and light blue, respectively) with 
the same domain from HER2_ECD 
(PDB ID: 1N8Z) (black).  
(B) Overlay of HER2_IV from the 
complex structure with DARPin G3 
(chain C in orange; chain D in 
raspberry) with the same domain 
from HER2_ECD (black).  
(C) Overlay of the different X-ray 
structures of DARPin G3, either co-
crystallized with HER2-subdomain 
IV or withou target (Zahnd et al. 
(2007)). The chains found in the 
complex structure (chain A in light 
blue; chain B in cyan) are very 
similar to the known structure of 
uncomplexed G3 (black) (PBD ID: 
2JAB). See Table S5 for a complete 
list of the corresponding RMSD 
values. 
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Fig. S4: Linker length of the bivalent DARPins 
The linker was modeled in β-strand conformation to illustrate the maximal distance that could 
be bridged by such a linker. In reality, significantly longer linkers will be needed, as the mean 
end-to-end distance of a flexible polymer scales with the square root of the extended linker 
length, and the fully extended conformation of a long linker will be sampled very rarely. 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1: Fitted off-rates of mono- and bivalent DARPins 
 
DARPin koff (s-1) 
G3 
9_20_G 
G_20_9 
6_20_G 
G_20_6 
1.76 × 10-4 
8.13 × 10-5 
4.46 × 10-5 
5.12 × 10-5 
4.80 × 10-5 
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Table S2: Statistics for data collection and refinement 
 
Complex Statistics 
HER2_I/9_29 
Data collection 
Space group 
Cell dimensions, Å 
 
AU content 
VM, Å3/Da 
Resolution limits, Å 
Observed reflections 
Completeness, % 
R-merge 
I/ 
Refinement 
Resolution range, Å 
Final R-cryst, R-free, % 
Number of residues 
Number of solvent molecules 
Number of atoms 
Mean B-factor, Å2 
rmsd (bonds), Å 
rmsd (angles), ° 
Ramachandran analysis, % 
 
HER2_I/9_26 
Data collection 
Space group 
Cell dimensions, Å 
 
AU content 
VM, Å3/Da 
Resolution limits, Å 
Observed reflections 
Completeness, % 
R-merge 
I/ 
Refinement 
Resolution range, Å 
Final R-cryst, R-free, % 
Number of residues 
Number of solvent molecules 
Number of atoms 
Mean B-factor, Å2 
rmsd (bonds), Å 
rmsd (angles), ° 
Ramachandran analysis, % 
 
HER2_IV/G3 
Data collection 
Space group 
Cell dimensions, Å 
 
AU content 
VM, Å3/Da 
Resolution limits, Å 
Observed reflections 
Completeness, % 
R-merge 
I/ 
Refinement 
Resolution range, Å 
Final R-cryst, R-free, % 
Number of residues 
Number of solvent molecules 
Number of atoms 
Mean B-factor, Å2 
rmsd (bonds), Å 
rmsd (angles), ° 
Ramachandran analysis, % 
 
 
oP: P212121 
a = 46.6, b = 80.5, c = 115.1 
 =  =  = 90° 
1 complex 
2.63 
50 – 2.55 
Total 53167, unique 14553, possible 14772 
98.7 (99.4)* 
7.1 (40.7)* 
17.83 (4.01)* 
 
50-2.55 
20.22, 25.39 
331 
31 
2559 
32.99 
0.008 
1.293 
97.2/2.8/0 
 
 
 
mC: C2 
a = 138.5, b = 60.7, c = 107.2 
 = 90°,  = 118.9°,  = 90° 
2 complexes 
2.40 
50 – 3.2 
Total 37684, unique 12785, possible 13151 
97.2 (98.3)* 
7.1 (20.8)* 
14.37 (5.94)* 
 
50-3.2 
31.31, 33.94 
547 
0 
3517 
48.66 
0.004 
0.766 
88.7/9.6/1.7 
 
 
 
hR: R32 
a = 195, b = 195, c = 112 
 = 90°,  = 90°,  = 120° 
2 complex 
1.95 
50 – 2.65 
Total 120455, unique 23767, possible 23791 
99.9 (99.9)* 
4.1 (51.1)* 
26.42 (3.54)* 
 
50-2.65 
21.32, 24.59 
385 
0 
2808 
47.60 
0.009 
1.204 
94.7/4.5/0.8 
 
* Values in parentheses refer to the highest-resolution shell 
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TableS3: List of the major interaction contacts in the HER2_I/9_29 complex 
 
9_29 interaction residue 
(repeat module)* 
Chain Interacting atoms 
 (distance in Å, interaction) 
HER2_I interaction 
residue* 
Chain 
HIS 
HIS 
LYS 
LYS 
LYS 
LYS 
LYS 
GLU 
GLU 
GLU 
GLU 
ARG 
ARG 
ARG 
ASP 
ASP 
ASP 
ASP 
PHE 
PHE 
PHE 
TYR 
TYR 
TYR 
TYR 
ILE 
LEU 
LEU 
ASN 
TYR 
ASP 
7 
8 
6 
16 
16 
16 
16 
20 
20 
20 
20 
23 
23 
23 
44 
44 
44 
44 
45† 
45† 
45† 
46† 
46† 
46† 
46† 
48† 
53 
53 
56† 
78† 
79† 
(tag) 
(tag) 
 (N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(N-cap) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(2) 
(2) 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
 
 
CG-OH (3.86, pi-stacking) 
 
 
NZ-OE (3.56, H-bond) 
NZ-OE (2.44, H-bond) 
 
 
 
OE2-OH (2.51, H-bond) 
 
NE-O (3.26, H-bond) 
 
 
 
OD2-N (3.03, H-bond) 
 
N-O (2.67, H-bond) 
 
 
 
 
OH-N (3.19, H-bond) 
 
 
 
 
 
 
 
ARG 
ARG 
TYR 
LEU 
LEU 
GLU 
GLU 
ASN 
LEU 
GLU 
TYR 
ASN 
LEU 
ALA 
LEU 
LEU 
THR 
ALA 
THR 
ILE 
ASP 
LYS 
THR 
TRP 
ILE 
ALA 
LEU 
LEU 
LEU 
LYS 
LYS 
135 
135 
90 
161 
32 
87 
87 
89 
159 
87 
90 
89 
157 
158 
161 
159 
160 
158 
160 
162 
143 
148 
160 
147 
145 
158 
159 
157 
157 
148 
148 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
 
*A cutoff of 4 Å was applied for interactions. 
†Amino acids are located in a randomized position of 9_29. 
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Table S4: List of the major interaction contacts in the HER2_IV/G3 complex 
 
G3 interaction residue 
(repeat module)* 
Chain H-bond (Å) HER2_IV interaction 
residue* 
Chain 
TYR 
LEU 
TYR 
ALA 
HIS 
HIS 
ASP 
ASP 
ALA 
ALA 
ILE 
ILE 
PHE 
PHE 
PHE 
PHE 
PHE 
ILE 
ILE 
ILE 
GLY 
HIS 
GLY 
ASN 
ASN 
ASN 
ASN 
GLY 
GLY 
ASN 
 
TYR 
TYR 
LEU 
LEU 
TYR 
ALA 
HIS 
HIS 
ASP 
ASP 
ALA 
ILE 
ILE 
ILE 
PHE 
LEU 
PHE 
PHE 
PHE 
ILE 
ILE 
HIS 
PHE 
GLY 
ASN 
ASN 
ASN 
GLY 
46† 
48† 
52‡ 
56† 
57† 
57† 
77 
77 
78† 
78† 
79† 
79† 
81† 
89† 
89† 
89† 
89† 
90† 
90† 
90† 
91 
92 
122‡ 
123 
123 
123 
123 
124 
124 
125 
 
46† 
46† 
48† 
48† 
52‡ 
56† 
57† 
57† 
77 
77 
78† 
79† 
79† 
79† 
81† 
86 
89† 
89† 
89† 
90† 
90† 
92 
112 
122‡ 
123 
123 
123 
124 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(2) 
(2) 
 (2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
 (2) 
(2) 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(1) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
(2) 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
C-cap 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
 
 
 
 
ND1-OE (2.90, 3.05) 
 
 
 
N-O (2.81) 
 
 
 
 
 
 
 
 
 
 
 
O-NH (3.14) 
 
O-ND (3.46) 
 
 
O-N (3.05) 
 
 
 
OD1-N (3.27) 
 
 
 
 
 
 
 
ND1-OE (2.61, 3.61) 
 
 
 
N-O (2.85) 
 
 
 
 
 
 
 
 
 
 
 
 
O-ND (2.92) 
 
 
O-N (3.01) 
 
ASP 
GLY 
LEU 
LEU 
GLU 
GLN 
GLY 
SER 
GLY 
SER 
SER 
PHE 
PHE 
VAL 
CYS 
VAL 
TYR 
VAL 
PHE 
VAL 
ARG 
PHE 
ASN 
ASN 
VAL 
ALA 
PHE 
ASN 
ALA 
ALA 
 
GLY 
ASP 
LEU 
GLY 
LEU 
LEU 
GLU 
GLN 
GLY 
SER 
GLY 
SER 
VAL 
PHE 
PHE 
VAL 
VAL 
CYS 
TYR 
PHE 
VAL 
PHE 
PHE 
ASN 
VAL 
ASN 
ALA 
ASN 
49 
50 
25 
25 
21 
26 
50 
51 
50 
51 
51 
55 
55 
33 
54 
52 
32 
33 
12 
24 
36 
12 
34 
34 
33 
35 
55 
34 
35 
35 
 
50 
49 
25 
50 
25 
25 
21 
26 
50 
51 
50 
51 
63 
55 
55 
52 
33 
54 
32 
12 
33 
12 
55 
34 
33 
34 
35 
34 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
 
*A cutoff of 4 Å was applied for interactions. 
† Positions randomized in DARPin library. 
‡Amino acids were affinity matured (Zahnd, et al. 2007). 
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Table S5: List of RMSD(CA) values (Å) of all solved structures. The pairwise comparisons  
were calculated both for the solved structures among each other and in comparison with the 
respective PDB-entries.  
 
 HER2_I 
(1N8Z) 
HER2_I 
(9_29_C) 
HER2_IV 
(1N8Z) 
HER2_IV 
(G3_C) 
G3 
(2JAB) 
G3 
(G3_A) 
HER2_I (9_29_C) 0.491      
HER2_I (9_26_A) 0.810 0.660     
HER2_I (9_26_C) 0.794 0.623     
HER2_IV (G3_C)   0.640    
HER2_IV (G3_D)   0.678 0.242   
G3 (G3_A)     0.645  
G3 (G3_B)     0.525 0.441 
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1 Summary 
Intermolecular crosslinking of extracellular domains I and IV of ErbB2 by bi-paratopic Designed 
Ankyrin Repeat Proteins (DARPins) yields bent-down signaling-incompetent receptors, 
incapable of productive homo- or heterodimerization with any other EGFR family member. The 
ensuing dephosphorylation of both ErbB2 and ErbB3 results in a persistent attenuation of both 
PI3K/PKB and RAS/MAPK pathway, and elicits apoptosis in 2D- and 3D-cell culture models as 
well as in tumor-bearing mice via induction of the pro-apoptotic protein BIM and caspase-9. 
Furthermore, the interdomain ErbB2 trapping was shown to inhibit EGFR or ErbB3 ligand-
induced cell motility, invasion and spheroid morphogenesis. We show that the sustained 
inhibition of both pathways has overcome feedback loops which otherwise reactivate the ErbB 
signaling network, robustly eliciting apoptosis. 
 
2 Significance 
We discovered and elucidated a new mechanism of sending ErbB2-dependent tumors to 
apoptosis. By creating a trap for ErbB2, in which the receptor is bent and kinases are unable to 
interact, all signaling from ErbB2 complexes is obstructed, leading to a pan-ErbB inhibition. This 
is necessary and sufficient to elicit apoptosis in ErbB2-addicted tumors. Our novel strategy is the 
first rational approach to engineer cell-specific apoptosis based on a structurally and 
mechanistically understood principle, and without using a toxin with potential off-tumor side 
effects. Our concept can add to the arsenal of monoclonal antibodies, kinase inhibitors and toxin 
conjugates, by molecularly designing novel ErbB2-targeted therapeutics, with the potential to 
avoid resistance because of their receptor-mediated cytotoxic and not cytostatic action. 
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3 Highlights 
- Novel biparatopic proteins block productive homo- and heterodimerization of ErbB2 
- Dephosphorylation of both ErbB2 and ErbB3 triggers the OFF-switch of ErbB network 
- Sustained inhibition of both PKB and MAPK pathways and elicits apoptosis via BIM 
- Apoptosis is elicited in vivo and causes tumor regression in mouse xenografts 
 
4 Introduction 
While human epidermal growth factor receptor type 2 (ErbB2, also referred to as HER2/neu) 
occurs in 25-30% of invasive breast cancer tumors (Berger et al. (1988); Slamon et al. (1987); 
Slamon et al. (1989)), no mechanism has yet been reported to kill a tumor cell solely based on 
interfering with its signaling. Nevertheless, since ErbB2 overexpression is found in 50% of 
ductal carcinomas in situ (DCIS) – noninvasive premalignant lesions of the mammary gland (van 
de Vijver et al. (1988)) – and is present both in the primary tumor and in metastatic lesions 
(Nahta and Esteva (2006)), the high receptor levels would provide a uniquely tumor-restricted 
target. The goal of the current work is to investigate how apoptosis induction through ErbB2 can 
be made possible, without using any toxic agent.  
The extracellular domain of ErbB2 adopts a constitutively extended conformation, 
making ErbB2 the preferred heterodimerization partner for the ligand-activated receptors of the 
ErbB family. ErbB2 is thus regarded as a non-autonomous amplifier of ErbB signaling that 
enhances affinity for ligands bound by other family members, attenuates receptor ubiquitination 
and increases receptor promiscuity by engaging a broader range of signaling adapters (Harari 
and Yarden (2000); Jones et al. (2006)). ErbB2 can potentiate signaling through spontaneous 
formation of signaling-competent ErbB2 homodimers that assemble at high ErbB2 
concentrations as found in breast tumors (Cho et al. (2003); Graus-Porta et al. (1997)). When 
overexpressed, ErbB2 becomes a key regulatory element driving cell proliferation, survival, 
migration and invasiveness of cancer cells. 
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  The activated ErbB receptors trigger multiple signaling pathways (Hynes and MacDonald 
(2009)). Most activated ErbB receptor complexes utilize growth- and survival-controlling 
signaling pathways such as MAPK, PI3K/PKB, JAK/STAT and PKC, but since each receptor 
recruits a specific set of phosphotyrosine-binding effector proteins (Hause et al. (2012); Schulze 
et al. (2005)), each ErbB member predominantly activates its own downstream signaling pattern 
(Alimandi et al. (1995); Stern (2008); Wallasch et al. (1995)). For instance, within ErbB2–ErbB3 
heterodimers, the phosphorylated cytoplasmic tail of ErbB3 strongly activates the PI3K/PKB 
survival pathway, whereas phosphorylated ErbB2 powerfully signals through the ERK MAPK 
pathway. This combination of PI3K/PKB and ERK signaling strongly enhances cell proliferation 
and survival, and for this reason ErbB2/3 forms a potent oncogenic unit (Holbro et al. (2003)). 
As for many other signaling, genetic or metabolic networks, the ErbB network displays two 
steady states, i.e. bistability, with ligands transiently switching it from OFF to ON state 
(Kholodenko et al. (2010)). Importantly, pathological ERBB2 amplification maintains signaling 
by favoring ErbB2-containing receptor dimers and by evading negative feedback regulation, 
thereby fixing the ON state (Reynolds et al. (2003)). Since diseases such as cancer efficiently 
exploit key regulatory elements of the host networks (Kitano (2003)), these essential hubs could 
consequently become their ‘Achilles heels’ (Weinstein (2002)). Such a vulnerability of cancer 
cells, also referred to as ‘oncogene addiction’, may thus provide valuable opportunity for 
targeted therapy (Weinstein and Joe (2008)). In fact, knockdown of ErbB2 triggers apoptosis in 
ErbB2-addicted breast cancer cells, while barely having an effect on cells that do not 
overexpress this gene (Colomer et al. (1994); Roh et al. (2000)). The current work is aimed to 
achieving the same phenotype on the protein level. 
Monoclonal antibodies (mAbs) against ErbB2 with therapeutic efficacy target only few 
epitopes (Boyer et al. (1999); Xu et al. (1993); Yip and Ward (2002)). The humanized murine 
mAb 4D5 (trastuzumab, Herceptin®) is directed against the membrane-proximal domain IV of 
ErbB2. It specifically inhibits the growth of breast cancer cell lines addicted to the ErbB2 
overexpression by attenuation of some of the receptor downstream signaling, resulting in cell 
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cycle arrest in G1 phase (Lane et al. (2000); Neve et al. (2000); Pietras et al. (1999); Yakes et al. 
(2002)). The anti-proliferative activity of trastuzumab has been proposed to be augmented by 
antibody-mediated internalization and degradation of ErbB2 receptor (Baselga et al. (2001); 
Sliwkowski et al. (1999)) or the suppression of ectodomain cleavage, also referred to as receptor 
shedding (Anido et al. (2006); Scaltriti et al. (2007)); however, these phenomena seem to be 
confined only to a subset of tumors overexpressing ErbB2 (Le et al. (2003); Nahta and Esteva 
(2004); Nahta et al. (2004)). Therefore, other conceivable mechanisms, such as dissociation of 
the ligand-independent ErbB2–ErbB3 heterodimers (Junttila et al. (2009)), are a likely 
component of the enigmatic overall molecular action of trastuzumab.  
Another approved ErbB2-binding antibody, 2C4 (pertuzumab, Perjeta®), binds adjacent 
to the domain II dimerization arm, thereby disturbing the heterodimerization of ErbB2 with the 
other ligand-bound EGFR-family members (Franklin et al. (2004)). Pertuzumab thus abrogates 
solely the ligand-stimulated growth, independent of ErbB2 overexpression. In fact, pertuzumab 
failed to show significant effects on the growth of ErbB2-overexpressing breast cancer cells in 
vitro (Nahta et al. (2004); Tanner et al. (2004)), implying that the in vivo effects of pertuzumab 
are critically potentiated by other cytotoxic mechanisms.  
Since none of the known ErbB2-targeting mAbs is sufficient to trigger a robust cell death 
response in single-agent formats, they cannot fully exploit the addiction to ErbB2 as a fragile 
point for therapeutic intervention. In addition, the intra-ErbB pathway compensation through 
feedback loops and other mechanisms rapidly neutralizes the perturbation caused by the 
approved antibodies, thereby leading to an acquirement of resistance against mAb treatment 
(Garrett and Arteaga (2011); Hynes and MacDonald (2009)). 
This issue has fostered the development of toxin-conjugated ErbB2-binding molecules that 
might give rise to a response in patients who failed trastuzumab therapy (Burris et al. (2011)).  
Trastuzumab emtansine (T-DM1) (Kadcyla®), a maytansinoid conjugate, is thought to be 
endocytosed with the slow internalization and recycling rates intrinsic to ErbB2 and thus to 
release the toxin. In a phase I clinical study thrombocytopenia was found to be a key dose-
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limiting toxicity (Krop et al. (2010)). In the pivotal phase III study, median progression-free 
survival was improved from 6.4 to 9.6 months, when comparing T-DM1 to capecitabine 
(Xeloda®) plus lapatinib (Tykerb®) (Verma et al. (2012)), leading to recent FDA approval. 
These encouraging data stimulate the search for novel mechanisms of action, which may pave 
the way for agents not requiring a conjugated toxin. 
A series of tyrosine kinase inhibitors (TKIs) blocking the ErbB intracellular kinase 
domains have also been developed, comprising both reversible and irreversible inhibitors with 
specificity ranging from monospecific EGFR inhibitors (gefitinib, erlotinib), dual-specificity EGFR 
and ErbB2 inhibitors (lapatinib, neratinib, afatinib), and broad-spectrum inhibitors (canertinib, 
JNJ-26483327) (Alvarez (2010)). TKIs elicit stronger biological responses in vitro than the highly 
specific yet less potent ErbB2-targeting antibodies (Geyer et al. (2006); Gomez et al. (2008)). 
However, the responses tend to be short-lived because of frequent induction of compensatory 
RTK signaling or activation of feedback loops in downstream signaling (Sergina et al. (2007)). 
Over the duration of the clinical treatment, mutations in the kinase itself or in downstream 
molecules may occur. 
In this study, we aimed at designing and mechanistically dissecting new agents that can 
completely inhibit the downstream signaling of ErbB2 up to the point of causing cell death in 
ErbB2-addicted breast cancer cells. High-affinity ErbB2-specific designed ankyrin repeat 
proteins (DARPins) (Binz et al. (2004); Boersma and Plückthun (2011)), recognizing distinct 
epitopes on extracellular domains I and IV (Steiner et al. (2008); Zahnd et al. (2007)) as 
determined by crystallography (Jost et al., 2013, cf. Chapter 3), were combined in bispecific 
constructs, composed of two different DARPins, designed to be in a particular orientation and to 
be connected by a very short flexible linker. The individual monomeric DARPins do not directly 
interfere with ErbB2 dimerization, nor do the bispecific constructs induce receptor 
internalization and downregulation. Instead, crosslinking of ErbB2 monomers by these 
bispecific DARPins separates the monomers by trapping them in a dimerization-incompetent 
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state, preventing both homo- and heterodimerization. This inhibition is highly dependent on the 
geometry of the bispecific constructs.  
Based on the X-ray structures of the complexes of the individual DARPins described in 
detail in an accompanying study, we have formulated models of such inhibited states (Jost et al., 
2013, cf. Chapter 3). These DARPin constructs, highly cytotoxic only for ErbB2-addicted cells, 
rely on a simultaneous and sustained inhibition of both the PI3K/PKB and RAS/MAPK signaling 
pathways, thus enforcing the OFF-state in the oncogene-addicted network.  Thus, this strategy 
constitutes a unique pan-ErbB targeting approach, as it prevents signaling-competent ErbB2 
homodimers, as well as ligand-bound and unliganded heterodimers with EGFR or ErbB3, 
thereby shutting down virtually the whole ErbB signaling network in ErbB2-addicted cancer 
cells. 
 
5 Results 
DARPins are synthetic binding protein derived from ankyrin repeat proteins, developed to 
expand the range of formats and applications beyond what is possible with immunoglobulin-
based proteins (Boersma and Plückthun (2011); Forrer et al. (2003)). Various DARPins binding 
to the ectodomain of ErbB2 and not crossreacting with other members of the EGFR superfamily 
were selected and affinity-matured by ribosome display and phage display (Steiner et al. (2008); 
Zahnd et al. (2006); Zahnd et al. (2007)). We tested the collection of monovalent anti-ErbB2 
DARPins in cell viability assays, but found no growth-inhibitory activity comparable to 
trastuzumab or pertuzumab (cf. Chapter 2). However, various bivalent and bispecific targeting 
molecules of varying flexibility, orientation and epitope specificity were constructed and 
screened, and in particular, binders targeting ErbB2 in a bi-epitopic manner, obtained by fusing 
two DARPins with distinct specificities, showed significant anti-proliferative and pro-apoptotic 
activity.  
After comprehensive scrutiny and validation in tumor cell culture models, which will be 
presented elsewhere, the most effective construction scheme proved to be a fusion of two 
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DARPins recognizing different domains of ErbB2, domain I and domain IV, connected through a 
very short flexible (Gly4Ser) linker, with the domain I binder at the N-terminus and the 
domain IV binder at the C-terminus (Jost et al., 2013, cf. Chapter 3) (Fig. S1A). The individual 
(monomeric) DARPins in these constructs do not interfere with ErbB2 signaling. Molecular 
modeling based on the crystal structures of the DARPins in complex with the recognized ErbB2 
domains (Jost et al., 2013, cf. Chapter 3) and on the full-length extracellular ErbB2 structures 
demonstrated that intramolecular binding would not be geometrically possible, not even in a 
hypothetical highly strained ErbB2 molecule.  
 
5.1 Bispecific DARPins crosslink two HER2 Molecules on the Surface of BT474 Cells 
From the markedly lower dissociation rate constants of the bispecific DARPins on BT474 cells 
(Fig. S1D, S1E), compared to their respective monovalent DARPin constituents, we conclude 
that in the bispecific anti-ErbB2 DARPins both DARPin domains are engaged in binding. Almost 
the same number of bivalent DARPins as monovalent DARPins can be bound (Fig. S1E).  
To directly confirm intermolecular binding on cells, we performed crosslinking experiments on 
the surface of BT474 cells (Fig. 1C). In the absence of DARPin, a mixture of ErbB2 monomers 
and dimers is detected. Monomeric DARPins get crosslinked to an ErbB2 molecule, without 
changing the fraction of ErbB2 dimers. In contrast, after preincubation with bispecific DARPins, 
we found strong enrichment of the dimer band, indicating two molecules of ErbB2 being linked 
by the bispecific DARPin.  Immunoblots clearly revealed that the high MW bands contain both 
ErbB2 and DARPins. 
 
5.2 Molecular Models of Bispecific DARPins in Complex With Full-Length ErbB2 
Explain their Activity 
In the most active bispecific DARPins (Fig. 1A), an N-terminal DARPin (either 926 or 929) 
(Steiner et al. (2008)), binding to ErbB2 domain I, is linked to a C-terminal DARPin, binding to 
domain IV, (either G3  (Zahnd et al. (2007)) or H14 (Steiner et al. (2008))). The constituent 
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DARPins are described in the Supplemental information. X-ray crystallography (Jost et al., 
2013, cf. Chapter 3) has shown that the domain I-binding DARPins 929 and 926 recognize the 
same epitope, while the epitopes of G3 and H14 on domain IV overlap, but are not identical: both 
DARPins compete with each other , but only H14 competes with trastuzumab (Jost et al., 2013, 
cf. Chapter 3).  
While all 4 bispecific combinations of N-terminal domain I and C-terminal domain IV 
binders lead to highly active molecules, we concentrate here on two of them, 926-Linker-G3 
(abbreviated 6-L1-G) and 929-Linker-H14 (abbreviated 9-L1-H), where the linker length (L1) 
indicates a length of one GGGGS unit.  
The main conclusion drawn from the crystal structures and the detailed atomic modeling 
(Jost et al., 2013, cf. Chapter 3) is that the bivalent DARPins cannot bind to both domains within 
one ErbB2 molecule, nor can they link two ErbB2 molecules in the canonical back-to-
conformation in an orientation that would enable signaling-competent homodimers. Instead, 
two ErbB2 molecules must be bridged in such a manner that domain I of one monomer is 
brought close to domain IV of the other monomer, thereby preventing the upright orientation of 
ErbB2 at the cell surface (Fig. 1B).  
This DARPin-linked arrangement of two ErbB2 molecules has two critical consequences 
that prevent ErbB2 receptor activation: (i) due to the constraints posed by the membrane 
anchoring, the transmembrane helices of the two ErbB2 monomers crosslinked by the bispecific 
DARPin are forced apart (Fig. 1B), as the large extracellular domains bend over, and (ii) the 
formation of signaling-competent homo- or heterodimeric back-to-back complexes (Garrett et al. 
(2003)), mediated by the dimerization loop in domain II, is prevented because proximity of the 
membrane obstructs access to the dimerization interface of the DARPin-bound bent ErbB2 
monomers. 
By geometrically separating the TM membrane and thus the juxtamembrane peptide 
through the bispecific DARPins, the kinases will neither be able to homo- nor heterodimerize. As 
shown in elegant studies from Kuriyan and coworkers (Arkhipov et al. (2013); Endres et al. 
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(2013)), the kinase domains of the EGFR family have only very low affinity for each other, and 
their mutual interaction and subsequent activation to form a signaling-competent asymmetric 
dimer is mediated by an interaction of the juxtamembrane regions, located between TM and 
kinase domain. This interaction, in turn, is only possible if the TM domains dimerize in a 
conserved GXXXG motif located near the cytoplasmic end, and this is prevented in our approach. 
While the literature lacks any structural evidence for the existence of a tethered form of 
ErbB2, it cannot rigorously be excluded that the described DARPin crosslinking would not 
induce it. In this case the pivot point would very likely be at the boundary between domain II 
and III (around residue R317), again described in detail elsewhere (Jost et al., 2013, cf. 
Chapter 3). Nonetheless, the conclusion about the inability of the TM domains to interact via the 
C-terminal GXXXG dimerization motif, the inability of the juxtamembrane peptides to interact, 
and consequently, the lack of signaling-competent kinase dimer formation as a function  of 
bispecific DARPin binding holds true just the same.  
Mixtures of monovalent or mixtures of homo-bivalent DARPins are inactive (Fig. S1AB), 
and the anti-proliferative activity of bispecific DARPins is highly dependent on the DARPin 
epitope, their order within the construct and the length of the flexible peptide linker (Fig. S1C), 
thus confirming the concept of a geometric induction of the signaling-incompetent ErbB2 
conformation by the active DARPins. 
In summary, based on the crystal structures of the DARPin-ErbB2 complexes and the 
detailed atomic modeling (Jost et al., 2013, cf. Chapter 3), we deduce that bispecific DARPins 6-
L1-G and 9-L1-H stabilize a form of ErbB2 which is devoid of signaling through its own kinase, 
can no longer trans-phosphorylate other ErbB2 molecules, nor ErbB3 molecules, nor be trans-
phosphorylated from other ErbB receptors.  
We now connect these structural conclusions with experimental receptor deactivation 
and with the induction of apoptosis in ErbB2-addicted cancer cells. 
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5.3 Anti-proliferative Activity of Bispecific DARPins In Vitro 
We have evaluated the anti-proliferative activity of bispecific DARPins by means of XTT cell 
proliferation assays on a panel of ErbB2-overexpressing breast cancer cell lines that were 
previously described as trastuzumab-sensitive (BT474, HCC1419, HCC2218, SKBR3, AU565, and 
ZR75-30). All ErbB2-dependent cell lines without exception showed high sensitivity to the 
bispecific DARPins 6-L1-G and 9-L1-H (Fig. 2A), decreasing the number of viable cells over four 
days of treatment, while trastuzumab at best maintained it, and pertuzumab showed an even 
smaller response. The IC50 values were in a similar range (200-500 pM) for the DARPins and the 
antibodies, thereby confirming the high potency of these bivalent ErbB2 binders. The activity is 
highly specific and could be completely reverted by competition with soluble ErbB2_ECD 
(Fig. S1F). 
The modest responses elicited by pertuzumab are expected due to the fact that the cells 
were grown without adding an external ErbB3 ligand. Notably, the anti-proliferative activity of 
bispecific DARPins also exceeded the activity of combined trastuzumab and pertuzumab in 
BT474 cells (Fig. S1G). In agreement with our model, the combination of either antibody with a 
bispecific DARPin leads to a reduction of the DARPins’ anti-tumor activity (Fig. S1H).   
In addition, we used MDA-MB-361 breast cancer cells with an activating mutation in the 
catalytic subunit alpha of PI3K (PIK3CA) (Kao et al. (2009)), which confers resistance to 
trastuzumab. The response of MDA-MB-361 (Fig. 2B) and other ErbB2-overexpressing cell lines 
with PIK3CA mutations (data not shown) is markedly lower for all treatments in general. 
Nonetheless, residual activity of DARPins 6-L1-G and 9-L1-H still brought about partial growth 
inhibition; however, without occurrence of cell death.  
To assess the ability to induce reproductive cell death, the anti-proliferative activity of all 
compounds was further monitored by clonogenic assays in BT474 cells. As shown in Fig. 2C, the 
4-day treatment with the bispecific DARPins resulted in an almost complete inhibition of the 
outgrowth of colonies, again markedly exceeding the ability of trastuzumab to reduce the 
clonogenic ability of this cell line. Moreover, the extent of reproductive cell death was several-
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fold higher than the actual death rates as determined by viability measurements, pointing to 
infliction of irreversible cell damage by the bispecific agents. 
 
5.4 Induction of G1 Arrest and Apoptosis 
As shown in Fig. 3A, upon treatment with 6-L1-G, 9-L1-H and trastuzumab, but not pertuzumab, 
the cell cycle profiles of BT474 cells exhibited a G1 phase accumulation with a concomitant 
reduction of cells passing to S and G2/M phases. This is also found for most other examined 
ErbB2-dependent cell lines (Fig. S2A). A quantitative fitting of the cell cycle histograms by the 
Dean-Jett-Fox algorithm (Fig. 3B) confirmed correlation between the accumulation of cells in G1 
phase and the growth inhibition observed by means of XTT proliferation assays (Fig. 2A). 
Importantly, only for the cytotoxic constructs 6-L1-G and 9-L1-H, but not for 
trastuzumab, an additional peak with sub-G1 DNA content was observed (Fig. 3A and 3C), 
which is a typical sign of apoptosis. Thus, these findings prompted us to perform analyses aimed 
at direct characterization of further hallmarks of apoptosis, comprising both early and late 
apoptotic markers. 
First, we analyzed the ErbB2-dependent breast cancer cells in TUNEL assays to 
quantitatively detect DNA as a result of apoptosis. As shown in Fig. 3D and Fig. S3B, the 
treatment with DARPins 6-L1-G and 9-L1-H resulted in an extensive TUNEL staining in the range 
of 30-50% in BT474, HCC1419, and HCC2218 cells (Fig. 3 D-E), while the TUNEL-positive 
populations were 15-20% in SKBR3, AU565 and ZR75-30 cells (Fig. S3B). Because of escape of 
post-apoptotic cell debris from TUNEL detection, the measurement is prone to some 
underestimation, especially if apoptosis has progressed far in very sensitive cells. Importantly, in 
all cell lines the extent of apoptosis induction by the bispecific DARPins surpassed the controls 
by almost two orders of magnitude; the antibodies trastuzumab and pertuzumab were only 
slightly above the background values of mock-treated cells. 
 Second, we probed the cells with Annexin V in conjunction with propidium iodide 
staining at low concentrations, monitoring early apoptotic flipping of phosphatidylserine and an 
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augmented permeability of cell membranes at late stages of cell death, respectively. Again, we 
detected an increase in populations of cells positive for either of these markers or both, 
proportional to the cytotoxic activity measured in XTT assays of the interrogated constructs 
(Fig. 3F).  
Third, we monitored activity of caspases and cleavage of their targets. To distinguish 
between intrinsic and extrinsic apoptotic pathways, we inspected initiator caspases casp-9 and 
casp-8 (Fig. 3G) (Danial and Korsmeyer (2004)). Both bispecific DARPins 6-L1-G and GDC-0941 
strongly activated casp-9, as did the PI3K inhibitor GDC-0941, while only TRAIL (TR10 ligand) 
was causing activation of casp-8. On the other hand, the effector caspases casp3/7 became 
activated, as expected, by all apoptotic stimuli irrespective of the source. We thus conclude that 
bispecific anti-ErbB2 DARPins, despite being nota bene extracellular ligands, activate the 
intrinsic apoptotic pathway.  
Forth, we analyzed crucial players involved in the execution phase of apoptosis. As 
shown in Fig. 3H, there was a rapid and intense degradation of the casp-3 target poly-(ADP-
ribose)-polymerase (PARP) observed in all cell lines upon treatment with the bispecific 
DARPins, whereas only a partial response was recorded for trastuzumab in a small subset of the 
examined cell lines. Furthermore, the upregulated expression of the BH3-only pro-apoptotic Bcl-
2-like protein 11 (BIM), also known as master regulator of apoptosis downstream of EGFR-
family receptors (Danial (2007); Ewings et al. (2007); Faber et al. (2011); Marani et al. (2004); 
Tanizaki et al. (2011)), reflected again the high potency of bispecific DARPins to unleash 
apoptosis.  
In summary, we conclude that the cytotoxic activity of ErbB2-biepitopic DARPins is 
mainly attributable to a potent induction of apoptosis in ErbB2-addicted tumor cells.  
 
5.5 Anti-Tumor Activity of Bispecific DARPins In Vivo 
To test the constructs in vivo, we first extended their in vivo half life by PEGylation (Zahnd et al. 
(2010)). To clearly distinguish the DARPin-mediated anti-tumor activity from unrelated effects, 
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e.g. complement or ADCC responses mediated by an antibody Fc domain, we have on purpose 
omitted such fusions and chosen PEGylation, even though its half-life extension may not be as 
powerful as the half-life extension provided by e.g. the fusion to an Fc or to another DARPin 
binding to serum albumin. 
We thus generated and tested a series of bispecific DARPins with a unique cysteine 
residue at either the N- or C-terminus, which could be subsequently derivatized by a PEG-
maleimide of 40 kDa (Tamaskovic et al. (2012)). We found that the bispecific DARPins modified 
with PEG40 right behind the N-terminal his tag did not reduce the maximal anti-proliferative 
activity on ErbB2-addicted cells in vitro (Fig. S3A), nor the binding on cells (data not shown).  
These constructs were termed 6-L1-G_N_PEG and 9-L1-H_N_PEG. 
For bioimaging studies, the PEGylated DARPins were additionally decorated with the far 
red dye Alexa Fluor 680 or the infrared fluorophore IRdye800, which were selectively attached 
to the N-terminal amino group (Tamaskovic et al. (2012)). The in vivo half-lives of these 
constructs were determined as 21.2 h (AUC 15.3 µmol/l·h) for 6-L1-G_N_PEG and 7.0 h 
(AUC 5.8 µmol/l·h) for 9-L1-H_N_PEG, being at least two orders of magnitude higher than the 
values of similar underivatized counterparts (Zahnd et al. (2010)). As shown in Fig. 4A, the 
PEGylated DARPins became efficiently enriched at the tumor site.  
We next examined whether the PEGylated bispecific DARPins show anti-tumor activity in vivo on 
BT474 xenografts. BT474 cells were implanted orthotopically in the mammary fat pad of SCID 
beige mice. After tumor establishment (about 2-3 weeks), the mice were treated with 20 mg/kg 
doses three times per week during a three-week period, and the tumor volume was monitored 
during and after treatment. As shown in Fig. 4B, both bispecific PEGylated DARPins caused 
tumor regression, while the non-targeted PEGylated bivalent DARPin (vehicle control) did not 
show an effect, similar to the PBS control. Although complete tumor remission could not be 
achieved and some post-treatment tumor regrowth was evident, likely due to the insufficient 
half-life of the PEGylated constructs, the obtained data unequivocally confirm the anti-tumor 
activity of bispecific DARPins in vivo.  
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IHC analysis of sections from the treated tumors demonstrated that the achieved 
therapeutic effect in vivo was due to apoptotic cell death, as manifested by an intense TUNEL 
staining, formation of apoptotic bodies and detection of a caspase-3 proteolytic fragment in 
tumor tissue (Fig. 4C). Furthermore, treatment with PEGylated bispecific DARPins resulted in 
substantially smaller tumors with large areas replaced by fibrous myxoid stroma 
within (Fig. 4C). These data confirm that the same mode of action of the bispecific DARPins is 
operative in vivo and in vitro. No weight loss or any other adverse symptom was detected in the 
treated mice, demonstrating that repeated doses of bispecific PEGylated DARPins were well 
tolerated, and similar data were obtained in naïve animals (data not shown). Further 
modifications of the molecular targeting format, such as fusions to serum albumin or Fc domains 
or tightly binding DARPin mediating these interactions, are expected to yield reagents with 
significantly improved PK/PD profile and higher specific cytotoxicity. 
 
5.6 Active Bispecific DARPins do not Influence ErbB2 Internalization 
Receptor internalization coupled to degradation is considered to be a process that robustly 
attenuates oncogenic signaling by targeting surface receptors for lysosomal degradation, even 
though for ErbB2, this is not a likely mechanism (see below). We investigated whether bispecific 
DARPins influence the expression level or the internalization rate of the ErbB2 receptor. As 
shown in Fig. 6A,D, the total expression level of ErbB2 did not change up to 72 hours post-
treatment in BT474 or SKBR3 cells, nor did it significantly alter in the other cell lines 
overexpressing ErbB2 (Fig. 6G). Direct probing of ErbB2_ECD on intact cells confirmed that 
ErbB2 receptor remained expressed on the cell surface during the whole time span of 
treatment (Fig. S3B-C).  
Most importantly, an examination of receptor trafficking after incubation with bispecific 
DARPins or with a mixture of the inactive monovalent counterparts did not uncover any 
substantial differences. Neither an increased internalization rate nor attenuated endosomal 
recycling was found for the DARPins with high anti-tumor activity, suggesting that the 
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cytotoxicity is not caused by such mechanisms (Fig. S3D-E). Taken together, these findings 
imply that the bispecific anti-ErbB2 DARPins achieve their cytotoxic activity by other 
mechanisms, e.g. through interference with ErbB2 downstream signaling, but not by modulating 
receptor trafficking. This is in contrast to what we and others recently reported for binders 
targeting the EGF receptor (Boersma et al. (2011); Hackel et al. (2012)).  
These findings are consistent with studies showing that the ErbB2 expression level 
remains unaffected by trastuzumab treatment (Junttila et al. (2009)), and that trastuzumab does 
not accelerate the internalization of ErbB2 (Hommelgaard et al. (2004)). It is noteworthy that 
the internalization rate of ErbB2 is inherently low (Hendriks et al. (2003)).  
 
5.7 Inhibition of ErbB2 Heterodimerization by Bispecific DARPins in the Presence and 
Absence of Ligands 
Since our bispecific DARPins targeting ErbB2 potentially affect the interaction of ErbB2 with 
ErbB3, we analyzed receptor dimerization after DARPin treatment. We stimulated ErbB2–ErbB3 
heterodimerization with the ErbB3 ligand heregulin-β1 (HRG) (Hynes and Lane (2005); Yarden 
and Sliwkowski (2001)) and analyzed heterodimerization in the presence or absence of ligand 
stimulation in BT474 cells by CoIP after crosslinking the cell surface receptors with thiol-
cleavable 3,3´-dithiobis[sulfosuccinimidylpropionate] (DTSSP), subsequent reduction and 
determination of the amount of ErbB2 and ErbB3 by immunoblotting. 
 Heterodimerization of ErbB2–ErbB3 is strongly stimulated by HRG in BT474 
cells (Fig. 5A). Trastuzumab did not interfere with ErbB2–ErbB3 heterodimerization upon HRG 
addition, while pertuzumab did effectively inhibit ErbB2–ErbB3 heterodimerization under these 
conditions, consistent with previous findings (Junttila et al. (2009)). Bispecific DARPins 
effectively inhibit ErbB2–ErbB3 heterodimerization, both in the presence and absence of HRG 
stimulation (Fig. 5A).  
The analysis of ErbB2/EGFR heterodimerization was performed analogously with SKBR3 
cells using the EGFR ligand EGF, since SKBR3 cells express significantly more EGFR than BT474 
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cells, while both are ErbB2 overexpressing cell lines and are highly dependent on ErbB3 
expression (Lee-Hoeflich et al. (2008)). As expected, we found stimulation of ErbB2/EGFR 
heterodimerization by EGF addition in SKBR3 cells (Fig. 5B). Bispecific DARPins strongly 
reduced ErbB2/EGFR heterodimerization in the presence or absence of EGF, while the effects of 
trastuzumab and pertuzumab were not pronounced (Fig. 5B).  
 
5.8 Bispecific DARPins Retain Anti-proliferative Activity in the Presence of Heregulin  
Addition of HRG stimulated the growth of BT474 control cells by only 20% (Fig. 5B). In the 
presence of HRG, trastuzumab loses its anti-proliferative activity completely, while in the 
absence of HRG, trastuzumab decreased proliferation by 50-60%. On the other hand, 
pertuzumab retained 20% anti-proliferative activity in presence and absence of HRG, 
respectively. The bispecific DARPins reduced cell growth by 50% in the presence of HRG and 
thus had the strongest effect on BT474 cell viability of all reagents tested under these 
conditions (Fig. 5B).  
 
5.9 Inhibition of Three-Dimensional Spheroid Growth and Morphogenesis 
We also investigated the effects of bispecific DARPins and monoclonal antibodies in a three-
dimensional culture of BT474 cells on a laminin-rich reconstituted basement membrane. In such 
an environment the tumor cells become organized into acini-like spheroid structures resembling 
ductal glandular architecture (Kenny et al. (2007)). As shown in Fig. 5D-E, both bispecific anti-
ErbB2 DARPins and, to a lesser extent, trastuzumab abrogated the 3D growth of BT474 
spheroids, while pertuzumab showed only a partial effect in the absence of HRG.  
We next investigated the effects of the different ErbB2-targeting agents on the spheroid 
morphogenesis induced by HRG. As shown in Fig. 5F-G, BT474 acini underwent morphogenesis 
manifested by pronounced budding/branching and invaded the surrounding matrix, which was 
robustly inhibited by either 6-L1-G, 9-L1-H, or pertuzumab, whereas trastuzumab or the non-
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targeted bivalent DARPin control had no effect. Hence, we conclude that the bispecific DARPins 
prevent the HRG-dependent morphogenesis of breast cancer cells,  (Fig. 5B).  
 
5.10 Bispecific DARPins Inhibit Cell Migration after Ligand Stimulation  
ErbB2 overexpression has been associated with visceral metastasis and micrometastatic bone 
marrow disease (Pantel et al. (1993); Slamon et al. (1987)). Correspondingly, enhanced 
expression of ErbB2 as well as stimulation with EGF or HRG in ErbB2-overexpressing cells have 
been reported to induce cell migration and invasion in an ErbB2-dependent manner (Le et al. 
(2012); Spencer et al. (2000)).  
We have therefore examined the effect of bispecific DARPins on cell motility in a wound-
healing assay with SKBR3 cells, high in both EGFR and ErbB3. As shown in Fig. 5H-K, both EGF 
and, in particular, HRG induced an extensive resealing of scratches in cell monolayer after a two-
day treatment. The EGF-induced cell migration was reversed by DARPins but only slowed down 
by treatment with both antibodies, correlating with the agents’ ability to disrupt the 
ErbB2/EGFR heterodimers (Fig. 5B). DARPins and pertuzumab reduced the potent HRG 
stimulation of cell migration, while trastuzumab showed no effect, again consistent with their 
effect on ErbB2/ErbB3 heterodimers.  
Consistent data were also found in a cell invasion assay (Fig. S3H). The impaired 
migration after DARPin treatment was correlated to reduction of ErbB2 phosphorylation at 
phospho-tyrosines pY-1222 and pY-1248 (Fig. 6A), i.e. the residues that were postulated to 
mediate the ErbB2-driven cell migration (Marone et al. (2004)). 
 
5.11 Bispecific DARPins but not Trastuzumab Inhibit ErbB2 Phosphorylations  
We analyzed multiple ErbB2 tyrosine phosphorylation sites in the C-terminal tail of ErbB2 
(Y1139, Y1169 Y1221/1222, Y1248) which serve as docking sites for a specific set of PTB-
domain-containing adaptor proteins (Hause et al. (2012); Jones et al. (2006); Schulze et al. 
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(2005)). Furthermore, we monitored the phosphorylation within the kinase lobe of ErbB2 
(Y877).  
After 24 h of treatment with bispecific DARPins, we detected a progressive and uniform 
reduction of ErbB2 Tyr phosphorylation of all sites in BT474 cells (Fig. 6A), which followed an 
exponential decay (Fig. S4A). Consistently, bispecific DARPins reduced phospho-ErbB2 levels in 
all ErbB2-dependent cancer cells (Fig. 6D,G). We confirmed the uniform dephosphorylation of 
all Tyr sites by immunoprecipitation of ErbB2 after treatment and subsequent detection of total 
phospho-Tyr content (Fig. 6C). Consistent with these observations, the adaptor protein GRB2 
(Fig. S4B) no longer binds.  
Importantly, the reduction of phospho-ErbB2 preceded a down-regulation of full-length 
ErbB2 expression, which was only observed in the population of late apoptotic, detached cells 
(Fig. S4C). This reflects enhanced degradation of ErbB2 during the execution of apoptosis, 
ErbB2 degradation thus being one of the effects and not the cause of apoptosis. Nonetheless, the 
appearance of truncated ErbB2 (p95) (shedding) was reduced after treatment with bispecific 
DARPins in BT474 cells (Fig. S4D).   
In contrast, we did not detect effects on ErbB2 phosphorylation after trastuzumab 
treatment, neither at the level of single Tyr phosphorylation sites (Fig. 6B) nor at the level of 
total ErbB2 phosphorylation (Fig. 6C). Similarly, ErbB2 phosphorylation remained unaffected by 
trastuzumab treatment in most of the other ErbB2-dependent cancer cell lines tested 
(Fig. 6C,G). Taken together, bispecific DARPins – but not trastuzumab – can efficiently inhibit 
the phosphorylation of the ErbB2 receptor.    
 
5.12 Bispecific DARPins Inhibit ErbB3 Phosphorylation by ErbB2 
The ErbB2 receptors, when overexpressed on the surface of cancer cells, are known to drive 
tumor growth in concert with ErbB3, thereby forming a potent oncogenic unit (Holbro et al. 
(2003); Lee-Hoeflich et al. (2008)). As shown in Fig. 6 E-G, the phosphorylation of the distal 
ErbB3-Y1289 site was reduced right after treatment with either bispecific DARPins or 
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trastuzumab and remained dephosphorylated during the entire treatment. Total expression 
levels of ErbB3 differ among ErbB2 overexpressing cell lines. Nonetheless, treatment with 
bispecific DARPins or trastuzumab reduced ErbB3 phosphorylation to a similar extent in 
HCC1419, HCC2218, SKBR3, AU565, and ZR75-30 (Fig. 6G). Interestingly, we observed 
consistent upregulation of ErbB3 expression after treatment with bispecific DARPins and 
trastuzumab in multiple ErbB2-dependent cell lines (Fig. 6E-G).    
 
5.13 Bispecific DARPins also Inhibit ErbB3 Activation after HRG Stimulation 
We also analyzed ErbB2 and ErbB3 phosphorylation after treatment with bispecific DARPins in 
combination with HRG stimulation (Fig. 6H). As expected, 1 nM HRG stimulated ErbB3 
phosphorylation effectively in SKBR3 cells. Trastuzumab did not inhibit ErbB3 phosphorylation 
detectably after ligand stimulation, while pertuzumab did so, consistent with previous findings 
(Sakai et al. (2007)). Bispecific DARPins, similar to pertuzumab, strongly impair ErbB3 
phosphorylation caused by HRG-stimulated heterodimerization with ErbB2. As detailed above, 
we also detected a significant ErbB2 dephosphorylation after treatment with bispecific DARPins 
and HRG.  
In summary, the inhibition of ErbB2–ErbB3 heterodimerization by bispecific DARPins – 
in the absence and presence of HRG – was observed both in experiments directly detecting the 
heterodimers on cells by co-immunoprecipitation (Fig. 5A) and in assays detecting the level of 
ErbB2 and ErbB3 phosphorylation (see Fig. 6H). 
 
5.14 Bispecific DARPins Efficiently Inhibit the PI3K/PKB Pathway 
Dephosphorylation of ErbB3 by trastuzumab treatment results in the loss of SH2 docking sites 
for the negative regulatory subunit p85 of phosphatidyl-inositol-3-kinase (PI3K), which 
consequently inhibits the catalytic subunit p110 (Junttila et al. (2009)). As shown in Fig. 7A,D,K, 
the phosphorylation of PKB (AKT), an important player downstream of p110, was diminished 
upon treatment by both trastuzumab and bispecific DARPins. However, the bispecific DARPins 
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caused stronger and, importantly, sustained dephosphorylation of PKB in all ErbB2-dependent 
cell lines. In contrast, trastuzumab induced a strong transient PKB dephosphorylation for up to 
6 h in BT474 and SKBR3 cells equivalently, but from this time point on, PKB became 
progressively re-phosphorylated (see also Fig. S4E).  
 
5.15 Bispecific DARPins Efficiently Inhibit the MAPK Pathway  
ErbB2 and EGFR receptor signaling, and especially signaling by homodimers, is closely 
associated to activation of the RAS/MAPK pathways (reviewed in (Yarden and Sliwkowski 
(2001))). We measured the output of the mitogenic signaling at the level of ERK. An initial strong 
and transient pulse of ERK phosphorylation was observed, ranging from 3- to 8-fold in BT474 or 
SKBR3 cells over the steady-state ERK phosphorylation levels, immediately after treating with 
either bispecific DARPins or trastuzumab (Fig. 7B,E). Stimulation of ERK phosphorylation by 
trastuzumab has been observed before (Gijsen et al. (2010)). It takes place already very early 
and at very low concentrations of all anti-ErbB2 agents (Fig. S4F), in a range where both 
trastuzumab and bispecific DARPins exhibit strong cytostatic or cytotoxic activity, 
respectively (cf. Fig. 2A and Fig. 3D,E).  
Importantly, only treatment with bispecific DARPins reduced ERK phosphorylation 
rapidly down to 20% of the initial steady state level in BT474, and phospho-ERK levels remained 
consistently low in all other cell lines (Fig. 7K) in a sustained manner (see also Fig. S4G). In 
contrast, trastuzumab induced only a transient stimulation of ERK-phosphorylation, which 
returns to the steady state phosphorylation level without ever going below, in the ErbB2-
dependent cell lines investigated, except in ZR75-30 cells. 
We did not observe a direct correlation of the pulsed ERK phosphorylation and the 
phospho-status of ErbB2 (Fig. 6A-D), and thus the phospho-ERK stimulus seems to be not 
directly caused by increased ErbB2 phosphorylation.  
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5.16 Downstream Effects of Bispecific DARPins on the Cell Cycle  
The examination of cell cycle regulators p27Kip1 (cyclin-dependent kinase inhibitor) and 
cyclinD1 (CDK4/6 activator), which governs G1/S-phase transition, revealed that their 
expression levels are affected by trastuzumab as reported (Lane et al. (2000)) and consistent 
with the recorded cell cycle profiles (Fig. 3A, Fig. S2A).  With bispecific DARPins, on the other 
hand, we observed stronger p27Kip1 upregulation in BT474 and SKBR3 cells (Fig. 7G,H) and 
stronger reduction of cyclinD1 expression in BT474 cells (Fig. 7I), starting after 12-24 hours of 
treatment. Other ErbB2-overexpressing cell lines showed similar effects for upregulation of 
p27Kip1, however down-regulation of cyclinD1 was not as pronounced in these cells compared 
to BT474 cells (Fig. 7K).  
 
5.17 Downstream Effects of Bispecific DARPins on Apoptosis 
The up-regulation of BIM expression (Fig. 3H and Fig. 7C,F) and cleavage of PARP (monitored 
by increased amounts of PARP p89) (Fig. 3H) was observed only after bispecific DARPin 
treatment in all ErbB2-dependent cell lines, but not after trastuzumab treatment. The one 
exception are ZR75-30 cells, which show some BIM upregulation and detectable phenotypic 
signs of apoptosis also upon treatment with trastuzumab.  
 
5.18 Plasticity of ErbB2 Signaling Network and Resistance against Anti-ErbB2 
Treatments 
We have summarized most significant findings on the ErbB2-driven signaling network by 
bispecific DARPins in a scheme (Fig. 7L). Since bispecific DARPins show strong impact on both 
the PI3K/PKB and the RAS/MAPK pathway, we assessed the plasticity of these pathways in 
BT474 cells after selective stimulation of each pathway individually. To stimulate PI3K activity 
(indirectly), we antagonized its back-reaction by inhibiting the tumor suppressor phosphatase 
and tensin homolog (PTEN) (Xiao et al. (2007)) by bis-peroxo(pyridine-2-carboxyl)oxovanadate 
(bpV(pic)) (Schmid et al. (2004)). Indeed, PTEN inhibition resulted in stimulation of PKB 
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phosphorylation independent of treatment (Fig. S4H). We observed that PTEN inhibition 
translated to a reduced activity of trastuzumab and bispecific DARPins in viability assays 
(Fig. S4I), but we still detected a cytotoxic effect of DARPins, indicating that they can overcome 
even stimulated PI3K action.  
To assess the MAPK pathway contribution, we directly stimulated protein kinase C (PKC) 
by 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA induced specific ERK phosphorylation 
after 2 h (Fig. S4K), which in turn translated to a reduced effect of trastuzumab and bispecific-
DARPins on cell viability. Note, however, that the anti-proliferative activity of trastuzumab 
treatment was reduced to a much higher extent than that of bispecific DARPins. 
 
6 Discussion 
By targeting two distinct epitopes of ErbB2 with appropriately designed bispecific binding 
proteins that completely disengage ErbB2 from the signaling network, we developed powerful 
agents with apoptotic activity against ErbB2-addicted breast cancer cells.  
We examined a broad panel of ErbB2-dependent tumor cell lines, all showing 20-50% 
apoptosis after a 3-day treatment with the bispecific DARPins. To our knowledge, this bi-
epitopic targeting is the only strategy described so far for ErbB2-targeting proteins inducing a 
potent apoptotic response. In contrast, the action of trastuzumab is limited to causing an arrest 
of proliferation in the G1 phase of the cell cycle. 
Importantly, this ability is retained in cells with p53 deficiency and low PTEN activity, 
which represents a common feature of cancer cells leading to emergence of resistance during 
trastuzumab treatment. Even under circumstances of a constitutively active PI3K-PKB-mTOR 
pathway, as a consequence of activating PIK3CA mutations, DARPins still displayed significant 
anti-proliferative activity. Finally, studies on orthotopically xenografted tumors confirmed that 
the bispecific DARPins retained the ability to induce apoptosis in vivo, and thus, the achieved 
apoptotic effect could be translated to the in vivo situation and was attributable to the same 
mode of action as in the cell culture tumor models. 
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6.1 The Pathway of Apoptosis Induction by bispecific DARPins 
As previously reported, the induction of apoptosis in ErbB2-amplified breast cancer tumors is 
dependent on the expression level of the BH3-only proapoptotic protein BIM (Tanizaki et al. 
(2011)). Ablation of BIM by RNAi leads to abolition of lapatinib-induced apoptosis, implying that 
BIM is controlled by survival signals emanating from ErbB receptors and itself critically 
controlling apoptosis (Faber et al. (2011)). BIM levels are mainly regulated by controlling its 
ubiquitination (Ewings et al. (2007)) via ERK phosphorylation (Marani et al. (2004)) and to a 
lesser extent by controlling FoxO3-mediated transcription, which stands under negative control 
of PKB. Through neutralization of anti-apoptotic proteins from the Bcl-2 family, the upregulation 
of BIM triggers activation of casp-9 (reviewed in (Danial (2007)), an apoptosome caspase that, in 
turn, is kept in check by PKB phosphorylation (Cardone et al. (1998)). 
Our results show that the upregulation of BIM is only detectable after sustained 
inhibition of both the ERK and PKB pathway, which is achieved after the treatment with 
bispecific DARPins. In contrast, the inhibition of PKB by trastuzumab, in the presence of an 
active ERK pathway, fails to augment expression of this pro-apoptotic protein.  
We thus conclude that the activation of the apoptotic program is enabled only in a 
background of simultaneous inhibition of both PKB and ERK signaling pathways (see scheme in 
Fig. 7L).  
 
6.2 Non-liganded ErbB2–ErbB3 Heterodimers 
Heterodimerization of overexpressed ErbB2 with ErbB3 is known to be essential to promote the 
growth of cancer cells (Holbro et al. (2003); Lee-Hoeflich et al. (2008)), and a hallmark of ErbB2-
overexpressing tumor cells is that non-liganded ErbB2–ErbB3 complexes form also in the 
absence of ErbB3 ligand (Junttila et al. (2009)). Such non-liganded ErbB2–ErbB3 heterodimers 
are thought to form different association complexes than the canonical back-to-back dimers, e.g. 
without depending on contacts between domains II, but still to be signaling-competent and 
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thereby driving the proliferation of ErbB2 overexpressing cells. The bispecific DARPins clearly 
prevent the formation of these complexes. 
Notably, a negative feedback loop linking inhibition of phospho-PKB to transcriptional 
upregulation of ErbB3 expression via the transcription factor FoxO3 has been recently described 
as a mechanism of resistance against tyrosine kinase inhibitors (TKI) (Garrett et al. (2011)), and 
it appears to be a general mechanism under the control of PKB (Chandarlapaty et al. (2011)). 
This feedback loop maintains oncogenic ErbB2/3 signaling, illustrating the robustness of the 
ErbB network against perturbations.  
We observed a rapid collapse of ErbB3 and PKB phosphorylation accompanied by a 
marked upregulation of ErbB3 expression after treatment with both bispecific DARPins and 
trastuzumab, indicating that the PKB/ErbB3 feedback loop also operates when targeting ErbB2 
via binding proteins. Despite of the high expression level, however, the ErbB3 receptor remained 
in an unphosphorylated state. Hence, the observed rapid decay of ErbB2–ErbB3 complexes in 
the absence of ErbB3 ligand, disengaging the active ErbB2 receptor kinase from its substrate, the 
ErbB3 tail, most likely accounts for the attenuation of PKB signaling. This entails a blockade of 
cell survival signals, caused by the ErbB2-trapping DARPins. 
 
6.3 Ligand-induced Heterodimers 
After ligand binding, ErbB3 adopts the extended conformation (Dawson et al. (2007)) and forms 
contacts via domain II and IV with its partner ErbB2 (Franco-Gonzalez et al. (2013); Franklin et 
al. (2004); Zhang et al. (2012)). It is believed that the heterodimerization between ErbB2 and 
EGF-activated EGFR is fairly similar, yet not identical (Cai et al. (2008); Macdonald-Obermann et 
al. (2012)). Bispecific DARPins are active against both ligand-stimulated ErbB2–ErbB3 and 
ErbB2–EGFR complexes to an equal or higher extent than the antibody pertuzumab, as shown in 
ligand-induced cell growth assays for three-dimensional spheroid morphogenesis, ligand-
dependent cell proliferation and the wound-healing migration or invasion and, in particular, by 
the co-immunoprecipitation studies. 
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In contrast, trastuzumab inhibited receptor heterodimerization after incubation with 
EGF only to a minor extent, and was inactive after stimulation with HRG. Hence, the bispecific 
DARPins combine properties of the two monoclonal antibodies in a single targeting molecule, 
with even greater activity. 
Inhibition of ErbB3 signaling has been proposed to up-regulate the protease ADAM17 
(TACE), which then becomes part of another reported feedback loop leading to an increased 
conversion of endogenous ligand precursors to active ligands (e.g. betacellulin and heregulin), 
thereby reactivating the ErbB2/3 signaling (Gijsen et al. (2010)). However, we did not observe 
increased amounts of phospho-ErbB3 after treatment of non-stimulated cells with any targeting 
agent, suggesting that this feedback loop is not operational in our model.  
While the reduction of PKB phosphorylation persisted for the whole period of DARPin 
treatment, the effect of trastuzumab on PKB phosphorylation was only transient, despite 
sustained dephosphorylation of ErbB3. This implies the existence of a crucial signaling bypass of 
ErbB3 in trastuzumab-treated cells (see below).  
 
6.4 ErbB2 Homodimers  
ErbB2 can form signaling-competent homodimers that stimulate the ERK pathway through 
activation of the small GTPase RAS (Ghosh et al. (2011)). We observed that all phospho-Tyr sites 
exhibited a slow exponential decay of phosphorylation, with half-lives of individual phospho-
sites varying between 12 to 20 h after treatment with bispecific DARPins, but not trastuzumab, 
leading to silencing of this pathway (Kawano et al. (2009)). 
Consistent with the observation that only bispecific DARPins lead to a 
dephosphorylation of ErbB2, only they inhibited ERK phosphorylation up to 90% in BT474 cells 
(after an initial pulse shown by both agents), while trastuzumab failed to overcome ErbB2 
phosphorylation and, consequently, ERK returned to steady-state phosphorylation levels after 
the phospho-ERK pulse. Because of this parallel behavior of phosho-ErbB2 and phospho-ERK, 
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we conclude, similar to previous reports (Ghosh et al. (2011)), that ERK activation is maintained 
mainly by the active ErbB2 homodimers. 
 
6.5 3D Model and Mechanism  
The model recently described (Jost et al., 2013, cf. Chapter 3) (Fig. 1B) accounts for the 
observed absence of (i) ErbB2–ErbB2 signaling complexes, (ii) ErbB2–ErbB3 signaling 
complexes in the absence of ligand (even though their geometry is not yet known), and finally 
(iii) the absence of complexes of ErbB2 with ligand-activated ErbB3 and/or EGFR. This 
prevention of productive ErbB2 complexes thus explains how the ErbB2-driven ErbB network is 
inhibited at multiple levels. Thus, this mode of action resembles the phenotypic effects of an 
ErbB2 knock-out (Cho et al. (2003); Graus-Porta et al. (1997)) and a pan-ErbB2 inhibition, which 
switches the ErbB network into the OFF state. 
The model builds on recent structural work on the mechanisms of kinase activation 
within the EGFR homodimer (Arkhipov et al. (2013); Endres et al. (2013)). Importantly, the 
interaction between the kinase domains themselves is very weak, and needs to be mediated by 
the juxtamembrane region, a peptide assuming different conformations, located between TM 
region and the kinase domain. Their dimerization requires in turn, that the TM domains of two 
ErbB receptors come together such that they can associate at the GXXXG motif close to the 
cytoplasmic side. As a consequence, this particular TM association mode may constitute a 
decisive switch. 
Our structural model, which is based on the structures of the DARPins with the HER2 
domains described in detail in an accompanying paper (Jost et al., 2013, cf. Chapter 3), shows 
that this particular TM association is prevented (Fig. 1B) by enforced separation of the 
extracellular domains by the bispecific DARPins, combined with a dimerization-incompetent 
orientation of the extracellular domain relative to the membrane. Coverage of the ErbB2 surface 
by the DARPins, combined with the constrained orientation of the ErbB2 monomers relative to 
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the membrane, can also be expected to interfere with alternative associations, such as the 
formation of tetramers and oligomers. 
 
6.6 Interconnection of ERK and PKB Pathway 
By using selective stimulators of either ERK or PKB pathway, we observed that the anti-tumor 
activity of bispecific DARPins was diminished. Hence, both the ERK and the PKB pathway 
mediate protection from apoptosis and stimulate growth, which illustrates the functional 
flexibility of both pathways and, thus, the potential to compensate for pathway specific 
perturbations (Yarden and Pines (2012)).  
While the ErbB network is more robust against ERK perturbation than against PI3K/PKB 
pathway perturbations, inhibition of PI3K/PKB eventually results in pathway switching and, 
consequently, in an increased dependency on ERK (Birtwistle et al. (2007)). By these means, a 
new steady-state signaling is established with nearly identical phenotypic outcome, probably 
requiring expression of additional components in the network (Amit et al. (2007)). 
Furthermore, a direct connection between activated RAS and the PI3K/PKB pathway 
creates an inter-pathway crosstalk (reviewed in (Castellano and Downward (2011))) that 
relieves the dependency on ErbB3, since the abundant active ErbB2 homodimers can stimulate 
PKB pathway via this alternative route. In context of ErbB2 targeting, the failure to achieve 
ErbB2 dephosphorylation as seen for trastuzumab treatment may thus result in reactivation of 
PKB despite persisting ErbB3 dephosphorylation. Consequently, this bypass of ErbB3 switches 
the ErbB network again into the ON state. In fact, the pharmacological interference with RAS 
function substantially potentiated the anti-tumor activity of trastuzumab and, as expected, the 
observed gain of cytotoxicity was accompanied both by inhibition of the ERK pathway as well as 
by prevention of the re-phosphorylation of PKB. In agreement with our findings, this 
observation again underlines the importance of simultaneous and sustained inhibition of both 
pathways for induction of apoptosis in the ErbB2-dependent cancer cells.  
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6.7 Overcoming Clinical Resistance 
The persisting problem in therapy of ErbB2-overexpressing tumors is that the majority of 
patients who achieve an initial response to trastuzumab or TKI treatment usually acquire 
resistance within several months (Blackwell et al. (2010); Esteva et al. (2002); Johnston et al. 
(2008); Slamon and Pegram (2001)). The resistance often arises due to the intra-ErbB family 
signal compensation, e.g. by ligand or receptor upregulation as well as by receptor shedding, or 
inter-pathway crosstalk with associated receptors such as IGF1R and cMET (Nahta et al. (2005); 
Ritter et al. (2007); Shattuck et al. (2008)). Hence, an efficient treatment regimen would ideally 
involve agents that (i) delay onset of resistance by interfering with the compensatory 
mechanisms and (ii) induce potent and rapid tumor cell death, thereby precluding adaptation of 
tumor cells to the treatment challenge. Since the ErbB2 trapping by bispecific DARPins is not 
constrained solely to ErbB2 homodimers, but it also extends to the other EGFR-family members 
forming the signaling-competent heterodimers with ErbB2, we believe that such a pan-ErbB 
targeting may be of particular importance to disable the compensatory mechanisms that 
frequently lead to the acquired resistance. 
Apoptosis is deregulated in many cancers, including the ErbB2-overexpressing breast 
tumors, thus conferring resistance to chemotherapy that primarily works by inducing apoptosis. 
A plethora of agents are currently being developed for lowering the apoptotic threshold mainly 
by modulating homeostasis of Bcl-2 proteins or by priming the extrinsic apoptotic pathway 
through targeting the tumor-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
receptors (reviewed in (Fesik (2005))). However, these substances lack tumor targeting 
capability, thus making healthy tissues also vulnerable. Therefore, there is a need for targeting 
agents potentiating the action of chemotherapeutics at the site of tumor, thereby increasing the 
specific tumor cytotoxicity. Drugs such as bispecific DARPins, designed to restore sensitivity to 
apoptosis exclusively in the targeted tumor cells, might thus be effective in tumor therapy also 
as sensitizer for increasing cell susceptibility to other cytotoxic compounds. 
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7 Conclusions 
In conclusion, our study has untangled the mechanism underlying a cancer cell-specific 
apoptotic response in ErbB2-addicted cells obtained via treatment with engineered receptor-
binding molecules, and we could demonstrate that this approach is effective. Nonetheless, it will 
have to be tested in future preclinical and clinical experiments whether the induction of 
apoptosis in tumors is rapid and potent enough in order to eliminate cells that otherwise would 
acquire resistance, bearing e.g. constitutively active PI3K, and to what degree cells with 
preexisting mutations would have a selective growth advantage. We believe, however, that the 
structure- and mechanism-based engineering of ErbB2 ligands, which induce cell-specific 
apoptosis, will be an important component of future therapies. The new insights arising from 
this study can thus aid in rational design of a novel class of extracellular receptor-targeting 
therapeutics. 
 
8 Experimental Procedures 
8.1 Cell Culture 
Breast cancer cell lines BT474, SKBR3, AU565, HCC1419, HCC2218, MDA-MB-361, ZR75-30 were 
obtained from American Type Culture Collection (ATCC; LGC Promochem). MDA-MB-361 were 
cultured in DMEM:Hams F12 (Sigma) supplemented with 20% heat-inactivated FCS (Amimed) 
and 100 U/ml penicillin/streptomycin (Sigma). All other cells were maintained in RPMI 1640 
medium (Life Technologies) containing 10% FCS and grown at 37°C in a humidified incubator 
with 5% CO2 atmosphere. 
 
8.2 XTT Cell Proliferation Assay 
Cells were seeded in 96-well plates at a density of 2,000 - 10,000 cells/cm2 predetermined for 
each breast cancer cell line. After 24 h, DARPins or MAbs were added in triplicates, and cells 
were incubated for another 96 h. XTT assay was developed according to manufacturer’s 
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instructions (Cell proliferation kit II; Roche). Absorbance was measured at 450 nm and 
expressed as percentage of the untreated control.  
 
8.3 Clonogenic Assay 
BT474 cells were treated for 4 days with 100 nM of anti-ErbB2 agents. Cells were then collected 
by trypsinization, washed three times with complete culture medium, serially diluted and 
seeded in fresh 6-well plates. Colonies were grown for 5 weeks, and the cell culture medium was 
refreshed twice per week. Colonies were fixed with glutaraldehyde, stained with crystal violet 
and the colony number was estimated in triplicate determination for a single dilution. 
 
8.4 Cell Migration Assay 
SKBR3 cell motility was assessed using a wound healing assay. The cells were seeded in 35 mm 
dishes at 2 × 105 cells/cm2 and allowed to adhere for 8 h. The confluent cell monolayers were 
wounded using sterile pipette tips to create an open “scratch” of 500 μm. The dislodged cells 
were removed by three washes with complete culture medium, and cells were incubated for 2 h 
with 100 nM targeting agents prior to addition of 1 nM HRG or 4 nM EGF. Migration into the 
open area was documented at 48 h post-scratching. The open scratched area of eight wound 
fields per treatment was quantified with TScratch software (Gebäck et al. (2009)) . 
 
8.5 Three-dimensional Growth Assay 
BT474 cells were seeded overnight at 1 × 104 cells/cm2 on top of commercially available 
laminin-rich extracellular matrix (Matrigel, BD Biosciences) following the manufacturer's 
protocol. Cells were treated with 100 nM targeting agents in the absence or presence of 1 nM 
HRG, and the culture medium was refreshed every 3 days. Growth and morphogenesis of acini 
were analyzed after twelve days by a modified XTT assay or by counting budding sites for three 
times 100 acini per treatment, respectively. 
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8.6 Flow cytometery: Cell Cycle, TUNEL and Annexin V 
Cells were seeded at 5,000 to 10,000 cells/cm2 under standard conditions 24 h prior to 
treatment with 100 nM of anti-ErbB2 agents. After three days, cells were collected by 
trypsinization and fixed in 70% EtOH or in 4% paraformaldehyde for propidium iodide 
(20 μg/ml;  2 Kunitz units/ml of RNAse) or TUNEL labeling (In-situ cell death detection kit, 
Roche), respectively. The AnnexinV/PI assay was performed with non-fixed cells treated for two 
days (ApoDETECT Kit; Life Technologies). The cell cycle distribution and apoptosis rate were 
quantified with FlowJo software. 
 
8.7 Mouse Xenograft Studies 
8-week-old female SCID beige mice were obtained from Charles River Laboratories and 
implanted with 0.025-mg, 90-day release, 17β-estradiol pellets (Innovative Research of 
America). After two days, 2 × 106 BT474 cells were resuspended in 100 μl of PBS and 
1:1 mixture with BD Matrigel was inoculated orthotopically into the mammary gland fat pad of 
mice. Once tumors reached a volume of 200 mm3, six to eight animals were selected and 
randomly assigned into four treatment cohorts with equal average tumor volumes. The DARPins 
were administered by i.v. injection three times per week in a total of nine doses of 20 mg/kg. 
Tumor diameters were serially measured every 2 days, and tumor volumes were calculated 
using the following formula: V = (L × W2)/2, where V = volume (cubic millimeters), L = length 
(millimeters), and W = width (millimeters). For immunohistochemistry analyses, the animals 
were perfused and tumors were resected on day 14 after initiation of treatment (Supplemental 
Experimental Procedures). Bioimaging studies were performed after single i.p. injection of 
1 mg/kg DARPin on IVIS 100 instrument (Caliper Life Sciences), and biodistribution was 
quantified with Living Image software All mice were maintained and handled under aseptic 
conditions. The studies were approved by the Cantonal Veterinary Office (Zurich, Switzerland). 
Housing and experimental procedures were in accordance with the Swiss animal protection law 
(see extended Materials and Methods).  
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(subsequent page) Figure 1. Mechanism of Action of Bispecific DARPins: (A) Model of 
bispecific DARPin 926-(GGGGS)-G3 (abbreviated 6-L1-G) with strong anti-tumor activity.  
(B) Model of the ErbB2 back-to-back homodimer (blue, shaded by domain) in complex with the 
monovalent DARPins 929 (red) and G3 (yellow), based on structures and models described in 
detail in Jost et al. (2013), cf. Chapter 3. The structures show that the individual DARPin 
epitopes do not directly overlap with canonical ErbB2 dimerization interfaces for homo- or 
heterodimerization (left) and indeed both monovalent DARPins as well as their mixtures lack 
anti-tumor activity. The short 17-Å GGGGS peptide linker is too short to even span the minimal 
distance (50 Å) between the C-terminus of DARPin 929 bound to one HER2 monomer and N-
terminus of G3 bound to a second monomer. Therefore the ErbB2 monomers have to bend over 
(right) from the upright position (ECD in white, hazy) to allow binding of both DARPins (ECD in 
shades of blue). The steric constraints imposed by the membrane force the transmembrane 
helices apart, as well as the attached kinases, and obstruct the dimerization interface of ErbB2.   
(C) Western blot of ErbB2 receptors crosslinked on the surface of BT474 cells in the absence and 
presence of monovalent, bivalent and bispecific DARPins (symbols at the bottom), with 
bis[sulfosuccinimidyl] suberate (BS3). The panel shows the anti-ErbB2 blot (top) with the 
corresponding anti-DARPin blot (middle) and the loading control anti-GAPDH (bottom). ErbB2–
bisp. DARPin–ErbB2, two ErbB2 molecules bridged by a bispecific DARPin. 
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(preceding page) Figure 2. Anti-Proliferative Activity Bispecific DARPins: (A-B) Inhibition 
of cell proliferation in 2D cultured ErbB2-overexpressing breast cancer cell lines derived from 
mammary gland adenocarcinomas, comprising BT474, HCC1419, HCC2218, SKBR3, AU565, 
ZR75-30 with intact PI3K pathway signaling pathway in (A), and MDA-MB-361 with PI3K 
activating mutations in (B). Cells were treated for four days with increasing concentrations of 
bispecific DARPins 6-L1-G and 9-L1-H, non-binding DARPin control O-L1-O (Off7-Gly4Ser-Off7), 
both monoclonal antibodies (trastuzumab; TZB or pertuzumab; PZB), or PBS alone (Ctrl). 
(C) Clonogenic assays of BT474 cells, treated for 4 days with 100 nM of indicated agent, and 
afterwards equal number of treated cancer cells were re-seeded, grown in absence of agents, 
while capacity of single cells to initiate colony outgrowth was measured after 5 weeks culturing. 
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(preceding page) Figure 3. Induction of Apoptosis by Bispecific DARPins:  
(A-C) Cell cycle distribution analysis of BT474 cells after 3 d treatment with indicated agents 
each at 100 nM concentration. Ethanol-fixed cells were stained with propidium iodide (PI, 20 
μg/ml) and analyzed by FACS. Depicted PI-staining histograms show cell cycle profiles of gated 
single cells and quantification with Dean-Jett-Fox algorithm (B). Cells with subG1 DNA content 
(red) represent post apoptotic cell population with marked degradation of genomic DNA that 
have been quantified separately (C). 
(D-E) TUNEL assays of treated BT474 cells in histograms (D) or quantification of HCC1419 and 
HCC2218 cells (E) showing apoptotic cell populations. Cells were treated with 100 nM of 
indicated agents for 3 d, PFA-fixed and triton-permeabilized, stained with terminal 
deoxynucleotidyl transferase (TdT) using dUTP-fluoresceine substrate and subsequently 
analyzed by FACS. Presented histograms depict the recorded TUNEL profiles of non-apoptotic 
(left peak, centered around 100) and apoptotic cells (right peak, centered around 102).  
(F) Annexin-V and propidium iodide (PI) assay of BT474 cells after 2 days treatment with 
100 nM of indicated agents. Population of early apoptotic cells was monitored by Annexin-
V_FITC detection (upper left and right quadrants) and staining for membrane permeability (PI at 
1 μg/ml) indicates late stages of cell death (upper and lower right quadrants). 
(G) Caspase activity assay for initiator caspases-8 and -9 as well as effector caspases-3/7 by 
specific chemiluminiscent substrates in cell extracts of treated BT474 cells. Cells were treated 
with bispecific DARPin and trastuzumab for 3 days or GDC-0941 and TRAIL for 12h. 
(H) Expression analysis of the apoptotic markers cleaved PARP (p89) and BIM by western blot 
in panel of ErbB2-dependent breast cancer cell lines after treatment with 6-L1-G, TZB or PBS 
control for 3 days. 
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Figure 4. Bispecific DARPins accumulate at the site of tumor and induce tumor regression 
in vivo: (A) Biodistribution analysis in BT474 xenografted mice, injected once (intravenously; 
1 mg/kg) with the Alexa680-conjugated and PEGylated DARPins or PBS. Mouse were imaged on 
an IVIS device for a period of ten days, while accumulation of 6-L1-G_PEG and 9-L1-H_PEG, but 
not the negative control DARPin (O-L1-O_PEG) can be observed at the site of implant in the right 
mammary fat pad. The urinal excretion of the injected agents is visualized as bladder staining. 
(B) Tumor growth inhibition by PEGylated bispecific DARPins in SCID beige mice with pre-
established BT474 xenografts.  Treatment schedule was started as soon as tumors size reached 
200 mm3 Agents were injected three times per week intravenously (20 mg/kg) as indicated by 
the arrows. The statistical significance between the treated (6-L1-G_PEG and 9-L1-H_PEG) and 
control (PBS, O-L1-O_PEG) cohorts was determined by student’s t-test (* p<0.001). 
(C) In situ immunohistochemical staining of apoptotic markers in treated BT474 xenografts. 
Representative tumor sections from PFA-fixed, paraffin-embedded tumors were analyzed by 
H&E, anti-ErbB2 antibody fluorescence, anti-cleaved caspase-3 peroxide, TUNEL fluorescence, 
and DAPI fluorescence staining. Enlargement of DAPI stained picture (bottom), shows apoptotic 
bodies after bispecific DARPin treatment. 
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(preceding page) Figure 5. Inhibition of ErbB2 Heterodimerization by Bispecific DARPins: 
(A-B) Formation of ErbB2 scaffolding heterodimers with and without ligand stimulation. ErbB2–
ErbB3 dimerization was triggered by addition of 1 nM heregulin-β1 (HRG) in BT474 cells (A) 
and ErbB2–EGFR dimerization was triggered by 1 nM epidermal growth factor (EGF) in SKBR3 
cells (B) after preincubation with 100 nM of indicated agents, respectively. Afterwards, surface 
receptors were crosslinked with the reducible crosslinker DTSSP, ErbB2 was 
immunoprecipitated by an anti-ErbB2-C-terminal antibody, samples were reduced and amount 
of co-immunoprecipitated receptor was analyzed by western blot.  
(C) XTT of cell proliferation assay of 2D cultured BT474 cells in presence of 1 nM ErbB3 ligand 
heregulin-β1 (HRG) and 100 nM of indicated treatment agents after 4 d of coincubation. 
(D-E) Three-dimensional cultures of mammary carcinoma BT474 cells were established using 
reconstituted basement membrane (Matrigel BD). Micrographs shown of BT474 spheroids after 
12 d treatment with indicated agents (D). The proliferation of treated spheroids was analyzed 
by XTT assay (E). 
(F-G) Induction of morphogenesis in 3D cultured BT474 cells. Acini branching was induced by 
addition of 1 nM heregulin-β1 (HRG) shortly after preincubation with 100 nM of indicated 
agents. The effect of the bispecific DARPins or MAbs was monitored after 12 d incubation (F). 
The extent of spheroid branching was quantified by scoring three times 100 acini that were 
classified into three populations, depending on the number of buds per acinus (G).  
(H-K) Effect of the ErbB2-targeting agents on cell migration in a wound-healing assay. SKBR3 
cells were seeded to confluence, and scratch a wound of 500 μm was made in the monolayer. 
Cells were treated with the indicated agents at 100 nM concentrations and co-stimulated with 4 
nM epidermal growth factor (EGF) (H) or with 1 nM heregulin-β1 (HRG) (I). Representative 
micrographs of four parallel scratches were taken after two days at 4x magnification. The cell 
motility was assessed after two days. Quantification of wound-healing assays. The open area 
(scratch) was analyzed with the TScratch software, and the migration was expressed as the 
percentage of open area and compared to mock-treated SKBR3 cells (K). 
 
 
 
 
 
 
 
 
 
 
(subsequent page) Figure 6. Inhibition of ErbB2 and ErbB3 Phosphorylation by Bispecific 
DARPins: (A-F) Quantitative infra red fluorescence western blot; integrated intensity signals 
are plotted as percent signals of internal control phosphorylation of untreated cells 24 h post 
seeding (0 min). Note that detached late apoptotic cells are excluded from analysis. Cells were 
treated in excess of medium with a single dose of 100 nM of either bispecific DARPin (6-L1-G) or 
trastuzumab (TZB) for the indicated times, and cell extracts were normalized for protein 
concentration by BCA assays. A collection of individual ErbB2 tyrosine phosphorylation sites of 
p185 in BT474 cells after treatment with DARPin (A) or trastuzumab (B) are shown.  
(C) Immunoprecipitation of ErbB2 and non specific anti-phospho Tyr blot quantification of p185 
from BT474 cells after treatment with both agents. (D) ErbB2 expression of p185 and 
phosphorylation of Y1248 in SKBR3 cells after treatment with both agents.  
(E-F) ErbB3 expression and phospho-status of Y1289 of p180 in BT474 (E) or SKBR3 (F) cells 
after treatment with both agents. (G) Expression and phosphorylation of p185 ErbB2 and Y1248 
or p180 ErbB3 and Y1289 in ErbB2 depended cell lines after 72h of treatment with single dose 
of 100 nM of both agents. (H) Heregulin-stimulated transphosphorylation in SKBR3 cells. 
Preincubated cells with indicated agents were stimulated with 1 nM HRG. The phosphorylation 
of ErbB2 Y1248 and ErbB3 Y1289 was determined by western blot. 
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(preceding page) Figure 7. Inhibition of ErbB2–ErbB2 and ErbB2–ErbB3 Mediated 
Downstream Signaling by Bispecific DARPins: (A-I) Analog to proceeding in Fig. 6 (see 
above). Phosphorylation of protein kinase B (AKT/PKB) at S473 was monitored in BT474 (A) or 
SKBR3 cells (D). Phosphorylation of Erk1/2 at Tyr204/Thr202 was monitored in BT474 (B) or 
SKBR3 cells (E). The expression of the pro-apoptotic protein Bcl-2 interacting mediator of cell 
death (BIM) was measured in BT474 (C) or SKBR3 cells (F) (see Fig. 3). Expression of the cyclin 
depended kinase inhibitor p27KIP1 was monitored in BT474 (G) or SKBR3 (H) cells. Expression 
of cyclinD1 (CycD1) was monitored in BT474 cells (I).  
(K) ErbB2-dependent cancer cell lines (AU565, HCC1419, HCC2218 and ZR75-30) were treated 
for 72 h with single dose of 100 nM of both agents. Phosphorylation of PKB and ERK as well as 
well as expression of cyclinD1, p27KIP1 (see above) and phosphatase and tensin homolog 
(PTEN) was monitored. (L) Signaling diagram connecting the ErbB2–ErbB3, ErbB2–ErbB2 and 
ErbB2–EGFR signaling output with PI3K/PKB or MAPK pathway activation. Reported positive 
(unbroken) and negative (dotted) interactions are indicated as lines, and the predominant origin 
of the signal is drawn as well: from ErbB2–ErbB3 oncogenic unit as green ovals, for the 
PI3K/PKB pathway; originating from ErbB2–ErbB2:  for the MAPK pathway as red squares. The 
model illustrates how the pathways are interconnected at several points, how inhibition of a 
single pathway releases negative feedbacks und thus why both have to be turned off 
simultaneously to achieve induction of apoptosis in ErbB2 dependent cancer cells. Since the 
bispecific DARPins obstruct ErbB2 from all drawn complexes, they act as a pan-ErbB inhibition 
response and induce apoptosis in a broad panel of ErbB2 dependent cancer cells. 
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(preceding page) Figure S1: Anti-Proliferative Activity of Monovalent and Bivalent 
DARPins, Binding to Cell Surface, Specificity of Anti-Proliferative Activity, Combination of 
Trastuzumab with Pertuzumab and Combination of Both Antibodies with Bispecific 
DARPins, measured on BT474 Cells 
(A) XTT cell proliferation assay detecting anti-proliferative activity on BT474 cells of 
monovalent DARPins (100 nM) and their combination (each 100 nM) after 4 d treatment. TZB, 
trastuzumab. All DARPins bind to ErbB2, except Off7. 
(B) XTT cell proliferation demonstrating the necessity to link the DARPins to a particular 
bispecific format. BT474 cells were measured after 4 d of treatment. The ErbB2 ECD_IV binding 
DARPin H14 displays a reduction of 20% viability, the ErbB2_I binding DARPin 929 shows no 
anti-proliferative activity and their combination shows anti-proliferative activity similar to H14 
treatment alone. The anti-proliferative activity of the bispecific DARPins is determined by the 
orientation of the monovalent DARPins within the bispecific constructs. The bispecific DARPins 
exist in an inactive orientation (H-L4-9) and active orientation (9-L4-H). The active orientation 
shows strong anti-proliferative activity that exceeds by far simple additive effects. 
(C) XTT cell proliferation assay measuring the effect of the flexible linker length within the 
active bispecific DARPin on anti-proliferative activity in BT474 cells after 4 d of treatment. 
Reducing the linker length from L4 (GGGGS)4 to L1 (GGGGS) increases the maximal anti-
proliferative activity. 
(D) Association rates of mono- and bivalent DARPins to ErbB2 receptor on the surface of BT474 
cells. Internalization was inhibited with azide prior to incubation. Alexa488-conjugated DARPins 
(indicated by an asterisk) were incubated for the indicated times at the indicated concentrations 
and mean fluorescence intensity (MFI) was recorded by FACS measurements. Association rate 
constants of 2.0 × 105 M-1 s-1 for H14, 0.7 × 105 M-1 s-1 for DARPin929, and 0.8 × 105 M-1 s-1 for 9-
L4-H were obtained. 
(E) Dissociation rate of mono- and bivalent DARPins from ErbB2 receptor on the surface of 
BT474 cells. Internalization was inhibited with azide prior to incubation. Alexa488-conjugated 
DARPins were bound to saturation, subsequently DARPins were competed for the indicated 
times with an excess of their respective non-labeled DARPin counterparts and MFI values were 
recorded by FACS measurements. Dissociation rate constants of 1.8 × 10-4 s-1 for H14, 2.2 × 10-3 
s-1 for DARPin 929, and 4.0 × 10-5 s-1 for DARPin 9-L1-H were obtained. From (D) and (E), 
functional affinities of KD = 1 nM can be calculated for DARPin H14, 33.5 nM for 929, and 0.5 nM 
for 9-L1-H on the surface of BT474 cells. 
(F) XTT cell proliferation assay showing the specificity of the anti-proliferative activity of 
bispecific DARPins (6-L1-G and 9-L1-H) and the antibodies trastuzumab (TZB) and pertuzumab 
(PZB) by competition with soluble full-length ErbB2_ECD on BT474 cells after 4 days of 
treatment. Anti-ErbB2 agents (each 100 nM) were preincubated with increasing concentrations 
of ErbB2_ECD and given to the cancer cells. Increasing concentrations of ErbB2_ECD reduced the 
anti-proliferative activity of each anti-ErbB2 agent to completion in a concentration-dependent 
manner. 
(G) XTT cell proliferation assay detecting the anti-proliferative activity of the equimolar 
combination of trastuzumab (TZB) with pertuzumab (PZB) on BT474 cells after 4 days of 
treatment. 
(F) XTT cell proliferation assay showing the effect of combination of bispecific DARPins at a 
constant concentration of 100 nM with increasing concentration of either trastuzumab (TZB) or 
pertuzumab (PZB) on the activity to BT474 cells after 4 days of treatment. With increasing 
concentration of either antibody, the strong anti-proliferative activity of bispecific DARPins is 
markedly reduced. Note that H14 competes with TZB for binding to ErbB2_IV, while G3 does not 
(data not shown). None of the monovalent DARPins (926, 929, H14, G3) competes with PZB for 
binding to ErbB2_ECD (data not shown). However, anti-proliferative activity of both bispecific 
DARPins is reduced by both antibodies, respectively. 
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Figure S2:  
Analysis of Cell Cycle Distribution and TUNEL Assay after Treatment with 6-L1-G and 
Trastuzumab on a Panel of ErbB2 Dependent Breast Cancer Cell Lines  
(A) Cell cylce distribution analysis of ErbB2-overexpressing cancer cells after 3 days of 
treatment with the indicated agents, each at 100 nM concentration. Ethanol-fixed cells were 
stained with propidium iodide (PI, 20 µg/ml) and analyzed by FACS. Depicted PI-stained 
histograms show cell cycle profiles of gated single cells and are quantified with the Dean-Jett-
Fox algorithm (indicated by the colors). (B) TUNEL assays of treated ErbB2-overexpressing 
cancer cells in histograms showing apoptotic cell populations. Cells were treated with 100 nM of 
indicated agents for 3 days, PFA-fixed and Triton-permeabilized, stained with terminal 
deoxynucleotidyl transferase (TdT) using dUTP-fluoresceine substrate and subsequently 
analyzed by FACS. Presented histograms depict the recorded TUNEL profiles of non-apoptotic 
(left peak, centered around 100) and apoptotic cells (right peak, centered up to 102). 
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Figure S3. Anti-proliferative Activity after PEGylation of Bispecific DARPins and Effect of 
Treatment with Bispecific DARPins on ErbB2 Receptor Surface Expression, 
Internalization and Recycling on BT474 Cells:  
(A) XTT cell proliferation assay showing the effect of PEGylation on both bispecific DARPins (6-
L1-G and 9-L1-H). Anti-proliferative activity was measured on BT474 cells after 4 days of 
treatment. The maximal anti-proliferative activity was not affected by PEGylation, while dose 
effectiveness was reduced. IC50 values of bispecific non-PEGylated DARPins increased from the 
picomolar range to the low nanomolar concentrations for PEGylated constructs. (B) ErbB2 
expression levels measured by FACS. Alexa488-conjugated anti-ErbB2 affibody (zHER2* 
(Eigenbrot et al., 2010), the asterisk indicating the label) was bound to ErbB2 on the surface of 
BT474 cells, which were treated with the indicated DARPins for up to 1 h. Note that zHER2* 
binds to ErbB2_III and does not compete with monovalent DARPins (926, 929, G3, H14) for 
binding to ErbB2 receptor (data not shown). (C) ErbB2 expression levels measured by FACS. 
Alexa488-conjugated monovalent DARPin (901*, the asterisk indicating the label) were bound to 
the surface of BT474 cells after preincubation with indicated DARPins for indicated times. ErbB2 
surface expression levels remained constant after treatment with bispecific DARPins. (D) Pulse-
Chase-Assay performed by FACS measurement, detecting the quenching of mono- and bivalent 
Alexa488-conjugated DARPins (indicated by an asterisk) that are recycled back to the surface on 
BT474 cells, remaining bound to ErbB2. Indicated agents were preincubated for 2 h at 37°C to 
allow for internalization, fluorescence of Alexa488-conjugated DARPins bound to the cell surface 
were quenched by an anti-Alexa488 antibody at 4°C, and afterwards cells were incubated for the 
indicated times in the presence of the quenching antibody at 37°C and remaining fluorescence 
was measured by FACS. Active and inactive constructs recycled with the same rate.  
(E) Internalization assay performed by FACS measurement. BT474 cells were treated for 2 h 
with 100 nM concentration of mono- and bivalent Alexa488-conjugated DARPins (indicated by an 
asterisk). Afterwards, surface fluorescence was quenched by incubation with anti-Alexa488 
antibody at 4°C and residual fluorescence was measured by FACS. Active and inactive constructs 
internalize with the same rate. (F) Effect of the ErbB2-targeting agents on cell invasion. SKBR3 
cells pre-seeded on a basement membrane matrix were treated with the indicated agents at 
100  nM concentrations and co-stimulated for 72 h with 1 nM heregulin-β1 (HRG). Cell invasion 
was expressed as relative invasion to the invasion of control-treated cells. 
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(preceding page) Figure S4. Bispecific DARPins induce ErbB2 Dephosphorylation and 
Consequently Inhibit Downstream Signaling of PKB and ERK Simultaneously and thereby 
Overcome Pathway Plasticity:  
(A) Quantitative western blot analysis of single Tyr phosphorylation sites and total Tyr 
phosphorylation of ErbB2 receptor in BT474 cells after treatment with bispecific DARPin (6-L1-
G). A single exponential decay function was fitted to integrated signal intensity signals.  
(B) Analysis of GRB2 dissociation from ErbB2 receptor after treatment of BT474 cells with 
indicated agents for 3 days. ErbB2 receptor was immunoprecipitated using 901-L4_zHER2 
coupled to beads. Reduced GRB2 CoIP-levels were detected after treatment with bispecific 
DARPins (6-L1-G and 9-L1-H), but not after trastuzumab (TZB) or pertuzumab (PTZ) treatment. 
(C) Detection of ErbB2 expression levels in late apoptotic SKBR3 cells after 3 days of treatment 
with bispecific DARPins. Adherent and detached cells were separately collected and subjected to 
western blot. Adherent cells show less PARP cleavage in comparison to detached cells (less 
PARP p89 visible). Constant expression levels of ErbB2 have been observed in adherent cells, 
while detached late apoptotic cells show reduced ErbB2 receptor expression level. The 
population of adherent cells greatly reduces over time and accumulates in the supernatant. 
Nonetheless, signaling analysis of adhering cells could be performed for up to 3 days, since the 
experiments could be scaled up, but examination after 3 days becomes increasingly difficult. 
(D) Western blot analysis of ErbB2_p95 expression in BT474 cells after treatment with 
bispecific DARPin 6-L1-G. 
(E) Quantitative western blot analysis of PKB phosphorylation in BT474 or SKBR3 cells after 
treatment with bispecific DARPin (6-L1-G) or trastuzumab (TZB). An exponential decay, coupled 
to a linear function was fitted to integrated signal intensities. 
(F) In-cell ELISA detecting ERK phosphorylation in BT474 cells after 1 h of treatment with 
indicated concentrations of bispecific DARPins or trastuzumab. 
(G) Quantitative western blot analysis of ERK phosphorylation in BT474 or SKBR3 cells after 
treatment with bispecific DARPin (6-L1-G) or trastuzumab (TZB). A single exponential decay 
function was fitted to integrated signal intensity signals. 
(H-L) Effect of selective stimulation of PI3K/PKB pathway by inhibition of PTEN with 
bisperoxo(pyridine-2-carboxyl)oxovanadate (TPA). In-cell ELISA detecting phospho-PKB (H) or 
phospho-ERK (K) levels in BT474 cells after 2 h of treatment with bispecific DARPins or 
trastuzumab and subsequent stimulation of PKB with bpV(pic), or ERK with TPA, for 15 min. Cell 
viability assay measuring the effect of combination of bispecific DARPins or trastuzumab with 
the agonistic PTEN inhibitor (I) or ERK stimulator (L). Note that the PTEN inhibitor had to be 
used at concentrations that showed anti-proliferative activity in control cells; however, the 
PTEN inhibitor induces growth stimulation in cancer cells treated with bispecific DARPins or 
trastuzumab. 
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1 Introduction 
Chapter five contains a collection of further methods and results conducted in the course of my 
PhD-project, that did not necessarily yield data for publications, but should still be mentioned 
for several reasons.  
First, there is a category of methods that have been used within the whole project and 
that certainly have expanded into the earlier chapters of this work. Still, such methods, like for 
instance the construction of the different flexible or inflexible linkers, deserve to be explained in 
more detail.  
Another less glorious category of methods are those that have been tried out without 
real success but with the final outcome that this was not the way to succeed (best examplified by 
the manifold experimental attempts within the struggle to obtain information on the epitopes of 
the HER2-binders). These methods and results are summarized in order to give an inspiration 
on what – at least theoretically – could work and on what all has been tried out. 
Last, not least, this Chapter summarizes methods and results that are part of side-
projects which are still ongoing and not completed, but that might yield interesting data in the 
near future and that therefore should not stay unmentioned. 
All methods and results are thematically grouped in subchapters. Basic techniques (like 
cloning or ELISA) were performed in analogy to the protocols given in the Material and Methods 
section of Chapters 2 to 4. All further techniques (like e.g. in vitro refolding) are explained 
within the respective subchapter. 
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2 Construction of bivalent DARPins 
All plasmids used in this work for the construction of bivalent DARPin-constructs were 
derivatives of vector pQiBi_22 (Figure 5.1:), which in turn is a lacIq-containing derivative of 
vector pQE30 from Qiagen. All pQiBi-vectors carry two cloning cassettes, one BamHI/HindIII 
cassette upstream and one BglII/BsaI cassette downstream of a sequence coding for the 
respective linker. Vectors coding for bivalent constructs (or e.g. SNAP-tag constructs used in 
Appendix 2) were obtained by sequentially cloning BamHI/HindIII-digested inserts into the two 
cassettes. HindIII/BglII cloning allowed the exchange of the linker sequence, varying either the 
length (e.g. (G4S)2 vs. (G4S), cf Chapter 3) or the rigidity (e.g. (G4S)2 vs. N6C, cf. Chapter 2) of the 
linker. 
Besides the flexible and rigid linkers described in Chapters 2 and 3, further linkers 
composed of a leucine zipper (scZIP (Pack and Plückthun (1992))) or a double helix motif 
(scdHLX (Pack et al. (1993))) were tested as well. These constructs, however, did not prove to 
show significant effects on the cell proliferation of BT474 cells. 
 
2.1 Construction of vectors coding for flexible linkers with various lengths  
pQiBi-vectors with flexible (G4S)n peptide linkers (with n = 1, 2, 4, 6 or 8) were prepared 
starting from vector “pQiBi_22” encoding an (G4S)4-linker.  
The coding sequence (cds) for the shortest flexible linker (G4S) was ordered as 
complementary oligonucleotides “G4S_for” and “G4S_rev” (from Microsynth), that were 
phosphorylated (using polynucleotide kinase (PNK)), annealed, and ligated into HindIII/BglII-
cut vector pQiBi.  
The coding sequences for the longer flexible linkers were created by ligating “building 
blocks” of linker sequences obtained via PCR on e.g. pQiBi_22 and pQiBi_11 (to generate (G4S)4 
and (G4S)2 building blocks for creation of (G4S)6) using primer-pairs “33_for2” × “QE_rev” and 
“QE_for” × “33_rev1”. Before ligation into HindIII/BglII-cut vector pQiBi, these „flexible linker 
building blocks“ were digested with HindIII x BpiI or BpiI x BglII, respectively.  
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Figure 5.1: Vector map of pQiBi_22_. This vector was the starting point for the cloning of all 
bispecific DARPins. All pQiBi-vectors carry two cloning cassettes, one BamHI/HindIII cassette 
upstream and one BglII/BsaI cassette downstream of a sequence coding for the respective 
linker. 
 
 
 
Table 5.1: Oligonucleotides used for the construction of flexible linkers by means of PCR. 
Nucleotides that introduce point mutations (in order to create a BpiI-recognition-site (5’-
GAAGAC-3’)) are highlighted in red. PTO-linkages, introduced instead of standard 
phosphodiester bonds close to the 3’-end of the primers, are indicated by asterisks (*). The PTO-
linkages were introduced in order to abolish the 3’→5’-proofreading-activity of the DNA-
polymerase, which would otherwise correct the point mutations introduced by the 
oligonucleotides (de Noronha and Mullins (1992)). 
Name Sequence (5’-3’) Comment 
G4S_for  
G4S_rev 
QE_for 
QE_rev 
33_for2 
33_rev1 
AGCTTGGCGGCGGTAGCT 
CTAGAGCTACCGCCGCCA 
CGGATAACAATTTCACACAG 
GTTCTGAGGTCATTACTGG 
GTCGACCTGCAGGAAGACTTGG*C*G 
TGTCGAAGACAGCGCCAGAACCGCCACCGCCAGA 
for annealing with G4S_rev 
for annealing with G4S_for 
 
 
for use with QE_rev 
for use with QE_for 
2.2 Construction of vectors coding for various rigid DARPin linkers 
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Consensus DARPins with more than 6 internal modules used as rigid linkers for the 
bivalent DARPins described in Chapter 2 were prepared following a “building block strategy” 
resembling the assembly strategy described in Section 2.1, where the upstream building block 
codes for a DARPin-N-cap and a defined number of internal consensus repeats, and the 
downstream building block codes for further internal consensus repeats and a DARPin-C-cap.  
The building blocks for the ligation of the chimeric DARPins cds were obtained via PCR 
on e.g. pQE30_N4C_ss using primer-pairs “NPR_f” × “bbN_rev” and “bbC_for” × “bbc_rev” (to 
generate “N4” and “4C” building blocks, i.e. constructs of the N-cap and 4 internal repeats or 4 
internal repeats and the C-cap, for the creation of the consensus N8C sequence). The building 
blocks were then BsaI-digested and ligated, before BamHI × HindIII -cloning into the expression-
vector pQE30_ss (pDST67). As nucleotide sequencing of long consensus DARPins (of a length 
where forward- and reverse- Sanger sequencing are required to determine the whole DARPin-
sequence) is not trivial due to the repetitive nature of the sequence, the primers bbN_rev and 
bbC_for at the building block boundaries were designed to introduce a silent mutation in the D of 
the GADVNA motif (GACGAT), allowing identification of this “ligation scar” within the 
consensus-DARPin-cds. 
The assembled NxC-consensus DARPins, which were meant to serve as linkers in the 
pQiBi-format, were finally extended via PCR for HindIII- and BglII-sites and linker glycines prior 
to cloning into pQiBi.  
Chimeric DARPins built up from both consensus and target-specific internal modules 
were constructed using the same assembly protocol (with e.g. consensus N2C and HER2-binding 
DARPin H14 as templates). These DARPins could be used for epitope characterization studies 
depicted in Figure 5.3:.  
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Table 5.2: Oligonucleotides used for the construction of chimeric DARPins (see Figure 5.2: for 
the construction scheme used). Nucleotides that introduce point mutations (in order to create a 
BsaI-recognition-site (5’-GGTCTC-3’)) are highlighted in red. Nucleotides that introduce a silent 
mutation (allowing the identification of this “ligation scar” within the assembled consensus-
DARPin-cds) are highlighted in blue. PTO-linkages, introduced instead of standard 
phosphodiester bonds close to the 3’-end of the primers, are indicated by asterisks (*). The PTO-
linkages were introduced in order to abolish the 3’→5’-proofreading-activity of the DNA-
polymerase, which would otherwise correct the point mutations introduced by the 
oligonucleotides (de Noronha and Mullins (1992)). 
Name Sequence (5’-3’) Comment 
NPR_f 
bbN_rev 
bbC_for 
bbC_rev 
2G_Hind 
2G_Bgl 
GGGAAAGGATCCGACCTGGGTAAGAAACTGCTGG 
CTTACCGAATTTGTCCTGGGTCTCAACATC*A*G 
CCTGATGGCTAACGGTCTCGATGTTAACGC 
ATTAAGCTTTTGCAGGATTTCAGCCAGG 
CCCAAGCTTGGTGGCTCTGACCTGGGTAAGAAACTGC 
GAAGATCTGCCACCTTGCAGGATTTCAGCCAGG 
 
introduces silent mutation 
introduces silent mutation 
 
introduces 2G-linker 
introduces 2G-linker 
 
 
 
Figure 5.2: Construction scheme for the creation of chimeric DARPins-cds. The “building blocks” 
were obtained via PCR on DARPin-cds, introducing BsaI-sites. Digestion with BamHI × BsaI for 
the N-terminal building block and HindIII × BsaI for the C-terminal building block allowed 
ligation of the building blocks into, e.g., vector pDST67 to obtain the chimeric DARPin cds for the 
expression of the chimeric DARPin. 
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Figure 5.3: Flow cytometry with DARPin H14 and chimeric H14-DARPins binding to BT474 
cells. DARPins H14_2C and N2_H14 are chimeric DARPins in which DARPin H14 has been 
elongated C- or N-terminally by introduction of 2 consensus repeat modules next to the 
respective capping repeat. DARPin binding at 100 nM to 0.5 × 106 cells in 1 ml PBS_BA was 
allowed for 1.5 h on ice. After two washings with ice-cold buffer, cells were incubated with an 
AlexaFluor488-conjugated α-His5-antibody (Qiagen) for another hour. Cells incubated without 
any binder or with antibody only served as controls.  
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2.3 Construction of pQi_scZIP and pQi_scdHLX 
Further bivalent DARPin-constructs were designed by replacing linker and downstream 
cloning cassette in pQiBi by a short PSTPPGSS linker sequence and sequences coding for either a 
leucine zipper (scZIP (Pack and Plückthun (1992))) or a four-helix bundle (scdHLX (Pack et al. 
(1993))). The resulting vectors pQi_scZIP and pQi_scdHLX still carry the BamHI/HindIII cassette 
in order to construct DARPins with the respective dimerization module at the C-terminus.  
Vector pQi_scZIP was later used as starting point by N. Stefan for the creation of  
pQiBi_LZ_, a vector that allows for the insertion of DARPin-cds N- and C-terminally oft he leucine 
zipper, creating tetravalent DARPin-constructs (Stefan et al. (2011)).  
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3 Approaches to gain insight into the DARPins’ epitopes 
Every biochemical research that involves binding proteins, no matter of which nature, will 
necessarily improve with increasing knowledge concerning the mode of binding. From the very 
beginning of the project the question of place and orientation of binding of the originally 
characterized DARPins was one of the central ones. No matter if thinking about the biological 
activity of monomeric DARPin H14 in comparison to its competitors for binding – DARPin G3 
and scFv 4D5 (Chapter 2), the question which binders to use for the construction and screening 
of bispecific DARPin constructs (Chapter 3), or the final and still ongoing interpretation and 
explanation of the strong cytotoxic effects caused by these bispecific DARPins – to name only a 
few examples; The question of the particular epitope and the DARPin’s orientation of binding 
was always obvious to ask. 
For that reason, efforts to characterize the DARPin epitopes on HER2 have been 
undertaken continuously in the course of the whole PhD-project. These trials were highly 
complicated by the nature of the DARPins’ target: The extracellular part of HER2 contains 50 
cysteines that are required to form 25 disulfides, very precisely matched, in order to allow the 
protein to fold correctly. This does, for instance, preclude HER2_ECD from simply being 
functionally expressed in the E. coli cytoplasm. The task to identify the correct epitopes is 
further hampered by the fact, that DARPins usually recognize conformational epitopes. The 
correct folding of the epitope can therefore be regarded as a prerequisite for successful epitope 
characterization experiments. 
The following smaller sections are meant to outline the different approaches in epitope 
characterization, that have been undertaken, besides the initial competition assays already 
described in Chapter 2 and in Chapter 3 and the final successful crystallization experiments 
described in Chapter 3.  
 
.  
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3.1 Refolding of HER2_IV 
The chronologically first anti-HER2 DARPin within the project, for which great interest in the 
epitope and the orientation of binding arose, was DARPin H14. Its special characteristic to have 
anti-proliferative effects on HER2 overexpressing cancer cells and its similarity to scFv 4D5 and 
yet difference to DARPin G3 (detailed in  
Chapter 2) made it very desirable to increase the structural knowledge on binding of H14. One 
side project arising quite early was therefore to produce HER2_IV – the subdomain recognized 
by H14 – in the correctly folded state. 
The first technique, which was tried out in order to produce correctly folded 
recombinant HER2_IV, was in vitro protein refolding. Starting with the cloning of the HER2_IV 
cds (A488-L629) into vector pAT222 for cytosolic expression of HER2_IV_A488-L629 with an N-
terminal Avi-tag and a C-terminal His6-tag, the subdomain was expressed in E. coli XL1-blue and 
found to form insoluble inclusion bodies. Following the review by Lange and Rudolph (2008) 
and protocols 1-3 given therein, the inclusion bodies were used as starting point to screen 
various refolding conditions, varying pH (in 0.1 M Tris/HCl buffered refolding buffer) and 
concentrations of L-Arg (as additive) and GSH/GSSG (as redox-shuffling system). 
The success of every refolding project strongly depends on being able to monitor the 
degree of correctly formed protein structure in order to discriminate the potential of the 
different refolding conditions. The fidelity of the chosen refolding efficacy test and its ability to 
monitor as many characteristics as possible, will decide on whether the refolding project is likely 
to succeed or not. 
For the refolding of HER2_IV it was crucial to find a condition in which all 20 cysteines 
formed the correct pattern of 10 disulfides. A correctly refolded HER2_IV would contain no free 
thiol group and would allow binding of trastuzumab and DARPin H14 and G3. Furthermore the 
POI should in the best case show monomeric running behaviour in size-exclusion 
chromatography (SEC), indicating that it does not form soluble aggregates. 
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The refolding condition yielding HER2_IV with most favourable characteristics was the 
refolding of solubilized inclusion bodies by rapid dilution into refolding buffer with 25 mM 
Tris/HCl, pH 9.0; 100 mM NaCl; 10% glycerol; 0.5 M L-Arg; 1.25 mM GSH and 0.25 mM GSSG. 
Inclusion bodies were previously solubilized in Tris buffered saline (TBS: 20 mM TRIS/HCl, pH 
8.0, 500 mM NaCl) containing 5 mM DTT.  
Immunoblots (IB) using trastuzumab as primary antibody for the detection of the 
correctly folded epitope on HER2_IV are shown in Figure 5.4: and Figure 5.5:. Detection of its 
correctly folded epitope by trastuzumab was performed by ELISA as well (Figure 5.5:). The 
experiment described in Figure 5.5: highlights the importance of the GSH:GSSG redox-shuffling 
system for proper refolding of the cysteine-rich HER2_IV_A488-L629. 
Besides trastuzumab-based refolding efficiency assays, the DPS-assay (Hansen et al. 
(2007)) and analytical SEC were performed to rank different refolding conditions. The results of 
these tests with HER2_IV_A488-L629 from the most promising refolding condition (detailed 
above) are depicted in Figure 5.7: and Figure 5.8:. 
It has to be mentioned, that in the course of the refolding trials the initial construct 
HER2_IV_A488-L629 (described above) was exchanged by the construct pD_HER2_IV_A488-
L629, carrying an N-terminal protein D fusion. Protein D (pD) – a protein from bacteriophage 
lambda – has previously been shown to assist folding and help keeping its fusion partner soluble 
(Forrer and Jaussi (1998)). As refolded HER2_IV_A488-L629, after being dialyzed against PBS, 
had shown an early running peak in analytical SEC, the pD-fusion was introduced to counteract 
oligomerization. 
However, even though the pD-equipped POI refolded via the favored refolding condition 
looked rather good in all described tests, indicating the presence of the properly folded 
trastuzumab epitope in a soluble monomeric protein without any free thiols, the 1D proton 
spectrum recorded in 1H NMR indicated that the refolded protein was still rather 
inhomogeneously folded ( 
Figure 5.9:).  
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As structural studies like protein X-ray crystallography require highly homogeneous 
protein material, the efforts to in vitro refold HER2_IV as starting material for crystallization 
screens with DARPin H14 were shelved at that time.  
 
 
 
 
 
 
 
Figure 5.4: HER2_IV from inclusion bodies in SDS-PAGE and trastuzumab-IB. HER2_IV_A488-
L629 expressed in E. coli XL1 blue was IMAC-purified from inclusion bodies and subjected to in 
vitro refolding by rapid dilution. For analysis, reduced (r) or non-reduced (nr) samples were 
loaded on 15% SDS-PAGE gels before (“IMAC-fractions”) or after in vitro refolding. Gels were 
either Coomassie-stained or subjected to immunoblotting using trastuzumab as primary 
antibody and anti-human_AP as secondary antibody. 
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Figure 5.5: Effect of the redox-shuffling system on refolding of the trastuzumab epitope. 
HER2_IV_A488-L629 was refolded in refolding buffer (25 mM Tris/HCl, pH 8.6; 100 mM NaCl; 
10% glycerol; 0.5 M L-Arg) without GSH/GSSH (1), or in the presence of 
1.25 mM GSH  : 0.25 mM GSSG (2) or 0.25 mM GSH : 1.25 mM GSSG (3). Refolded protein from 
different refolding conditions was then analysed by SDS-PAGE (left), trastuzumab IB (middle) 
and ELISA (with trastuzumab as primary antibody) (right). 
 
 
 
 
 
 
 
 
Figure 5.6: ELISA with DARPins H14 and G3 binding to refolded HER2_IV_A488-L629. 
HER2_IV_A488-L629 was refolded in refolding buffer (25 mM Tris/HCl, pH 8.6; 100 mM NaCl; 
10% glycerol; 0.5 M L-Arg; 0.25 mM GSH; 1.25 mM GSSG).  
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Figure 5.7: HPLC run from a DPS-assay for quantification of free thiols in refolded 
HER2_IV_A488-L629. In orer to quantify the free thiol, 280 pmol of refolded and dialyzed 
HER2_IV was incubated with 0.36 mM 4-DPS (4.4’-dithiodipyridine), 6 M urea, 0.2 mM EDTA, 
and 0.1 M citrate at pH 4.5 for 30 min before HPLC analysis. For quantification of the total 
amount of thiol, an equal amount of HER2_IV was treated with 30% (w/v) alkaline sodium 
borohydride (BH) and incubated at 50°C for 30 min to reduce all disulfide bonds. Prior to 
quantification with DPS, all BH was destroyed by the addition of 1.8 M HCl. The peak eluting 
after 6‘ 30‘’ in the reduced sample (“HER2_IV reduced”) corresponds to 4-thiopyridone 
stoichiometrically released in the reaction of 4-DPS with the thiols reduced on purpose. 
According to the DPS-assay, the original refolded HER2_IV (“HER2_IV non reduced”) does not 
contain any free thiols. The peaks eluting early at 5 min are irrelevant solvent peaks (reported 
by Hansen et al. (2007), as well). 
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Figure 5.8: Analytical Size Exclusion Chromatography (SEC) with pD_HER2_IV_A488-L629, 
refolded by rapid dilution. Absorbance at 280 nm (blue line) and 260 mm (red line) is shown. 
Elution volumes of the molecular weight standard consisting of BSA (66 kDa), SHP (50 kDa) and 
cytochrome c (12.4 kDa) are indicated in gray dotted lines. The peak eluting at about 1.75 ml is 
most probably composed of remains from the refolding buffer.  
 
 
 
 
 
 
 
 
 
Table 5.3: Summary of apparent and expected molecular weights of pD_HER2_IV_A488-L629 
calculated from the SEC-run shown in Figure 5.8:. 
sample retention volume (ml) MWapp (kDa) MWseq (kDa) 
pD_HER2_IV_A488-L629 1.18 31.4 27.8 
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Figure 5.9: 1H-NMR spectrum of refolded HER2_IV_A488-L629 (recorded by C. Ewald). 500 µl of 
a 200 µM protein solution in PBS150 were mixed with 10% D2O and measured using a Baker AV-
700 MHz spectrometer. The recorded spectrum shows no peaks beyond 8.5 ppm, indicating that 
the protein is rather inhomogeneously folded. The 1D proton spectrum of a homogeneously 
folded protein should contain a cluster of peaks (derived from methylprotons) around 1 ppm 
and another cluster of peaks above 8.5 ppm (derived from amide protons). 
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3.2 Refolding of further extracellular HER2-subdomains 
Besides the efforts to obtain properly folded HER2_IV for structural studies with DARPins H14 
and G3, known to bind HER2_IV, the need for an at least rough epitope mapping of the anti-HER2 
DARPins known to bind within HER2 domains I-III became apparent as soon as those DARPins 
were found to build powerful bispecific constructs (detailed in and Chapter 4). In order to allow 
an epitope mapping – at least on the domain level, the coding sequences for the three 
extracellular subdomains I, II and III of HER2 were subcloned via ligation-independent cloning 
(LIC) into the vector pEa_HP-lacIq-T5-avi-gpD-his6 (ID eLIC_043, kindly provided by Yvonne 
Neldner) yielding POIs with N-terminal Avi-, pD- and His6-tag for cytoplasmatic expression in 
E. coli. Proteins were purified from inclusion bodies and refolded via dialysis in refolding buffer 
containing 25 mM Tris/HCl, pH 8.5; 100 mM NaCl; 10% glycerol; 0.5 M L-Arg; 0.25 mM GSH 
and 1.25 mM GSSG.  
Refolded HER2 domains were used for epitope estimation studies of HER2-binding 
DARPins from phage display selections on HER2_I-III. For this, a competition ELISA set-up was 
chosen with DARPin-binding to immobilized HER2_ECD (“HER2_623biot” used for initial 
selection) being competed with the refolded HER2 domains. Figure 5.10: shows the result of a 
competition ELISA performed with 25 nM DARPin competed with 1 µM refolded domain for 
binding to HER2_623biot, immobilized on neutravidin coated wells. Comparison of the signals 
from competition mixtures with the signals obtained from non-competed binding suggests that 
all binders except DARPin H14 might bind HER2_I. 
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Figure 5.10: Competition ELISA with HER2-binding DARPins competed by different refolded 
HER2 domains. 25 nM solutions of HER2 binders were preincubated for 1 h at RT either without 
(“no competition”) or with 1 µM of the respective refolded HER2 domains. Precincubated 
volumes were than applied to an ELISA with immobilized HER2_ECD (coated with 100 µl of a 
15 nM solution per well on neutravidin-precoated plates).  
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3.3 Chemical Linkage of Peptides onto Scaffolds (CLiPS) 
Besides the above-mentioned refolding trials of the extracellular HER2-subdomains, one further 
technique of conformational epitope-mapping, namely CLiPS (Chemical Linkage of Peptides onto 
Scaffolds) (Timmerman et al. (2005)), was tested in a collaboration with Pepscan Presto BV, Inc.  
The CLiPS-methodology (CLIPScan™) involves cyclization of small linear peptides (20-
30 aa) with two or three cysteines via reaction with a small synthetic entity carrying reactive 
benzyl bromides.  
In our case, 5000 different HER2-CLIPS peptides, covering the whole HER2_ECD, were 
synthesized and immobilized onto chips. DARPin binding was tested at 1 µg/ml (~ 55 nM) in 
PBS containing 1% Tween, followed by detection of the DARPins’ His-tag via primary and 
secondary antibodies. 
Unfortunately, the CLIPScan-method did not provide useful data for any of the tested 
HER2-binding DARPins. Even though the positive control (trastuzumab) had worked nicely on 
the generated HER2-CLIPS-library, the epitope mapping for the DARPins was inconsistent with 
data from ELISA-measurements, that had e.g. shown binding of the 9.xx-DARPins to HER2_I but 
not to HER2_III (data, that was later confirmed by X-ray crystallography). One possible 
explanation for this inconsistency might lie in the high stability of the DARPins: Within the 
screening procedure, the chips containing the HER2-peptide-library are usually reused for 
several binders after a thorough stripping-step. It is likely that some of the bound DARPins 
resisted that stripping and remained bound to the chip. However, this would not explain another 
inconsistency, which is the CLIPScan-mapping of e.g. the DARPin 9_26 epitope to a region on 
HER2 subdomain III. Since accoding to today’s knowledge, based on data from ELISA, SEC and X-
ray crystallography, none of the known HER2-binding DARPins has its epitope on HER2_III, this 
CLIPScan-output is cleary wrong. It remains to be seen, if the CLIPScan-technology might be 
used for epitope mapping of DARPins with other targets.  
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In the case of the HER2-binding DARPins the approach yielding cleary the most reliable 
epitope data has proven to be the expression of single HER2_ECD subdomains, followed by 
ELISA (cf. Chapter 2 and Appendix 3) and crystallization (cf. Chapter 2). 
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3.4 Xtal- conditions screened 
The most interesting HER2-binding DARPins proved to be DARPins 9_26 and 9_29, binding to 
HER2_I, and DARPins G3 and H_14, binding to HER2_IV, as described above. As Chapter 3 only 
lists the crystallization conditions which finally yielded the well diffracting crystals, but by far 
not all conditions screened, the following section is supposed to supplement this information. 
Besides screening different putative crystallization conditions (listed in Table 5.4: to 
Table 5.11:), different formats both of the respective DARPin (e.g. old C-cap, new C-cap, 
chimeric versions) or its domain (e.g. glycosylated, non-glycosylated, single or fused domains) 
were tested. 
In general, all different SEC-purified DARPin:target complexes to be tested in the 
crystallization screens were brought to concentrations of 8 to 12 g/l in TBS150 and then screened 
in sitting drops with three drops per condition (usually 100+100, 200+100 and 100+200 
[nl protein solution + nl mother liquor]). 
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Table 5.4: Grid screen “GS001” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 3 0.2 M Li2SO4 0.1 M malonic acid 5 % w/v PEG 4000 
A02 3 0.2 M Li2SO4 0.1 M malonic acid 10 % w/v PEG 4000 
A03 3 0.2 M Li2SO4 0.1 M malonic acid 15 % w/v PEG 4000 
A04 3 0.2 M Li2SO4 0.1 M malonic acid 20 % w/v PEG 4000 
A05 3 0.2 M Li2SO4 0.1 M malonic acid 25 % w/v PEG 4000 
A06 3 0.2 M Li2SO4 0.1 M malonic acid 30 % w/v PEG 4000 
A07 3 
   
0.1 M malonic acid 5 % w/v PEG 8000 
A08 3 
   
0.1 M malonic acid 10 % w/v PEG 8000 
A09 3 
   
0.1 M malonic acid 15 % w/v PEG 8000 
A10 3 
   
0.1 M malonic acid 20 % w/v PEG 8000 
A11 3 
   
0.1 M malonic acid 25 % w/v PEG 8000 
A12 3 
   
0.1 M malonic acid 30 % w/v PEG 8000 
B01 4 0.2 M Li2SO4 0.05 M succinic acid 5 % w/v PEG 4000 
B02 4 0.2 M Li2SO4 0.05 M succinic acid 10 % w/v PEG 4000 
B03 4 0.2 M Li2SO4 0.05 M succinic acid 15 % w/v PEG 4000 
B04 4 0.2 M Li2SO4 0.05 M succinic acid 20 % w/v PEG 4000 
B05 4 0.2 M Li2SO4 0.05 M succinic acid 25 % w/v PEG 4000 
B06 4 0.2 M Li2SO4 0.05 M succinic acid 30 % w/v PEG 4000 
B07 4 
   
0.05 M succinic acid 5 % w/v PEG 8000 
B08 4 
   
0.05 M succinic acid 10 % w/v PEG 8000 
B09 4 
   
0.05 M succinic acid 15 % w/v PEG 8000 
B10 4 
   
0.05 M succinic acid 20 % w/v PEG 8000 
B11 4 
   
0.05 M succinic acid 25 % w/v PEG 8000 
B12 4 
   
0.05 M succinic acid 30 % w/v PEG 8000 
C01 5 0.2 M Li2SO4 0.1 M citric acid 5 % w/v PEG 4000 
C02 5 0.2 M Li2SO4 0.1 M citric acid 10 % w/v PEG 4000 
C03 5 0.2 M Li2SO4 0.1 M citric acid 15 % w/v PEG 4000 
C04 5 0.2 M Li2SO4 0.1 M citric acid 20 % w/v PEG 4000 
C05 5 0.2 M Li2SO4 0.1 M citric acid 25 % w/v PEG 4000 
C06 5 0.2 M Li2SO4 0.1 M citric acid 30 % w/v PEG 4000 
C07 5 
   
0.1 M citric acid 5 % w/v PEG 8000 
C08 5 
   
0.1 M citric acid 10 % w/v PEG 8000 
C09 5 
   
0.1 M citric acid 15 % w/v PEG 8000 
C10 5 
   
0.1 M citric acid 20 % w/v PEG 8000 
C11 5 
   
0.1 M citric acid 25 % w/v PEG 8000 
C12 5 
   
0.1 M citric acid 30 % w/v PEG 8000 
D01 6 0.2 M Li2SO4 0.1 M MES 5 % w/v PEG 4000 
D02 6 0.2 M Li2SO4 0.1 M MES 10 % w/v PEG 4000 
D03 6 0.2 M Li2SO4 0.1 M MES 15 % w/v PEG 4000 
D04 6 0.2 M Li2SO4 0.1 M MES 20 % w/v PEG 4000 
D05 6 0.2 M Li2SO4 0.1 M MES 25 % w/v PEG 4000 
D06 6 0.2 M Li2SO4 0.1 M MES 30 % w/v PEG 4000 
D07 6 
   
0.1 M MES 5 % w/v PEG 8000 
D08 6 
   
0.1 M MES 10 % w/v PEG 8000 
D09 6 
   
0.1 M MES 15 % w/v PEG 8000 
D10 6 
   
0.1 M MES 20 % w/v PEG 8000 
D11 6 
   
0.1 M MES 25 % w/v PEG 8000 
D12 6 
   
0.1 M MES 30 % w/v PEG 8000 
E01 7 0.2 M Li2SO4 0.1 M MOPS 5 % w/v PEG 4000 
E02 7 0.2 M Li2SO4 0.1 M MOPS 10 % w/v PEG 4000 
E03 7 0.2 M Li2SO4 0.1 M MOPS 15 % w/v PEG 4000 
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E04 7 0.2 M Li2SO4 0.1 M MOPS 20 % w/v PEG 4000 
E05 7 0.2 M Li2SO4 0.1 M MOPS 25 % w/v PEG 4000 
E06 7 0.2 M Li2SO4 0.1 M MOPS 30 % w/v PEG 4000 
E07 7 
   
0.1 M MOPS 5 % w/v PEG 8000 
E08 7 
   
0.1 M MOPS 10 % w/v PEG 8000 
E09 7 
   
0.1 M MOPS 15 % w/v PEG 8000 
E10 7 
   
0.1 M MOPS 20 % w/v PEG 8000 
E11 7 
   
0.1 M MOPS 25 % w/v PEG 8000 
E12 7 
   
0.1 M MOPS 30 % w/v PEG 8000 
F01 8 0.2 M Li2SO4 0.1 M HEPES 5 % w/v PEG 4000 
F02 8 0.2 M Li2SO4 0.1 M HEPES 10 % w/v PEG 4000 
F03 8 0.2 M Li2SO4 0.1 M HEPES 15 % w/v PEG 4000 
F04 8 0.2 M Li2SO4 0.1 M HEPES 20 % w/v PEG 4000 
F05 8 0.2 M Li2SO4 0.1 M HEPES 25 % w/v PEG 4000 
F06 8 0.2 M Li2SO4 0.1 M HEPES 30 % w/v PEG 4000 
F07 8 
   
0.1 M HEPES 5 % w/v PEG 8000 
F08 8 
   
0.1 M HEPES 10 % w/v PEG 8000 
F09 8 
   
0.1 M HEPES 15 % w/v PEG 8000 
F10 8 
   
0.1 M HEPES 20 % w/v PEG 8000 
F11 8 
   
0.1 M HEPES 25 % w/v PEG 8000 
F12 8 
   
0.1 M HEPES 30 % w/v PEG 8000 
G01 9 0.2 M Li2SO4 0.02 M TAPS 5 % w/v PEG 4000 
G02 9 0.2 M Li2SO4 0.02 M TAPS 10 % w/v PEG 4000 
G03 9 0.2 M Li2SO4 0.02 M TAPS 15 % w/v PEG 4000 
G04 9 0.2 M Li2SO4 0.02 M TAPS 20 % w/v PEG 4000 
G05 9 0.2 M Li2SO4 0.02 M TAPS 25 % w/v PEG 4000 
G06 9 0.2 M Li2SO4 0.02 M TAPS 30 % w/v PEG 4000 
G07 9 
   
0.02 M TAPS 5 % w/v PEG 8000 
G08 9 
   
0.02 M TAPS 10 % w/v PEG 8000 
G09 9 
   
0.02 M TAPS 15 % w/v PEG 8000 
G10 9 
   
0.02 M TAPS 20 % w/v PEG 8000 
G11 9 
   
0.02 M TAPS 25 % w/v PEG 8000 
G12 9 
   
0.02 M TAPS 30 % w/v PEG 8000 
H01 10 0.2 M Li2SO4 0.02 M CAPS 5 % w/v PEG 4000 
H02 10 0.2 M Li2SO4 0.02 M CAPS 10 % w/v PEG 4000 
H03 10 0.2 M Li2SO4 0.02 M CAPS 15 % w/v PEG 4000 
H04 10 0.2 M Li2SO4 0.02 M CAPS 20 % w/v PEG 4000 
H05 10 0.2 M Li2SO4 0.02 M CAPS 25 % w/v PEG 4000 
H06 10 0.2 M Li2SO4 0.02 M CAPS 30 % w/v PEG 4000 
H07 10 
   
0.02 M CAPS 5 % w/v PEG 8000 
H08 10 
   
0.02 M CAPS 10 % w/v PEG 8000 
H09 10 
   
0.02 M CAPS 15 % w/v PEG 8000 
H10 10 
   
0.02 M CAPS 20 % w/v PEG 8000 
H11 10 
   
0.02 M CAPS 25 % w/v PEG 8000 
H12 10 
   
0.02 M CAPS 30 % w/v PEG 8000 
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Table 5.5: Grid screen “GS002” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 3       0.1 M malonic acid 15 % (NH4)2SO4 (at 4°C saturated) 
A02 3 
   
0.1 M malonic acid 20 % (NH4)2SO4 (at 4°C saturated) 
A03 3 
   
0.1 M malonic acid 25 % (NH4)2SO4 (at 4°C saturated) 
A04 3 
   
0.1 M malonic acid 30 % (NH4)2SO4 (at 4°C saturated) 
A05 3 
   
0.1 M malonic acid 35 % (NH4)2SO4 (at 4°C saturated) 
A06 3 
   
0.1 M malonic acid 40 % (NH4)2SO4 (at 4°C saturated) 
A07 3 
   
0.1 M malonic acid 45 % (NH4)2SO4 (at 4°C saturated) 
A08 3 
   
0.1 M malonic acid 50 % (NH4)2SO4 (at 4°C saturated) 
A09 3 
   
0.1 M malonic acid 55 % (NH4)2SO4 (at 4°C saturated) 
A10 3 
   
0.1 M malonic acid 60 % (NH4)2SO4 (at 4°C saturated) 
A11 3 
   
0.1 M malonic acid 70 % (NH4)2SO4 (at 4°C saturated) 
A12 3 
   
0.1 M malonic acid 80 % (NH4)2SO4 (at 4°C saturated) 
B01 4       0.05 M succinic acid 15 % (NH4)2SO4 (at 4°C saturated) 
B02 4 
   
0.05 M succinic acid 20 % (NH4)2SO4 (at 4°C saturated) 
B03 4 
   
0.05 M succinic acid 25 % (NH4)2SO4 (at 4°C saturated) 
B04 4 
   
0.05 M succinic acid 30 % (NH4)2SO4 (at 4°C saturated) 
B05 4 
   
0.05 M succinic acid 35 % (NH4)2SO4 (at 4°C saturated) 
B06 4 
   
0.05 M succinic acid 40 % (NH4)2SO4 (at 4°C saturated) 
B07 4 
   
0.05 M succinic acid 45 % (NH4)2SO4 (at 4°C saturated) 
B08 4 
   
0.05 M succinic acid 50 % (NH4)2SO4 (at 4°C saturated) 
B09 4 
   
0.05 M succinic acid 55 % (NH4)2SO4 (at 4°C saturated) 
B10 4 
   
0.05 M succinic acid 60 % (NH4)2SO4 (at 4°C saturated) 
B11 4 
   
0.05 M succinic acid 70 % (NH4)2SO4 (at 4°C saturated) 
B12 4 
   
0.05 M succinic acid 80 % (NH4)2SO4 (at 4°C saturated) 
C01 5       0.1 M citric acid 15 % (NH4)2SO4 (at 4°C saturated) 
C02 5 
   
0.1 M citric acid 20 % (NH4)2SO4 (at 4°C saturated) 
C03 5 
   
0.1 M citric acid 25 % (NH4)2SO4 (at 4°C saturated) 
C04 5 
   
0.1 M citric acid 30 % (NH4)2SO4 (at 4°C saturated) 
C05 5 
   
0.1 M citric acid 35 % (NH4)2SO4 (at 4°C saturated) 
C06 5 
   
0.1 M citric acid 40 % (NH4)2SO4 (at 4°C saturated) 
C07 5 
   
0.1 M citric acid 45 % (NH4)2SO4 (at 4°C saturated) 
C08 5 
   
0.1 M citric acid 50 % (NH4)2SO4 (at 4°C saturated) 
C09 5 
   
0.1 M citric acid 55 % (NH4)2SO4 (at 4°C saturated) 
C10 5 
   
0.1 M citric acid 60 % (NH4)2SO4 (at 4°C saturated) 
C11 5 
   
0.1 M citric acid 70 % (NH4)2SO4 (at 4°C saturated) 
C12 5 
   
0.1 M citric acid 80 % (NH4)2SO4 (at 4°C saturated) 
D01 6       0.1 M MES 15 % (NH4)2SO4 (at 4°C saturated) 
D02 6 
   
0.1 M MES 20 % (NH4)2SO4 (at 4°C saturated) 
D03 6 
   
0.1 M MES 25 % (NH4)2SO4 (at 4°C saturated) 
D04 6 
   
0.1 M MES 30 % (NH4)2SO4 (at 4°C saturated) 
D05 6 
   
0.1 M MES 35 % (NH4)2SO4 (at 4°C saturated) 
D06 6 
   
0.1 M MES 40 % (NH4)2SO4 (at 4°C saturated) 
D07 6 
   
0.1 M MES 45 % (NH4)2SO4 (at 4°C saturated) 
D08 6 
   
0.1 M MES 50 % (NH4)2SO4 (at 4°C saturated) 
D09 6 
   
0.1 M MES 55 % (NH4)2SO4 (at 4°C saturated) 
D10 6 
   
0.1 M MES 60 % (NH4)2SO4 (at 4°C saturated) 
D11 6 
   
0.1 M MES 70 % (NH4)2SO4 (at 4°C saturated) 
D12 6 
   
0.1 M MES 80 % (NH4)2SO4 (at 4°C saturated) 
E01 7       0.1 M MOPS 15 % (NH4)2SO4 (at 4°C saturated) 
E02 7 
   
0.1 M MOPS 20 % (NH4)2SO4 (at 4°C saturated) 
E03 7 
   
0.1 M MOPS 25 % (NH4)2SO4 (at 4°C saturated) 
Further Methods and Results  179 
 
E04 7 
   
0.1 M MOPS 30 % (NH4)2SO4 (at 4°C saturated) 
E05 7 
   
0.1 M MOPS 35 % (NH4)2SO4 (at 4°C saturated) 
E06 7 
   
0.1 M MOPS 40 % (NH4)2SO4 (at 4°C saturated) 
E07 7 
   
0.1 M MOPS 45 % (NH4)2SO4 (at 4°C saturated) 
E08 7 
   
0.1 M MOPS 50 % (NH4)2SO4 (at 4°C saturated) 
E09 7 
   
0.1 M MOPS 55 % (NH4)2SO4 (at 4°C saturated) 
E10 7 
   
0.1 M MOPS 60 % (NH4)2SO4 (at 4°C saturated) 
E11 7 
   
0.1 M MOPS 70 % (NH4)2SO4 (at 4°C saturated) 
E12 7 
   
0.1 M MOPS 80 % (NH4)2SO4 (at 4°C saturated) 
F01 8       0.1 M HEPES 15 % (NH4)2SO4 (at 4°C saturated) 
F02 8 
   
0.1 M HEPES 20 % (NH4)2SO4 (at 4°C saturated) 
F03 8 
   
0.1 M HEPES 25 % (NH4)2SO4 (at 4°C saturated) 
F04 8 
   
0.1 M HEPES 30 % (NH4)2SO4 (at 4°C saturated) 
F05 8 
   
0.1 M HEPES 35 % (NH4)2SO4 (at 4°C saturated) 
F06 8 
   
0.1 M HEPES 40 % (NH4)2SO4 (at 4°C saturated) 
F07 8 
   
0.1 M HEPES 45 % (NH4)2SO4 (at 4°C saturated) 
F08 8 
   
0.1 M HEPES 50 % (NH4)2SO4 (at 4°C saturated) 
F09 8 
   
0.1 M HEPES 55 % (NH4)2SO4 (at 4°C saturated) 
F10 8 
   
0.1 M HEPES 60 % (NH4)2SO4 (at 4°C saturated) 
F11 8 
   
0.1 M HEPES 70 % (NH4)2SO4 (at 4°C saturated) 
F12 8 
   
0.1 M HEPES 80 % (NH4)2SO4 (at 4°C saturated) 
G01 9       0.02 M TAPS 15 % (NH4)2SO4 (at 4°C saturated) 
G02 9 
   
0.02 M TAPS 20 % (NH4)2SO4 (at 4°C saturated) 
G03 9 
   
0.02 M TAPS 25 % (NH4)2SO4 (at 4°C saturated) 
G04 9 
   
0.02 M TAPS 30 % (NH4)2SO4 (at 4°C saturated) 
G05 9 
   
0.02 M TAPS 35 % (NH4)2SO4 (at 4°C saturated) 
G06 9 
   
0.02 M TAPS 40 % (NH4)2SO4 (at 4°C saturated) 
G07 9 
   
0.02 M TAPS 45 % (NH4)2SO4 (at 4°C saturated) 
G08 9 
   
0.02 M TAPS 50 % (NH4)2SO4 (at 4°C saturated) 
G09 9 
   
0.02 M TAPS 55 % (NH4)2SO4 (at 4°C saturated) 
G10 9 
   
0.02 M TAPS 60 % (NH4)2SO4 (at 4°C saturated) 
G11 9 
   
0.02 M TAPS 70 % (NH4)2SO4 (at 4°C saturated) 
G12 9 
   
0.02 M TAPS 80 % (NH4)2SO4 (at 4°C saturated) 
H01 10       0.02 M CAPS 15 % (NH4)2SO4 (at 4°C saturated) 
H02 10 
   
0.02 M CAPS 20 % (NH4)2SO4 (at 4°C saturated) 
H03 10 
   
0.02 M CAPS 25 % (NH4)2SO4 (at 4°C saturated) 
H04 10 
   
0.02 M CAPS 30 % (NH4)2SO4 (at 4°C saturated) 
H05 10 
   
0.02 M CAPS 35 % (NH4)2SO4 (at 4°C saturated) 
H06 10 
   
0.02 M CAPS 40 % (NH4)2SO4 (at 4°C saturated) 
H07 10 
   
0.02 M CAPS 45 % (NH4)2SO4 (at 4°C saturated) 
H08 10 
   
0.02 M CAPS 50 % (NH4)2SO4 (at 4°C saturated) 
H09 10 
   
0.02 M CAPS 55 % (NH4)2SO4 (at 4°C saturated) 
H10 10 
   
0.02 M CAPS 60 % (NH4)2SO4 (at 4°C saturated) 
H11 10 
   
0.02 M CAPS 70 % (NH4)2SO4 (at 4°C saturated) 
H12 10 
   
0.02 M CAPS 80 % (NH4)2SO4 (at 4°C saturated) 
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Table 5.6: Grid screen “GS003” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 3 0.2 M Li2SO4 0.1 M malonic acid 5 % w/v PEG 4000 
A02 3 0.2 M Li2SO4 0.1 M malonic acid 10 % w/v PEG 4000 
A03 3 0.2 M Li2SO4 0.1 M malonic acid 15 % w/v PEG 4000 
A04 3 0.2 M Li2SO4 0.1 M malonic acid 20 % w/v PEG 4000 
A05 3 0.2 M Li2SO4 0.1 M malonic acid 25 % w/v PEG 4000 
A06 3 0.2 M Li2SO4 0.1 M malonic acid 30 % w/v PEG 4000 
A07 3 
   
0.1 M malonic acid 5 % w/v PEG 6000 
A08 3 
   
0.1 M malonic acid 10 % w/v PEG 6000 
A09 3 
   
0.1 M malonic acid 15 % w/v PEG 6000 
A10 3 
   
0.1 M malonic acid 20 % w/v PEG 6000 
A11 3 
   
0.1 M malonic acid 25 % w/v PEG 6000 
A12 3 
   
0.1 M malonic acid 30 % w/v PEG 6000 
B01 4 0.2 M Li2SO4 0.05 M succinic acid 5 % w/v PEG 4000 
B02 4 0.2 M Li2SO4 0.05 M succinic acid 10 % w/v PEG 4000 
B03 4 0.2 M Li2SO4 0.05 M succinic acid 15 % w/v PEG 4000 
B04 4 0.2 M Li2SO4 0.05 M succinic acid 20 % w/v PEG 4000 
B05 4 0.2 M Li2SO4 0.05 M succinic acid 25 % w/v PEG 4000 
B06 4 0.2 M Li2SO4 0.05 M succinic acid 30 % w/v PEG 4000 
B07 4 
   
0.05 M succinic acid 5 % w/v PEG 6000 
B08 4 
   
0.05 M succinic acid 10 % w/v PEG 6000 
B09 4 
   
0.05 M succinic acid 15 % w/v PEG 6000 
B10 4 
   
0.05 M succinic acid 20 % w/v PEG 6000 
B11 4 
   
0.05 M succinic acid 25 % w/v PEG 6000 
B12 4 
   
0.05 M succinic acid 30 % w/v PEG 6000 
C01 5 0.2 M Li2SO4 0.1 M citric acid 5 % w/v PEG 4000 
C02 5 0.2 M Li2SO4 0.1 M citric acid 10 % w/v PEG 4000 
C03 5 0.2 M Li2SO4 0.1 M citric acid 15 % w/v PEG 4000 
C04 5 0.2 M Li2SO4 0.1 M citric acid 20 % w/v PEG 4000 
C05 5 0.2 M Li2SO4 0.1 M citric acid 25 % w/v PEG 4000 
C06 5 0.2 M Li2SO4 0.1 M citric acid 30 % w/v PEG 4000 
C07 5 
   
0.1 M citric acid 5 % w/v PEG 6000 
C08 5 
   
0.1 M citric acid 10 % w/v PEG 6000 
C09 5 
   
0.1 M citric acid 15 % w/v PEG 6000 
C10 5 
   
0.1 M citric acid 20 % w/v PEG 6000 
C11 5 
   
0.1 M citric acid 25 % w/v PEG 6000 
C12 5 
   
0.1 M citric acid 30 % w/v PEG 6000 
D01 6 0.2 M Li2SO4 0.1 M MES 5 % w/v PEG 4000 
D02 6 0.2 M Li2SO4 0.1 M MES 10 % w/v PEG 4000 
D03 6 0.2 M Li2SO4 0.1 M MES 15 % w/v PEG 4000 
D04 6 0.2 M Li2SO4 0.1 M MES 20 % w/v PEG 4000 
D05 6 0.2 M Li2SO4 0.1 M MES 25 % w/v PEG 4000 
D06 6 0.2 M Li2SO4 0.1 M MES 30 % w/v PEG 4000 
D07 6 
   
0.1 M MES 5 % w/v PEG 6000 
D08 6 
   
0.1 M MES 10 % w/v PEG 6000 
D09 6 
   
0.1 M MES 15 % w/v PEG 6000 
D10 6 
   
0.1 M MES 20 % w/v PEG 6000 
D11 6 
   
0.1 M MES 25 % w/v PEG 6000 
D12 6 
   
0.1 M MES 30 % w/v PEG 6000 
E01 7 0.2 M Li2SO4 0.1 M MOPS 5 % w/v PEG 4000 
E02 7 0.2 M Li2SO4 0.1 M MOPS 10 % w/v PEG 4000 
E03 7 0.2 M Li2SO4 0.1 M MOPS 15 % w/v PEG 4000 
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E04 7 0.2 M Li2SO4 0.1 M MOPS 20 % w/v PEG 4000 
E05 7 0.2 M Li2SO4 0.1 M MOPS 25 % w/v PEG 4000 
E06 7 0.2 M Li2SO4 0.1 M MOPS 30 % w/v PEG 4000 
E07 7 
   
0.1 M MOPS 5 % w/v PEG 6000 
E08 7 
   
0.1 M MOPS 10 % w/v PEG 6000 
E09 7 
   
0.1 M MOPS 15 % w/v PEG 6000 
E10 7 
   
0.1 M MOPS 20 % w/v PEG 6000 
E11 7 
   
0.1 M MOPS 25 % w/v PEG 6000 
E12 7 
   
0.1 M MOPS 30 % w/v PEG 6000 
F01 8 0.2 M Li2SO4 0.1 M HEPES 5 % w/v PEG 4000 
F02 8 0.2 M Li2SO4 0.1 M HEPES 10 % w/v PEG 4000 
F03 8 0.2 M Li2SO4 0.1 M HEPES 15 % w/v PEG 4000 
F04 8 0.2 M Li2SO4 0.1 M HEPES 20 % w/v PEG 4000 
F05 8 0.2 M Li2SO4 0.1 M HEPES 25 % w/v PEG 4000 
F06 8 0.2 M Li2SO4 0.1 M HEPES 30 % w/v PEG 4000 
F07 8 
   
0.1 M HEPES 5 % w/v PEG 6000 
F08 8 
   
0.1 M HEPES 10 % w/v PEG 6000 
F09 8 
   
0.1 M HEPES 15 % w/v PEG 6000 
F10 8 
   
0.1 M HEPES 20 % w/v PEG 6000 
F11 8 
   
0.1 M HEPES 25 % w/v PEG 6000 
F12 8 
   
0.1 M HEPES 30 % w/v PEG 6000 
G01 9 0.2 M Li2SO4 0.02 M TAPS 5 % w/v PEG 4000 
G02 9 0.2 M Li2SO4 0.02 M TAPS 10 % w/v PEG 4000 
G03 9 0.2 M Li2SO4 0.02 M TAPS 15 % w/v PEG 4000 
G04 9 0.2 M Li2SO4 0.02 M TAPS 20 % w/v PEG 4000 
G05 9 0.2 M Li2SO4 0.02 M TAPS 25 % w/v PEG 4000 
G06 9 0.2 M Li2SO4 0.02 M TAPS 30 % w/v PEG 4000 
G07 9 
   
0.02 M TAPS 5 % w/v PEG 6000 
G08 9 
   
0.02 M TAPS 10 % w/v PEG 6000 
G09 9 
   
0.02 M TAPS 15 % w/v PEG 6000 
G10 9 
   
0.02 M TAPS 20 % w/v PEG 6000 
G11 9 
   
0.02 M TAPS 25 % w/v PEG 6000 
G12 9 
   
0.02 M TAPS 30 % w/v PEG 6000 
H01 10 0.2 M Li2SO4 0.02 M CAPS 5 % w/v PEG 4000 
H02 10 0.2 M Li2SO4 0.02 M CAPS 10 % w/v PEG 4000 
H03 10 0.2 M Li2SO4 0.02 M CAPS 15 % w/v PEG 4000 
H04 10 0.2 M Li2SO4 0.02 M CAPS 20 % w/v PEG 4000 
H05 10 0.2 M Li2SO4 0.02 M CAPS 25 % w/v PEG 4000 
H06 10 0.2 M Li2SO4 0.02 M CAPS 30 % w/v PEG 4000 
H07 10 
   
0.02 M CAPS 5 % w/v PEG 6000 
H08 10 
   
0.02 M CAPS 10 % w/v PEG 6000 
H09 10 
   
0.02 M CAPS 15 % w/v PEG 6000 
H10 10 
   
0.02 M CAPS 20 % w/v PEG 6000 
H11 10 
   
0.02 M CAPS 25 % w/v PEG 6000 
H12 10 
   
0.02 M CAPS 30 % w/v PEG 6000 
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Table 5.7: Grid screen “GS007” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
 
Well pH Value Units Name Value Units Name Value Units Name 
 
A01 5.5 0.3 M Na-Acetate 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A02 5.5 0.2 M Li2SO4 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A03 5.5 0.2 M MgCl2 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A04 5.5 0.2 M KBr 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A05 5.5 0.2 M KSCN 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A06 5.5 0.8 M Na-Formate 0.1 M Na-Acetate 25 % PEG 2K MME 
 
A07 5.5 0.3 M Na-Acetate 0.1 M Na-Acetate 15 % PEG 4K 
 
A08 5.5 0.2 M Li2SO4 0.1 M Na-Acetate 15 % PEG 4K 
 
A09 5.5 0.2 M MgCl2 0.1 M Na-Acetate 15 % PEG 4K 
 
A10 5.5 0.2 M KBr 0.1 M Na-Acetate 15 % PEG 4K 
 
A11 5.5 0.2 M KSCN 0.1 M Na-Acetate 15 % PEG 4K 
 
A12 5.5 0.8 M Na-Formate 0.1 M Na-Acetate 15 % PEG 4K 
 
B01 5.5 0.3 M Na-Acetate 0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B02 5.5 0.2 M Li2SO4 0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B03 5.5 0.2 M MgCl2 0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B04 5.5 0.2 M KBr 0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B05 5.5 0.2 M KSCN 0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B06 5.5 0.8 M Na-Formate  0.1 M Na-Acetate 10 % PEG 8K PEG 1K 
B06 
       
10 % PEG 1K 
 
B07 5.5 0.3 M Na-Acetate 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
B08 5.5 0.2 M Li2SO4 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
B09 5.5 0.2 M MgCl2 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
B10 5.5 0.2 M KBr 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
B11 5.5 0.2 M KSCN 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
B12 5.5 0.8 M Na-Formate 0.1 M Na-Acetate 8 % PEG 20K PEG550 MME 
C01 5.5       0.1 M Na-Acetate 1.5 M (NH4)2SO4 
 
C02 5.5 0.8 M Li2SO4 0.1 M Na-Acetate 
   
 
C03 5.5 
   
0.1 M Na-Acetate 2 M Na-Formate 
 
C04 5.5 0.5 M KH2PO4 0.1 M Na-Acetate 
   
 
C05 5.5 0.2 M Ca-Acetate 0.1 M Na-Acetate 25 % PEG 2KMME 
 
C06 5.5 0.2 M Ca-Acetate 0.1 M Na-Acetate 15 % PEG 4K 
 
C07 5.5 
   
0.1 M Na-Acetate 2.7 M (NH4)2SO4 
 
C08 5.5 
   
0.1 M Na-Acetate 1.8 M  Li2SO4 
 
C09 5.5 
   
0.1 M Na-Acetate 4 M Na-Formate 
 
C10 5.5 
   
0.1 M Na-Acetate 1 M KH2PO4 
 
C11 5.5 0.2 M Ca-Acetate 0.1 M Na-Acetate 10 % PEG 8K 
 
C11 
       
10 % PEG 1K 
 
C12 5.5 0.2 M Ca-Acetate 0.1 M Na-Acetate 8 % PEG 20K 
 
C12 
       
8 % PEG 550MME 
 
D01 5.5       0.1 M Na-Acetate 40 %  MPD 
 
D02 5.5 
   
0.1 M Na-Acetate 40 %   Butane-diol 
 
D03 5.5 0.005 M CdCl2 0.1 M Na-Acetate 20 % PEG 4K 
 
D04 5.5 0.15 M KSCN 0.1 M Na-Acetate 20 % PEG 550 MME 
 
D05 5.5 0.15 M KSCN 0.1 M Na-Acetate 20 % PEG 600 
 
D06 5.5 0.15 M KSCN 0.1 M Na-Acetate 20 % PEG 1.5K 
 
D07 5.5 
   
0.1 M Na-Acetate 35 %  Isopropanol 
 
D08 5.5 
   
0.1 M Na-Acetate 30 %  Jeffamine 600M 
 
D09 5.5 0.005 M NiCl2 0.1 M Na-Acetate 20 %  PEG 4K 
 
D10 5.5 0.15 M KSCN 0.1 M Na-Acetate 18 % PEG 3350 
 
D11 5.5 0.15 M KSCN 0.1 M Na-Acetate 18 % PEG 5K MME 
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D12 5.5 0.15 M KSCN 0.1 M Na-Acetate 15 % PEG 6K 
 
E01 6.5 0.3 M Na-Acetate 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E02 6.5 0.2 M Li2SO4 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E03 6.5 0.2 M MgCl2 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E04 6.5 0.2 M KBr 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E05 6.5 0.2 M KSCN 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E06 6.5 0.8 M Na-Formate 0.1 M Na-Cacodylate 25 % PEG 2K MME 
 
E07 6.5 0.3 M Na-Acetate 0.1 M Na-Cacodylate 15 % PEG 4K 
 
E08 6.5 0.2 M Li2SO4 0.1 M Na-Cacodylate 15 % PEG 4K 
 
E09 6.5 0.2 M MgCl2 0.1 M Na-Cacodylate 15 % PEG 4K 
 
E10 6.5 0.2 M KBr 0.1 M Na-Cacodylate 15 % PEG 4K 
 
E11 6.5 0.2 M KSCN 0.1 M Na-Cacodylate 15 % PEG 4K 
 
E12 6.5 0.8 M Na-Formate 0.1 M Na-Cacodylate 15 % PEG 4K 
 
F01 6.5 0.3 M Na-Acetate 0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F02 6.5 0.2 M Li2SO4 0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F03 6.5 0.2 M MgCl2 0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F04 6.5 0.2 M KBr 0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F05 6.5 0.2 M KSCN 0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F06 6.5 0.8 M Na-Formate  0.1 M Na-Cacodylate 10 % PEG 8K 
PEG 1K 
F07 6.5 0.3 M Na-Acetate 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
F08 6.5 0.2 M Li2SO4 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
F09 6.5 0.2 M MgCl2 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
F10 6.5 0.2 M KBr 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
F11 6.5 0.2 M KSCN 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
F12 6.5 0.8 M Na-Formate 0.1 M Na-Cacodylate 8 % PEG 20K PEG550 MME 
G01 6.5       0.1 M Na-Cacodylate 1.5 M (NH4)2SO4 
 
G02 6.5 0.8 M Li2SO4 0.1 M Na-Cacodylate 
   
 
G03 6.5 
   
0.1 M Na-Cacodylate 2 M Na-Formate 
 
G04 6.5 0.5 M KH2PO4 0.1 M Na-Cacodylate 
   
 
G05 6.5 0.2 M Ca-Acetate 0.1 M Na-Cacodylate 25 % PEG 2KMME 
 
G06 6.5 0.2 M Ca-Acetate 0.1 M Na-Cacodylate 15 % PEG 4K 
 
G07 6.5 
   
0.1 M Na-Cacodylate 2.7 M (NH4)2SO4 
 
G08 6.5 
   
0.1 M Na-Cacodylate 1.8 M  Li2SO4 
 
G09 6.5 
   
0.1 M Na-Cacodylate 4 M Na-Formate 
 
G10 6.5 
   
0.1 M Na-Cacodylate 1 M KH2PO4 
 
G11 6.5 0.2 M Ca-Acetate 0.1 M Na-Cacodylate 10 % PEG 8K 
 
G11 
       
10 % PEG 1K 
 
G12 6.5 0.2 M Ca-Acetate 0.1 M Na-Cacodylate 8 % PEG 20K PEG 550MME 
H01 6.5       0.1 M Na-Cacodylate 40 %  MPD 
 
H02 6.5 
   
0.1 M Na-Cacodylate 40 %   Butane-diol 
 
H03 6.5 0.005 M CdCl2 0.1 M Na-Cacodylate 20 % PEG 4K 
 
H04 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 20 % PEG 550 MME 
 
H05 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 20 % PEG 600 
 
H06 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 20 % PEG 1.5K 
 
H07 6.5 
   
0.1 M Na-Cacodylate 35 %  Isopropanol 
 
H08 6.5 
   
0.1 M Na-Cacodylate 30 %  Jeffamine 600M 
 
H09 6.5 0.005 M NiCl2 0.1 M Na-Cacodylate 20 %  PEG 4K 
 
H10 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 18 % PEG 3350 
 
H11 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 18 % PEG 5K MME 
 
H12 6.5 0.15 M KSCN 0.1 M Na-Cacodylate 15 % PEG 6K 
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Table 5.8: Grid screen “GS008” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
 
Well pH Value Units Name Value Units Name Value Units Name 
 
A01 7.5 0.3 M Na-Acetate 0.1 M TRIS 25 % PEG 2K MME 
 
A02 7.5 0.2 M Li2SO4 0.1 M TRIS 25 % PEG 2K MME 
 
A03 7.5 0.2 M MgCl2 0.1 M TRIS 25 % PEG 2K MME 
 
A04 7.5 0.2 M KBr 0.1 M TRIS 25 % PEG 2K MME 
 
A05 7.5 0.2 M KSCN 0.1 M TRIS 25 % PEG 2K MME 
 
A06 7.5 0.8 M Na-Formate 0.1 M TRIS 25 % PEG 2K MME 
 
A07 7.5 0.3 M Na-Acetate 0.1 M TRIS 15 % PEG 4K 
 
A08 7.5 0.2 M Li2SO4 0.1 M TRIS 15 % PEG 4K 
 
A09 7.5 0.2 M MgCl2 0.1 M TRIS 15 % PEG 4K 
 
A10 7.5 0.2 M KBr 0.1 M TRIS 15 % PEG 4K 
 
A11 7.5 0.2 M KSCN 0.1 M TRIS 15 % PEG 4K 
 
A12 7.5 0.8 M Na-Formate 0.1 M TRIS 15 % PEG 4K 
 
B01 7.5 0.3 M Na-Acetate 0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B02 7.5 0.2 M Li2SO4 0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B03 7.5 0.2 M MgCl2 0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B04 7.5 0.2 M KBr 0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B05 7.5 0.2 M KSCN 0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B06 7.5 0.8 M Na-Formate  0.1 M TRIS 10 % PEG 8K 
PEG 1K 
B07 7.5 0.3 M Na-Acetate 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
B08 7.5 0.2 M Li2SO4 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
B09 7.5 0.2 M MgCl2 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
B10 7.5 0.2 M KBr 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
B11 7.5 0.2 M KSCN 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
B12 7.5 0.8 M Na-Formate 0.1 M TRIS 8 % PEG 20K 
PEG550 MME 
C01 7.5       0.1 M TRIS 1.5 M (NH4)2SO4 
 
C02 7.5 0.8 M Li2SO4 0.1 M TRIS 
   
 
C03 7.5 
   
0.1 M TRIS 2 M Na-Formate 
 
C04 7.5 0.5 M KH2PO4 0.1 M TRIS 
   
 
C05 7.5 0.2 M Ca-Acetate 0.1 M TRIS 25 % PEG 2KMME 
 
C06 7.5 0.2 M Ca-Acetate 0.1 M TRIS 15 % PEG 4K 
 
C07 7.5 
   
0.1 M TRIS 2.7 M (NH4)2SO4 
 
C08 7.5 
   
0.1 M TRIS 1.8 M  Li2SO4 
 
C09 7.5 
   
0.1 M TRIS 4 M Na-Formate 
 
C10 7.5 
   
0.1 M TRIS 1 M KH2PO4 
 
C11 7.5 0.2 M Ca-Acetate 0.1 M TRIS 10 % PEG 8K PEG 1K 
C12 7.5 0.2 M Ca-Acetate 0.1 M TRIS 8 % PEG 20K PEG 550MME 
D01 7.5       0.1 M TRIS 40 %  MPD 
 
D02 7.5 
   
0.1 M TRIS 40 %   Butane-diol 
 
D03 7.5 0.005 M CdCl2 0.1 M TRIS 20 % PEG 4K 
 
D04 7.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 550 MME 
 
D05 7.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 600 
 
D06 7.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 1.5K 
 
D07 7.5 
   
0.1 M TRIS 35 %  Isopropanol 
 
D08 7.5 
   
0.1 M TRIS 30 %  Jeffamine 600M 
 
D09 7.5 0.005 M NiCl2 0.1 M TRIS 20 %  PEG 4K 
 
D10 7.5 0.15 M KSCN 0.1 M TRIS 18 % PEG 3350 
 
D11 7.5 0.15 M KSCN 0.1 M TRIS 18 % PEG 5K MME 
 
D12 7.5 0.15 M KSCN 0.1 M TRIS 15 % PEG 6K 
 
E01 8.5 0.3 M Na-Acetate 0.1 M TRIS 25 % PEG 2K MME 
 
E02 8.5 0.2 M Li2SO4 0.1 M TRIS 25 % PEG 2K MME 
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E03 8.5 0.2 M MgCl2 0.1 M TRIS 25 % PEG 2K MME 
 
E04 8.5 0.2 M KBr 0.1 M TRIS 25 % PEG 2K MME 
 
E05 8.5 0.2 M KSCN 0.1 M TRIS 25 % PEG 2K MME 
 
E06 8.5 0.8 M Na-Formate 0.1 M TRIS 25 % PEG 2K MME 
 
E07 8.5 0.3 M Na-Acetate 0.1 M TRIS 15 % PEG 4K 
 
E08 8.5 0.2 M Li2SO4 0.1 M TRIS 15 % PEG 4K 
 
E09 8.5 0.2 M MgCl2 0.1 M TRIS 15 % PEG 4K 
 
E10 8.5 0.2 M KBr 0.1 M TRIS 15 % PEG 4K 
 
E11 8.5 0.2 M KSCN 0.1 M TRIS 15 % PEG 4K 
 
E12 8.5 0.8 M Na-Formate 0.1 M TRIS 15 % PEG 4K 
 
F01 8.5 0.3 M Na-Acetate 0.1 M TRIS 10 % PEG 8K PEG 1K 
F02 8.5 0.2 M Li2SO4 0.1 M TRIS 10 % PEG 8K PEG 1K 
F03 8.5 0.2 M MgCl2 0.1 M TRIS 10 % PEG 8K PEG 1K 
F04 8.5 0.2 M KBr 0.1 M TRIS 10 % PEG 8K PEG 1K 
F05 8.5 0.2 M KSCN 0.1 M TRIS 10 % PEG 8K PEG 1K 
F06 8.5 0.8 M Na-Formate  0.1 M TRIS 10 % PEG 8K PEG 1K 
F07 8.5 0.3 M Na-Acetate 0.1 M TRIS 8 % PEG 20K PEG550 MME 
F08 8.5 0.2 M Li2SO4 0.1 M TRIS 8 % PEG 20K PEG550 MME 
F09 8.5 0.2 M MgCl2 0.1 M TRIS 8 % PEG 20K PEG550 MME 
F10 8.5 0.2 M KBr 0.1 M TRIS 8 % PEG 20K PEG550 MME 
F11 8.5 0.2 M KSCN 0.1 M TRIS 8 % PEG 20K PEG550 MME 
F12 8.5 0.8 M Na-Formate 0.1 M TRIS 8 % PEG 20K PEG550 MME 
G01 8.5       0.1 M TRIS 1.5 M (NH4)2SO4 
 
G02 8.5 0.8 M Li2SO4 0.1 M TRIS 
   
 
G03 8.5 
   
0.1 M TRIS 2 M Na-Formate 
 
G04 8.5 0.5 M KH2PO4 0.1 M TRIS 
   
 
G05 8.5 0.2 M Ca-Acetate 0.1 M TRIS 25 % PEG 2KMME 
 
G06 8.5 0.2 M Ca-Acetate 0.1 M TRIS 15 % PEG 4K 
 
G07 8.5 
   
0.1 M TRIS 2.7 M (NH4)2SO4 
 
G08 8.5 
   
0.1 M TRIS 1.8 M  Li2SO4 
 
G09 8.5 
   
0.1 M TRIS 4 M Na-Formate 
 
G10 8.5 
   
0.1 M TRIS 1 M KH2PO4 
 
G11 8.5 0.2 M Ca-Acetate 0.1 M TRIS 10 % PEG 8K 
 
G11 
       
10 % PEG 1K 
 
G12 8.5 0.2 M Ca-Acetate 0.1 M TRIS 8 % PEG 20K 
 
G12 
       
8 % PEG 550MME 
 
H01 8.5       0.1 M TRIS 40 %  MPD 
 
H02 8.5 
   
0.1 M TRIS 40 %   Butane-diol 
 
H03 8.5 0.005 M CdCl2 0.1 M TRIS 20 % PEG 4K 
 
H04 8.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 550 MME 
 
H05 8.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 600 
 
H06 8.5 0.15 M KSCN 0.1 M TRIS 20 % PEG 1.5K 
 
H07 8.5 
   
0.1 M TRIS 35 %  Isopropanol 
 
H08 8.5 
   
0.1 M TRIS 30 %  Jeffamine 600M 
 
H09 8.5 0.005 M NiCl2 0.1 M TRIS 20 %  PEG 4K 
 
H10 8.5 0.15 M KSCN 0.1 M TRIS 18 % PEG 3350 
 
H11 8.5 0.15 M KSCN 0.1 M TRIS 18 % PEG 5K MME 
 
H12 8.5 0.15 M KSCN 0.1 M TRIS 15 % PEG 6K 
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Table 5.9: Grid screen “GS027” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 4.5 0.2 M Li2SO4 0.1 M NaCH3COO 50 % PEG 400 
A02 5.5        0.1 M tri-sodium citrate  20 % PEG 3000 
A03   0.2 M ammonium citrate 
   
20 % PEG 3350 
A04 4.6 0.02 M CaCl2 0.1 M NaCH3COO 30 % MPD 
A05   0.2 M Mg(HCO2)2  
   
20 % PEG 3350 
A06 4.2 0.2 M Li2SO4 0.1 M C6H5K3O7 20 % PEG 1000 
A07 9.5        0.1 M CHES 20 % PEG 8000 
A08   0.2 M NH4HCO2  
  
  20 % PEG 3350 
A09   0.2 M NH4Cl  
   
20 % PEG 3350 
A10   0.2 M KHCO2 
   
20 % PEG 3350 
A11 8.5 0.2 M (NH4)3PO4 0.1 M TRIS 50 % MPD 
A12   0.2 M potassium nitrate  
   
20 % PEG 3350 
B01 4       0.1 M Citric acid 0.8 M NH4(SO4)2 
B02   0.2 M NaSCN 
   
20 % PEG 3350 
B03 9        0.1 M BICINE 20 % PEG 6000 
B04 7.5        0.1 M HEPES 10 % PEG 8000 
B04 
 
  
 
  
   
8 % Ethylene glycol 
B05 6.5        0.1 M Na(CH3)2AsOO 40 % MPD 
B05 
 
  
 
  
   
5 % PEG 8000 
B06 4.2        0.1 M phosphate-citrate 40 % Ethanol 
B06 
 
  
 
  
   
5 % PEG 1000 
B07 4.6        0.1 M NaCH3COO 8 % PEG 4000 
B08 7 0.2 M MgCl2 0.1 M TRIS 10 % PEG 8000 
B09 5        0.1 M Citric acid 20 % PEG 6000 
B10 6.5 0.2 M MgCl2 0.1 M Na(CH3)2AsOO 50 % PEG 200 
B11         
   
1.6 M tri-sodium citrate 
B12   0.2 M tri-potassium citrate  
   
20 % PEG 3350 
C01 4.2 0.2 M NaCl 0.1 M C6H5K3O7 20 % PEG 8000 
C02 4 1 M Li2SO4 0.1 M Citric acid 20 % PEG 6000 
C03   0.2  M ammonium nitrate  
   
20 % PEG 3350 
C04 7        0.1 M HEPES 10 % PEG 6000 
C05 7.5       0.1 M HEPES 0.8 M Na3PO4  
C05 
 
  
 
  0.1 
  
0.8 M K3PO4 
C06 4.2        0.1 M phosphate-citrate 40 % PEG 300 
C07 4.5 0.2 M Zn(CH3COO)2 0.1 M NaCH3COO 10 % PEG 3000 
C08 8.5        0.1 M TRIS 20 % Ethanol 
C09 6.2        0.1 M Na/K phosphate 25 % 1,2 propandiol + Glycerol (10%) 
C10 9        0.1 M BICINE 10 % PEG 20000 
C10 
 
  
 
  
   
2 % Dioxane 
C11 4.6       0.1 M NaCH3COO 2 M NH4(SO4)2 
C12          
   
10 % PEG 1000  PEG 8000 
D01                24 % PEG 1500 
D01 
 
  
 
  
   
20 % Glycerol 
D02 7.5 0.2 M MgCl2 0.1 M HEPES 30 % PEG 400 
D03 6.2 0.2 M NaCl 0.1 M Na3PO4 50 % PEG 200 
D04 4.5 0.2 M Li2SO4 0.1 M NaCH3COO 30 % PEG 8000 
D05 7.5       0.1 M HEPES 70 % MPD 
D06 8.5 0.2 M MgCl2 0.1 M TRIS 20 % PEG 8000 
D07 8.5 0.2 M Li2SO4 0.1 M TRIS 40 % PEG 400 
D08 8        0.1 M TRIS 40 % MPD 
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D09   0.17 M NH4(SO4)2 
   
25.5 % PEG 4000 + Glycerol (15%) 
D10 6.5 0.2 M Ca(CH3COO)2 0.1 M Na(CH3)2AsOO 40 % PEG 300 
D11 4.6 0.14 M CaCl2  0.07 M NaCH3COO 14 % Isopropanol + Glycerol (30%) 
D12   0.04 M K3PO4 
   
16 % PEG 8000 + Glycerol (20%) 
E01 6.5       0.1 M Na(CH3)2AsOO 1 M  tri-sodium citrate 
E02 6.5 0.2 M NaCl 0.1 M Na(CH3)2AsOO 2 M NH4(SO4)2 
E03 7.5 0.2 M NaCl 0.1 M HEPES 10 % Isopropanol 
E04 8.5 0.2 M Li2SO4 0.1 M TRIS 1.26 M NH4(SO4)2 
E05 10        0.1 M CAPS 40 % MPD 
E06 8 0.2 M Zn(CH3COO)2 0.1 M Imidazole 20 % PEG 3000 
E07 6.5 0.2 M Zn(CH3COO)2 0.1 M Na(CH3)2AsOO 10 % Isopropanol 
E08 4.5       0.1 M Na acetate 1 M di-ammonium phosphate 
E09 6.5       0.1 M MES 1.6 M Mg(SO4)2 
E10 9        0.1 M BICINE 10 % PEG 6000 
E11 6.5 0.16 M Ca(CH3COO)2 0.08 M Na(CH3)2AsOO 14.4 % PEG 8000 
E11 
 
  
 
  
   
20 % Glycerol 
E12 8        0.1 M Imidazole 10 % PEG 8000 
F01 6.5 0.05 M CsCl2 0.1 M MES 30 % Jeffamine M-600 
F02 5       0.1 M Citric acid 3.2 M NH4(SO4)2 
F03 8        0.1 M TRIS 20 % MPD 
F04 7.5        0.1 M HEPES 20 % Jeffamine M-600 
F05 8.5 0.2 M MgCl2 0.1 M TRIS 50 % Ethylene glycol 
F06 9        0.1 M BICINE 10 % MPD 
F07 7       
   
0.8 M Succinic acid 
F08 7       
   
2.1 M DL-Malic acid 
F09 7       
   
2.4 M Sodium malonate 
F10 7 0.5 % Jeffamine ED-2001 0.1 M HEPES 1.1 M Sodium malonate 
F11 7 1 % PEG 2000 MME  0.1 M HEPES 1 M Succinic acid 
F12 7        0.1 M HEPES 30 % Jeffamine M-600 
G01 7        0.1 M HEPES 30 % Jeffamine ED-2001 
G02 7.5 0.02 M MgCl2 0.1 M HEPES 22 % Polyacrylic acid 5100 
G03 8.5 0.01 M CoCl2 0.1 M TRIS 20 % Polyvinylpyrrolidone 
G04 8.5 0.2 M Trimethylamine N-oxide 0.1 M TRIS 20 % PEG 2000 MME  
G05 7.5 0.005 M CoCl, CdCl, MgCl2, NiCl2 0.1 M HEPES 12 % PEG 3350 
G06 7 0.2 M Sodium malonate pH 7.0 
   
20 % PEG 3350 
G07 7 0.1 M Succinic acid pH 7.0 
   
15 % PEG 3350 
G08 7 0.15 M DL-Malic acid pH 7.0 
   
20 % PEG 3350 
G09   0.1 M KSCN 
   
30 % PEG 2000 MME  
G10   0.15 M KBr 
   
30 % PEG 2000 MME  
G11 5.5   
 
  0.1 M Bis-TRIS 2 M NH4(SO4)2 
G12 5.5   
 
  0.1 M Bis-TRIS 3 M NaCl 
H01 5.5       0.1 M Bis-TRIS 0.3 M Mg(HCO2)2   
H02 5.5 1 % PEG 3350 0.1 M Bis-TRIS 1 M NH4(SO4)2 
H03 5.5     
 
0.1 M Bis-TRIS 25 % PEG 3350 
H04 5.5 0.2 M CaCl2  0.1 M Bis-TRIS 45 % MPD 
H05 5.5 0.2 M NH4CH3COO 0.1 M Bis-TRIS 45 % MPD 
H06 5.5 0.1 M NH4CH3COO 0.1 M Bis-TRIS 17 % 10,000 
H07 5.5 0.2 M NH4CH3COO 0.1 M Bis-TRIS 25 % PEG 3350 
H08 5.5 0.2 M NaCl 0.1 M Bis-TRIS 25 % PEG 3350 
H09 5.5 0.2 M Li2SO4 0.1 M Bis-TRIS 25 % PEG 3350 
H10 5.5 0.2 M NH4CH3COO 0.1 M Bis-TRIS 25 % PEG 3350 
H11 5.5 0.2 M MgCl2 0.1 M Bis-TRIS 25 % PEG 3350 
H12 7.5 0.2 M NH4CH3COO 0.1 M HEPES 45 % MPD 
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Table 5.10: Grid screen “GS034” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 2.5       0.1 M citric acid 15 % Na2SO4 
A02 2.5 
   
0.1 M citric acid 25 % Na2SO4 
A03 2.5 
   
0.1 M citric acid 35 % Na2SO4 
A04 2.5 
   
0.1 M citric acid 50 % Na2SO4 
A05 2.5 
   
0.1 M citric acid 65 % Na2SO4 
A06 2.5 
   
0.1 M citric acid 80 % Na2SO4 
A07 2.5 
   
0.1 M citric acid 10 %  MPD 
A08 2.5 
   
0.1 M citric acid 20 %  MPD 
A09 2.5 
   
0.1 M citric acid 30 %  MPD 
A10 2.5 
   
0.1 M citric acid 45 %  MPD 
A11 2.5 
   
0.1 M citric acid 60 %  MPD 
A12 2.5 
   
0.1 M citric acid 80 %  MPD 
B01 2.9       0.1 M citric acid 15 % Na2SO4 
B02 2.9 
   
0.1 M citric acid 25 % Na2SO4 
B03 2.9 
   
0.1 M citric acid 35 % Na2SO4 
B04 2.9 
   
0.1 M citric acid 50 % Na2SO4 
B05 2.9 
   
0.1 M citric acid 65 % Na2SO4 
B06 2.9 
   
0.1 M citric acid 80 % Na2SO4 
B07 2.9 
   
0.1 M citric acid 10 %  MPD 
B08 2.9 
   
0.1 M citric acid 20 %  MPD 
B09 2.9 
   
0.1 M citric acid 30 %  MPD 
B10 2.9 
   
0.1 M citric acid 45 %  MPD 
B11 2.9 
   
0.1 M citric acid 60 %  MPD 
B12 2.9 
   
0.1 M citric acid 80 %  MPD 
C01 3.3       0.1 M citric acid 15 % Na2SO4 
C02 3.3 
   
0.1 M citric acid 25 % Na2SO4 
C03 3.3 
   
0.1 M citric acid 35 % Na2SO4 
C04 3.3 
   
0.1 M citric acid 50 % Na2SO4 
C05 3.3 
   
0.1 M citric acid 65 % Na2SO4 
C06 3.3 
   
0.1 M citric acid 80 % Na2SO4 
C07 3.3 
   
0.1 M citric acid 10 %  MPD 
C08 3.3 
   
0.1 M citric acid 20 %  MPD 
C09 3.3 
   
0.1 M citric acid 30 %  MPD 
C10 3.3 
   
0.1 M citric acid 45 %  MPD 
C11 3.3 
   
0.1 M citric acid 60 %  MPD 
C12 3.3 
   
0.1 M citric acid 80 %  MPD 
D01 3.7       0.1 M citric acid 15 % Na2SO4 
D02 3.7 
   
0.1 M citric acid 25 % Na2SO4 
D03 3.7 
   
0.1 M citric acid 35 % Na2SO4 
D04 3.7 
   
0.1 M citric acid 50 % Na2SO4 
D05 3.7 
   
0.1 M citric acid 65 % Na2SO4 
D06 3.7 
   
0.1 M citric acid 80 % Na2SO4 
D07 3.7 
   
0.1 M citric acid 10 %  MPD 
D08 3.7 
   
0.1 M citric acid 20 %  MPD 
D09 3.7 
   
0.1 M citric acid 30 %  MPD 
D10 3.7 
   
0.1 M citric acid 45 %  MPD 
D11 3.7 
   
0.1 M citric acid 60 %  MPD 
D12 3.7 
   
0.1 M citric acid 80 %  MPD 
E01 2.5       0.1 M citric acid 10 %  PEG 400 
E02 2.5 
   
0.1 M citric acid 15 %  PEG 400 
E03 2.5 
   
0.1 M citric acid 20 % v/v PEG 400 
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E04 2.5 
   
0.1 M citric acid 25 % v/v PEG 400 
E05 2.5 
   
0.1 M citric acid 35 % v/v PEG 400 
E06 2.5 
   
0.1 M citric acid 50 % v/v PEG 400 
E07 2.5 
   
0.1 M citric acid 5 % w/v PEG 6000 
E08 2.5 
   
0.1 M citric acid 10 % w/v PEG 6000 
E09 2.5 
   
0.1 M citric acid 15 % w/v PEG 6000 
E10 2.5 
   
0.1 M citric acid 20 % w/v PEG 6000 
E11 2.5 
   
0.1 M citric acid 25 % w/v PEG 6000 
E12 2.5 
   
0.1 M citric acid 30 % w/v PEG 6000 
F01 2.9       0.1 M citric acid 10 % v/v PEG 400 
F02 2.9 
   
0.1 M citric acid 15 % v/v PEG 400 
F03 2.9 
   
0.1 M citric acid 20 % v/v PEG 400 
F04 2.9 
   
0.1 M citric acid 25 % v/v PEG 400 
F05 2.9 
   
0.1 M citric acid 35 % v/v PEG 400 
F06 2.9 
   
0.1 M citric acid 50 % v/v PEG 400 
F07 2.9 
   
0.1 M citric acid 5 % w/v PEG 6000 
F08 2.9 
   
0.1 M citric acid 10 % w/v PEG 6000 
F09 2.9 
   
0.1 M citric acid 15 % w/v PEG 6000 
F10 2.9 
   
0.1 M citric acid 20 % w/v PEG 6000 
F11 2.9 
   
0.1 M citric acid 25 % w/v PEG 6000 
F12 2.9 
   
0.1 M citric acid 30 % w/v PEG 6000 
G01 3.3       0.1 M citric acid 10 % v/v PEG 400 
G02 3.3 
   
0.1 M citric acid 15 % v/v PEG 400 
G03 3.3 
   
0.1 M citric acid 20 % v/v PEG 400 
G04 3.3 
   
0.1 M citric acid 25 % v/v PEG 400 
G05 3.3 
   
0.1 M citric acid 35 % v/v PEG 400 
G06 3.3 
   
0.1 M citric acid 50 % v/v PEG 400 
G07 3.3 
   
0.1 M citric acid 5 % w/v PEG 6000 
G08 3.3 
   
0.1 M citric acid 10 % w/v PEG 6000 
G09 3.3 
   
0.1 M citric acid 15 % w/v PEG 6000 
G10 3.3 
   
0.1 M citric acid 20 % w/v PEG 6000 
G11 3.3 
   
0.1 M citric acid 25 % w/v PEG 6000 
G12 3.3 
   
0.1 M citric acid 30 % w/v PEG 6000 
H01 3.7       0.1 M citric acid 10 % v/v PEG 400 
H02 3.7 
   
0.1 M citric acid 15 % v/v PEG 400 
H03 3.7 
   
0.1 M citric acid 20 % v/v PEG 400 
H04 3.7 
   
0.1 M citric acid 25 % v/v PEG 400 
H05 3.7 
   
0.1 M citric acid 35 % v/v PEG 400 
H06 3.7 
   
0.1 M citric acid 50 % v/v PEG 400 
H07 3.7 
   
0.1 M citric acid 5 % w/v PEG 6000 
H08 3.7 
   
0.1 M citric acid 10 % w/v PEG 6000 
H09 3.7 
   
0.1 M citric acid 15 % w/v PEG 6000 
H10 3.7 
   
0.1 M citric acid 20 % w/v PEG 6000 
H11 3.7 
   
0.1 M citric acid 25 % w/v PEG 6000 
H12 3.7 
   
0.1 M citric acid 30 % w/v PEG 6000 
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Table 5.11: Grid screen “GS048” used for primary screening of crystallization conditions. 
  
Salt Buffer Precipitant 
Well pH Value Units Name Value Units Name Value Units Name 
A01 4.6 0.02 M CaCl2(H2O)2 0.1 M NaCH3COO·3H2O 30 % MPD 
A02 
       
0.4 M NaKC4H4O6·4H2O 
A03 
       
0.4 M NH4H2PO4 
A04 8.5 
   
0.1 M TRIS 2.0 M (NH4)2SO4 
A05 7.5 0.2 M NaH2C6H5O7 0.1 M HEPES 30 % MPD 
A06 8.5 0.2 M MgCl2·6H2O 0.1 M TRIS 30 % PEG 4,000 
A07 6.5 
   
0.1 M Na(CH3)2AsOO·3H2O    1.4 M NaCH3COO·3H2O 
A08 6.5 0.2 M NaH2C6H5O7 0.1 M Na(CH3)2AsOO·3H2O    30 % 2-Propanol 
A09 5.6 0.2 M NH4CH3COO 0.1 M Na(CH3)2AsOO·3H2O    30 % PEG 4,000 
A10 4.6 0.2 M NH4CH3COO 0.1 M NaCH3COO·3H2O 30 % PEG 4,000 
A11 5.6 
   
0.1 M NaH2C6H5O7 1.0 M NH4H2PO4 
A12 7.5 0.2 M MgCl2·6H2O 0.1 M HEPES 30 % 2-Propanol 
B01 8.5 0.2 M NaH2C6H5O7 0.1 M TRIS 30 % PEG 400 
B02 7.5 0.2 M CaCl2 ·2H2O 0.1 M HEPES 28 % PEG 400 
B03 6.5 0.2 M (NH4)2SO4 0.1 M Na(CH3)2AsOO·3H2O    30 % PEG 8,000 
B04 7.5 
   
0.1 M HEPES 1.5 M (Li)2SO4(H2O) 
B05 8.5 0.2 M (Li)2SO4(H2O) 0.1 M TRIS 30 % PEG 4,000 
B06 6.5 0.2 M Mg(CH3COO)2·4H2O 0.1 M Na(CH3)2AsOO·3H2O    20 % PEG 8,000 
B07 8.5 0.2 M (NH4)2SO4 0.1 M TRIS 30 % 2-Propanol 
B08 4.6 0.2 M (NH4)2SO4 0.1 M NaCH3COO·3H2O 25 % PEG 4,000 
B09 6.5 0.2 M Mg(CH3COO)2·4H2O 0.1 M Na(CH3)2AsOO·3H2O    30 % MPD 
B10 8.5 0.2 M NaCH3COO·3H2O 0.1 M TRIS 30 % PEG 4,000 
B11 7.5 0.2 M MgCl2·6H2O 0.1 M HEPES 30 % PEG 400 
B12 4.6 0.2 M CaCl2·2H2O 0.1 M NaCH3COO(H2O)3 20 % 2-Propanol 
C01 6.5       0.1 M Imidazole 1 M NaCH3COO·3H2O 
C02 5.6 0.2 M NH4CH3COO 0.1 M Na citrate tribasic ·2H2O 30 % MPD 
C03 7.5 0.2 M Na citrate tribasic ·2H2O 0.1 M HEPES 20 % 2-Propanol 
C04 6.5 0.2 M NaCH3COO·3H2O 0.1 M Na(CH3)2AsOO·3H2O    30 % PEG 8,000 
C05 7.5 
   
0.1 M HEPES 0.8 M NaKC4H4O6·4H2O 
C06 
 
0.2 M (NH4)2SO4 
   
30 % PEG 8,000 
C07 
 
0.2 M (NH4)2SO4 
   
30 % PEG 4,000 
C08 
       
2.0 M (NH4)2SO4 
C09 
       
4.0 M Sodium formate 
C10 4.6 
   
0.1 M NaCH3COO(H2O)3 2.0 M Sodium formate 
C11 7.5 
   
0.1 M HEPES 0.8 M NaH2PO4·H2O 
C11 
       
0.8 M NH4H2PO4 
C12 8.5 
   
0.1 M TRIS 8 % PEG 8,000 
D01 4.6       0.1 M NaCH3COO(H2O)3 8 % PEG 4,000 
D02 7.5 
   
0.1 M HEPES 1.4 M Na citrate tribasic dihydrate 
D03 7.5 
   
0.1 M HEPES 2 % PEG 400 
D03 
       
2.0 M (NH4)2SO4 
D04 5.6 
   
0.1 M Na citrate tribasic ·2H2O 20 % 2-Propanol 
D04 
       
20 % PEG 4,000 
D05 7.5 
   
0.1 M HEPES 10 % 2-Propanol 
D05 
       
20 % PEG 4,000 
D06 
 
0.05 M NH4H2PO4 
  
20 % PEG 8,000 
D07 
       
30 % PEG 1,500 
D08 
       
0.2 M Mg formate dihydrate 
D09 6.5 0.2 M Zn(CH3COO)2·2H2O 0.1 M Na(CH3)2AsOO·3H2O    18 % PEG 8,000 
D10 6.5 0.2 M Ca(CH3COO)2·H2O  0.1 M Na(CH3)2AsOO·3H2O    18 % PEG 8,000 
D11 4.6 
   
0.1 M NaCH3COO·3H2O 2.0 M (NH4)2SO4 
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D12 8.5 
   
0.1 M TRIS 2.0 M NH4H2PO4 
E01   2 M NaCl             
E02 
 
0.5 M NaCl 
      
E02 
 
0.01 M MgCl2·6H2O 
     
E03 
       
25 % Ethylene glycol 
E04 
       
35 % 1,4-Dioxane 
E05 
 
2.0 M (NH4)2SO4 
   
5 % 2-Propanol 
E06 
       
1.0 M Imidazole pH 7.0 
E07 
       
10 % PEG 1000   PEG 8000 
E08 
 
1.5 M NaCl 
   
10 % Ethanol 
E09 4.6 
   
0.1 M NaCH3COO·3H2O 2.0 M NaCl 
E10 4.6 0.2 M NaCl 0.1 M NaCH3COO·3H2O 30 % MPD 
E11 4.6 0.01 M CoCl2·6H2O 0.1 M NaCH3COO·3H2O 1.0 M 1,6-Hexanediol 
E12 4.6 0.1 M CaCl2·H2O 0.1 M NaCH3COO·3H2O 30 % PEG 400 
F01 4.6 0.2 M (NH4)2SO4  0.1 M NaCH3COO·3H2O 30 % PEG MME 2,000 
F02 5.6 0.2 M NaKC4H4O6·4H2O 0.1 M NaH2C6H5O7 2.0 M (NH4)2SO4 
F03 5.6 0.5 M (NH4)2SO4 0.1 M NaH2C6H5O7 1.0 M (Li)2SO4·H2O 
F04 5.6 0.5 M NaCl 0.1 M NaH2C6H5O7 2 % Ethylene imine polymer 
F05 5.6 
   
0.1 M NaH2C6H5O7 35 % tert-Butanol 
F06 5.6 0.01 M FeCl3·6H2O 0.1 M NaH2C6H5O7 10 % Jeffamine M-600 
F07 5.6 
   
0.1 M NaH2C6H5O7 2.5 M 1,6-Hexanediol 
F08 6.5 
   
0.1 M MES·H2O 1.6 M MgSO4·7H2O 
F09 6.5 0.1 M NaH2PO4·H2O 0.1 M MES·H2O 2.0 M NaCl 
F09 
 
0.1 M KH2PO4 
     
F10 6.5 
   
0.1 M MES·H2O 12 % PEG 20,000 
F11 6.5 1.6 M (NH4)2SO4 0.1 M MES·H2O 10 % 1,4-Dioxane 
F12 6.5 0.05 M CsCl 0.1 M MES·H2O 30 % Jeffamine M-600 
G01 6.5 0.01 M CoCl2·6H2O 0.1 M MES·H2O 1.8 M (NH4)2SO4 
G02 6.5 0.2 M (NH4)2SO4 0.1 M MES·H2O 30 % PEG MME 5,000 
G03 6.5 0.01 M Zn(SO4)2·7H2O 0.1 M MES·H2O 25 % PEG MME 550 
G04 
       
1.6 M Na citrate tribasic dihydrate 
G05 7.5 0.5 M (NH4)2SO4 0.1 M HEPES 30 % MPD 
G06 7.5 
      
10 % PEG 6,000 + MPD (5%) 
G07 7.5 
   
0.1 M HEPES 20 % Jeffamine M-600 
G08 7.5 0.1 M NaCl 0.1 M HEPES 1.6 M (NH4)2SO4 
G09 7.5 
   
0.1 M HEPES 2.0 M (NH4)2SO4 
G10 7.5 0.05 M CdSO4·H2O 0.1 M HEPES 1.0 M NaCH3COO·3H2O 
G11 7.5 
   
0.1 M HEPES 70 % MPD 
G12 7.5 
   
0.1 M HEPES 4.3 M NaCl 
H01 7.5       0.1 M HEPES 10 % PEG 8,000 
H01 
       
8 % Ethylene glycol 
H02 7.5 
   
0.1 M HEPES 20 % PEG 10,000 
H03 8.5 0.2 M MgCl2·6H2O 0.1 M TRIS 3.4 M 1,6-Hexanediol 
H04 8.5 
   
0.1 M TRIS 25 % tert-Butanol 
H05 8.5 0.01 M NiCl2·6H2O 0.1 M TRIS 1.0 M (Li)2SO4·H2O 
H06 8.5 1.5 M (NH4)2SO4 0.1 M TRIS 12 % Glycerol 
H07 8.5 0.2 M NH4H2PO4 0.1 M TRIS 50 % MPD 
H08 8.5 
   
0.1 M TRIS 20 % Ethanol 
H09 8.5 0.01 M NiCl2·6H2O 0.1 M TRIS 20 % PEG MME 2,000 
H10 9.0 0.1 M NaCl 0.1 M BICINE 20 % PEG MME 550 
H11 9.0 
   
0.1 M BICINE 2.0 M MgCl2(H2O)6 
H12 9.0 
   
0.1 M BICINE 2 % 1,4-Dioxane 
H12 
       
10 % PEG 20,000 
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3.5 Preliminary work and cloning for Sf9-expression 
Previous to the Sf9 production of the different recombinant HER2-subdomains used for epitope 
mapping and crystallization experiments (as described in the Supplementary Text of 
Chapter 3), the respective baculoviral genome (bacmid) had to be prepared. We made use of the 
donor vector pFLmLIC (Figure 5.11:) to introduce the recombinant subdomain coding 
sequences into the bacmid EmBacY (Figure 5.12:). The donor vector pFLmLIC can be equipped 
with the respective subdomain-sequence via ligation-independent cloning (LIC) of the PCR-
amplified insert (replacing a SacB-cassette and thereby allowing for negative selection on 
sucrose containing plates). The LIC-protocol was performed using chemocompetent E. coli XL1-
blue cells and the pFLmLIC-derivatives were purified using a standard plasmid purification kit 
(”QIAprep Spin”, Qiagen). Integration of parts of the donor vector into the bacmid is performed 
in bacteria as well. For this purpose, we made use of the E. coli strain DH10 EmBacY that carries 
the EmBacY bacmid and a helper plasmid encoding the transposase required for the Tn7 
transposition of the gene of interest (GOI) from the donor vector to the bacmid. Transfection of 
chemocompetent E. coli EmBacY cells with pFLmLIC, followed by overnight recovery at 37°C in 
the absence of antibiotics (to allow for the transposition to occur) and plating on 2YT agar 
(containing 0.1 g/l XGal, 200 µM IPTG and all antibiotics for which pFLmLIC and EmBacY encode 
resistences) allowed for blue/white screening of clones containing bacmid DNA coding for the 
respective HER2 domain. 
The bacmid DNA from bacterial cultures, inoculated with single white clones, was purified via 
isopropyl alcohol precipitation as described elsewhere (Fitzgerald et al. (2006)). 
Baculoviruses were obtained via transfection of adherent Sf9 cells with bacmid DNA (Fitzgerald 
et al. (2006)) and used for infection for expression like described in the SI-Text of Chapter 3. 
 
 
 
 
Further Methods and Results  193 
 
 
Figure 5.11:  Schematic representation of the donor vector pFlmLIC. The plasmid contains an 
expression cassette comprising LIC sites, a polyhedrin promoter (Pph) and a melittin signal 
sequence. A beta lactamase gene (bla) is used for selection after initial transformation into E. coli 
XL1 blue. Transposon elements (Tn7L, Tn7R) and the resistance marker for gentamycin are 
used to assure and monitor the successful transposition into the bacmid in E. coli DH10 EmBacY. 
 
 
Figure 5.12:  Schematic presentation of bacmid EmBacY used for the production of HER2 
subdomains in Sf9 insect cells. The modified viral genome is shown in a schematic 
representation. The Tn7 attachment site is located within a LacZα gene; insertion of Tn7 
elements from e.g. pFl derivatives therefore produces a white phenotype when plated on agar 
containing XGal and IPTG. The viral genes v-cath and chiA are disrupted by replacement with an 
antibiotic marker and a non-functional LoxP sequence (both not shown for reasons of clarity) 
(see Craig and Berger (2011)).  
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3.6 Immunoprecipitation with DARPins 
It is very informative to monitor the alterations in the phosphorylation pattern of HER2 in the 
course of the treatment with the different anti-proliferative or even cytotoxic HER2-binding 
DARPin formats discussed within this thesis (like e.g. discussed in Chapter 4, using 
immunoblotting of phosphorylated HER2-residues).  
Another method besides immunoblotting, that could be used to monitor phosphorylated 
HER2-residues, is mass spectrometry. One prerequisite to perform this method in a quantitative 
way is the purification of HER2 from the treated cells. Furthermore, the use of SILAC (stable 
isotope labelling by amino acids in cell culture) is needed, which means that the cells need to be 
grown for at least 4 generations in isotopically labelled medium (we used K8R10 labeled RPMI-
1640 from Cambridge Isotope Laboratories which contains Lys with 8 D atoms and Arg with 10 
D atoms). Mass spectrometry of immunoprecipitated HER2 from cells grown under SILAC-
conditions can be used to quantify the changes in the phosphorylation patterns of the 
cytoplasmic tail of HER2 upon treatment with the DARPin constructs. 
In order to perform such SILAC experiments for the quantification of the intracellular 
phosphorylation levels of HER2 from untreated, DARPin- and trastuzumab-treated cells, we 
developed an immunoprecipitation method using a bispecific DARPin-Affibody-fusion protein as 
affinity reagent. This affinity reagent, the construct 9_01_20_zHER2 (thereafter reffered to as 
“01_zHER2”) was used to generate immunoprecipitation resins. These matrices were then used 
to immunoprecipitate and purify HER2 protein from BT474 cells that had been grown either 
untreated or treated with either DARPins or trastuzumab.  
Generation of 01_zHER2-coated Ultralink Biosupport immunoprecipitation matrices 
(Thermo Scientific) was initially performed according to the instructions given by the supplier. 
Briefly, 2 mg of 01_zHER2 at a concentration of about 5 g/l was added to 10 mg of the 
immunoprecipitation resin and shaken at room temperature overnight. The reaction was then 
quenched overnight by addition of 1 ml of 1 M TRIS, pH 7.6 and subsequently washed with 1 M 
NaCl and PBS.  
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Per immunoprecipitation-aliquot, 2 × 106 BT474 cells were washed with cold PBS, 
scraped in ice-cold buffer IP_L (PBS containing 1% Triton X-100) and lysed in this buffer. In 
addition, “cOmplete” protease inhibitors (Roche), “PhosSTOP” phosphatase inhibitors (Roche), 
25 mM NaF, 1 mM NaVO4 and 10 mM β-glycerophosphate were added to inhibit protease and 
phosphatase activities and all procedures were performed on ice. The supernatant of the lysed 
cells (obtained by centrifugation (20,000 × g, 30 min, 4°C)) was applied to 20 mg of 01_zHER2-
coupled resin and shaken for 2 h at 4°C. After washing the resin three times with buffer IP_L, 
bound HER2 was eluted in four fractions by shaking the resin for 15 min at 4°C in 400 µl buffer 
IP_E each (10 mM glycine, pH 1.0). The elutions were individually precipitated by adding 1.2 ml 
of ice-cold acetone, vortexing and incubating the fractions overnight at -20°C. The mixtures were 
then centrifuged in a tabletop centrifuge (20,000 × g, 30 min, , 4°C) and the supernatant 
discarded. The resulting pellets were dryed on ice and then subjected to analysis by mass 
spectroscopy by Yibo Wu (group of Prof. R. Aebersold, ETH Zürich). For a general overview of 
the IP-aliquots prepared for one SILAC-experiment see Figure 5.13:. 
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Figure 5.13: List of the IP-aliquots prepared for quantitative phosphomapping of HER2 by mass 
spectrometry. In this particular experimental set up, BT474 cells treated with either 
trastuzumab (4D5) or DARPin G3_N6C_G3 (GNG) were compared. In general, all samples were 
prepared in duplicates both from cells grown in unlabeled medium (Light, blue) and isotopically 
labeled medium (Heavy, red). Each treatment condition was performed in biological triplicates 
(IP1–IP3), each stemming from 2 × 106 cells. The protein precipitates E1–E4 were pooled and 
subjected to three different proteolytic digests using Glu-C, Asp-N or trypsin, followed by 
analysis by mass spectrometry. 
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3.7 Cell proliferation assays with further interesting constructs 
One of the big advantages of the DARPin-fold, namely the possibility to easily generate and test 
multivalent binders in different formats, led to cell proliferation tests with further constructs, 
besides the rigidly linked homo-bivalent constructs discussed in Chapter 2 and the flexibly 
linked bispecific constructs detailed in Chapter 3 and Chapter 4. 
Since DARPins binding to the HER2-homologues EGFR and HER4 had been selected 
recently (Steiner et al. (2008)), it seemed likely to produce further bispecific DARPin constructs 
that would not only recognize two different subdomains of one receptor-homologue (like 
described in Chapters 3 and 4) but different receptor-homologues, per se. 
This section is meant to give a brief outline of the most interesting hetero-bispecific 
DARPin-constructs (i.e. constructs specific for two different HER-homologs), that could be 
identified in XTT-assays on BT474 cells. The bivalent binders were constructed from DARPins 
E.01 (α-EGFR), E.69 (α-EGFR), G3 (α-HER2) or B4.50 (α-HER4) lacking any anti-proliferative 
effect on BT474 cells in the monovalent format (Figure 5.14:). As seen with homo-bispecific 
HER2-binding constructs (i.e. constructs bivalently binding HER2), the most interesting hetero-
bispecific constructs tested were the ones with flexible linkers. Furthermore, in agreement with 
the results obtained with the bispecific HER2-binding DARPins (Chapter 3), shortening of the 
linker improved the anti-proliferative effect (Figure 5.15: and Figure 5.16:). In general, the 
most effective hetero-bispecific constructs were those composed of the HER2_IV-binding 
DARPin G3 in combination with either HER4-binding DARPin B4.50 or one of the EGFR-binding 
DARPins E.01 or E.69. Hetero-bispecific constructs with a HER2_I-binding DARPin could not be 
found to show significant effects on BT474 cell proliferation (cf. construct 9.26_11_E.01 in 
Figure 5.14:). 
The main part of this work was performed in collaboration with Jakob Stüber and further 
details (and constructs that proved to be of no further interest) can be found in his master’s 
thesis. Figure 5.17: is added in addition to the data discussed in Chapter 2. Interestingly, 
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bivalent fusion of scFv 4D5 via a double helix motive (4D5-scdHLX) abolishes the slight 
antiproliferative effect caused by the monovalent scFv 4D5.  
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Figure 5.14: Cell proliferation assay (XTT) on BT474 cells with dilution series of different 
monovalent DARPins or different hetero-bispecific DARPins (_22_, _11_ or _01_ indicate linker 
length of 20, 10 or 5 aa). Cells were seeded with 10,000 cells × cm-2 and allowed to attach for 24 
hours. Cell viability after an additional four days of growth with or without treatment (PBS) was 
measured by XTT-assays (indicated as OD450). Cells grown in the presence of 1 µM 9.26_01_G3 
(cf. Chapter 2) served as control. 
 
 
 
Figure 5.15: Cell proliferation assay (XTT) with dilution series of hetero bispecific DARPins 
composed of DARPins E01 or E69 (α-EGFR) and DARPin G3 (α-HER2) on BT474 cells. Cells were 
seeded with 10,000 cells × cm-2 and allowed to attach for 24 hours. Cell viability after additional 
four days of growth with or without treatment (Ctrl) was measured by XTT-assays (indicated as 
OD450). Cells grown without treatment (CTRL) or in the presence of 100 nM trastuzumab served 
as control. 
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Figure 5.16: Cell proliferation assay on BT474 cells with dilution series of hetero bispecific 
DARPins composed of DARPin B4.50 (α-HER4) and DARPin G3 (α-HER2). The constructs differ 
in linker length (5, 10, 20 or 30 aa). Cells were seeded with 10,000 cells × cm-2 and allowed to 
attach for 24 hours. Cell viability after additional four days of growth with or without treatment 
was measured by XTT-assays (indicated as OD450). Cells grown without treatment (CTRL) or in 
the presence of 100 nM trastuzumab served as control. 
 
 
 
 
Figure 5.17: Cell proliferation assay with dilution series of monovalent scFv 4D5 and bivalent 
4D5-scdHLX on BT474 cells. Cells were seeded with 10,000 cells × cm-2 and allowed to attach for 
24 hours. Cell viability after additional four days of growth with or without treatment (Ctrl) was 
measured by XTT-assays (indicated as OD450). Cells grown without treatment (CTRL) or in the 
presence of 100 nM trastuzumab served as control.  
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1 Discussion and Conclusions 
During the last two decades, targeted tumor therapy has gained and still increases importance in 
the treatment of breast cancer. The prevailing class of binding molecules currently used are 
undoubtedly immunoglobulins (antibodies); nonetheless, antibody therapy of patients with 
metastatic breast cancer has been shown to be largely insufficient (Cobleigh et al. (1999)). 
Furthermore, the rather complex molecular architecture, limited stability and their tendency to 
aggregate make antibodies rather difficult (and expensive) to produce. This clearly argues for 
new, complementary approaches of targeted tumor therapy, making use of new, complementary 
binding scaffolds. 
The ideal alternative to antibodies as tumor targeting and tumoricidal molecules would 
have to improve all of the above mentioned limitations, meaning it would have to be a molecular 
format of binders that have a simple fold (preferably produceable in bacteria), 
thermodynamically stable and non-aggregating. Such ideal binders would furthermore have to 
bind their respective targets with high affinity and specificity, and exhibit a long serum half life 
and good tolerance in vivo. The tumoricidal effects should either be caused by binding alone or 
should be attachable to the binder by easy fusion of effector molecules (either genetically or via 
simple directed chemistry). 
Designed Ankyrin Repeat Proteins (DARPins) that have been developed within the last 
decade as a new class of binding proteins (cf. Section 1.10) fulfill nearly all of the above 
mentioned demands on ideal tumor targeting molecules. Solely the serum half life of DARPins is 
by far not as good as the serum half life of immunoglobulins, but can in principle be improved by 
making use of one of the DARPin-advantages, namely the feasible genetic fusion of another 
serum albumin binding DARPin, the chemical fusion of serum albumin itself or of a PEG moiety. 
The question whether DARPins binding HER2 could be used for efficient tumor targeting 
of HER2 overexpressing cancer cells was the starting point of my diploma thesis, and the 
question how to improve the tumoricidal effects found for the monovalent HER2-binding 
DARPin H14 was consequentially the starting point of my PhD thesis.  
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With anti-HER2 DARPin constructs bivalently bridging pairs of HER2 molecules in a rigid 
manner (Chapter 2) and with DARPin constructs bispecifically binding HER2 molecules at 
subdomains I and IV (Chapters 3 and 4), we were able to develop HER2-binding DARPins with 
cytostatic and even cytotoxic effects on HER2 overexpressing and HER2 addicted cancer cells. 
Since these cancer cells are dependent on HER2 signaling for proliferation, the DARPin-induced 
interference with the receptor steady state leads to anti-proliferative effects that are caused by 
binding only. The reason for the observed difference in effectiveness of the homo-bivalent rigid 
constructs in comparison to the (more potent) flexibly linked bispecific constructs lies most 
likely in the difference in DARPin-induced interference with the conformation of the HER2_ECD. 
Whereas the homo bivalent rigid constructs just bridge HER2 molecules in the (still) open 
confirmation, binding of the flexibly linked bispecific constructs induces at least half of the 
bound HER2 ECDs to “bow down”. Therefore the latter DARPin constructs prevent HER2 
dimerization, both canonical and lateral, and both homo- and heterodimerization, far more 
effectively than the homo-bivalent rigid constructs. 
The crystal structures of three different HER2-binding DARPins provided within this 
thesis are crucial for the explanation of the observed tumoricidal effects. In addition, the 
obtained information on the DARPin epitopes on HER2 did stimulate and affect several fruitful 
collaborations aiming to use DARPins as a targeting domain for lentiviral vectors (Appendix 1), 
as binding moieties in proximity ligation (Appendix 2) and for ligand based receptor 
identification on living cells (Appendix 3). 
 
The success in developing bivalent and bispecific HER2-binding DARPin constructs with 
antiproliferative effects on HER2 addicted cancer cells raises the question whether the lessons 
lerned within this project might be applicable to other binders or other oncogenes.  
In fact we are quite certain that the strategy to abolish HER2 signaling e.g by binding 
HER2_I and HER2_IV with one binding molecule should be applicable to other formats like 
antibody fragments or affibodies. We believe that the “blueprint” provided here is neither 
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limited to certain epitopes on HER2, nor to the DARPin format, which is why we have applied for 
a patent protecting the principle of causing strong tumoricidal effects on HER2 addicted cells 
with bispecific binders against HER2_I and _IV. 
The final goal of the overall project, that is to elicit cytotoxic effects on HER2 
overexpressing tumors in human, obviously still awaits to be reached, hopefully by an industrial 
partner capable to undertake this final step. Like described above, crucial aspects like the 
constructs’ immunogenicity in human and means to improve serum half life will have to be 
taken into account. The final DARPin-constructs for in vivo tests in human will most probably 
have to be redesigned (e.g. removing T-cell epitopes), which should however be easily doable 
thanks to the rigid DARPin fold and the well defined blueprint for tumoricidal anti-HER2-
constructs. 
 
 
2 Outlook 
The effort to obtain a complex structure of DARPin H14 which has been discussed in Chapter 2 
is currently ongoing and we are still busy with screening e.g. rigid DARPin-betalactamase-
fusions and DARPin-DARPin-fusions for crystal formation in complex with HER2_IV (a project 
performed as the master’s thesis work of Ms. Ye Xie). 
Likewise ongoing is the SILAC project described in Section 3.6 of Chapter 5. 
 
One interesting continuation of the here presented study is of course the attempt to transfer the 
blueprints for effective antiproliferative DARPin constructs onto constructs composed of 
alternative binding scaffolds on the one hand, and onto constructs binding other targets than 
HER2 on the other hand. The hetero-bispecific constructs described in Section 3.7 of Chapter 5, 
that is constructs composed of DARPins binding EGFR and HER2 or HER4 and HER2, have so far 
mainly been tested on the HER2 overexpressing cell line BT474. It would of course be 
interesting to test such heterospecific constructs on other cell lines with other patterns of 
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overexpressed ErbB receptors. Furthermore, it would be interesting to screen for further 
binders, e.g. to HER3 to then use such new monovalent binders for the incorporation into further 
bispecific constructs. Obviously, the feasibility of easy molecular construction made possible by 
the DARPin fold allows for nearly too many things to think of at one time. 
The hetero-bispecific constructs binding HER4 and HER2 await further characterization. 
Different from the EGFR binding DARPins E.01 and E.69, that have been mapped to bind to 
subdomains III and I, respectively (Boersma et al. (2011)), the epitope of DARPin B4.50 has so 
far not been mapped on HER4_I-III (which had been used for panning). The required expression 
of single HER4 domains I, II and III for an approximate epitope mapping on domain level is 
currently ongoing.  
The detailed knowledge on the epitopes of the DARPins best suited for the assembly of 
efficient bispecific constructs, in combination with the possibility to produce “tailor-made” parts 
of the target subdomain in Sf9 cell expression established within this thesis, would allow to 
select new binders by means of ribosome or phage display. 
Along the same lines it would be possible to select for further DARPins binding to new 
epitopes, e.g. on the lateral site of HER2, to preclude non-canonical receptor dimers like shown 
for the DNA aptamer A30 (Chen et al. (2003)). 
Again, production of “tailor-made” target protein in Sf9 cells could allow to direct the 
DARPin selection to the epitope of highest interest. 
 
One project that has recently been started as collaboration with the lab of Prof. David Baker aims 
for the ab initio in silico design of an HER3 binding DARPin. Inspired by the high accuracy with 
which computational docking could be used to predict the binding of DARPin G3 to HER2_IV 
(Apendix 4) we would like to do the reverse and use computational docking and homology 
modeling to design a DARPin that binds to HER3_IV in a similar way like DARPin G3 binds to 
HER2_IV. The rigid nature of both the binder and the target and the high homology between the 
respective epitope on HER2 and HER3 are prerequisites that should facilitate this endeavor. 
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Certainly such homology modeling will not directly come up with an ab initio blueprint for a high 
affinity binder, but affinity can of course always be improved by means of affinity maturation 
and prescibing the epitope and the direction of binding would be a very interesting new 
achievement.  
 
Another far simpler follow-up study could make further use of the crystal structures of DARPins 
9.29 and 9.26. The complex structures presented in Chapter 3 interestingly show that both N3C 
DARPins bind via their N-cap and first two internal repeat modules only. As the third internal 
repeat module and the C-cap do not make interactions with the target, one could either think of 
removing the third internal module, or elongating the DARPin as a C-terminally elongated 
chimeric DARPin (using the protocol for the assembly of chimeric DARPins given in Section 2.2 
of Chapter 5).  
Incorporating such a shortened or elongated DARPin 9.29 into the bispecific constructs 
discussed in Chapters 3 and 4 would of course be interesting as well.  
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for proximity ligation 
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Appendix 4 
Structural Model for the Interaction of a 
Designed Ankyrin Repeat Protein with the 
Human Epidermal Growth Factor Receptor 2 
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1 Abbreviations 
2YT  2x concentrated yeast tryptone medium 
aa   amino acid 
AP  alkaline phosphatase 
bp  base pairs 
bla  beta lactamase 
BSA  bovine serum albumin 
CAPS  N-cyclohexyl-3-aminopropanesulfonic acid 
CDR  complementarity determining region 
cds  coding sequence / coding sequences 
DARPin designed ankyrin repeat protein 
DPS  dithiodipyridine 
DTT  dithiothreitol 
ECD  extracellular domain 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
FCS  fetal calf serum 
GOI  gene of interest 
GSH  glutathione 
GSSG  glutathione disulfide 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER  human epidermal growth factor receptor 
IB  immunoblot 
IEX  ion exchange chromatography 
Ig  immunoglobulin 
IMAC  immobilized metal ion affinity chromatography 
IPTG  isopropyl-β-D-thiogalactoside 
KD  equilibrium dissociation constant 
kDa  kiloDalton 
koff  dissociation rate constant 
kon  association rate constant 
mAb  monoclonal antibody 
MBP  maltose binding protein 
MES  2-(N-morpholino)ethanesulfonic acid 
MFI  median fluorescence intensity 
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MMP  matrix metalloproteinase 
MOPS  3-(N-morpholino)propanesulfonic acid 
MW  molecular weight 
Ni-NTA nickel-nitrilotriacetic acid 
OD  optical density 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
pD  protein D from phage lambda 
PD  phage display 
PDB  Protein Data Bank 
PDB ID  Protein Data Bank identification number 
PEG  polyethylene glycol 
PNK  polynucleotide kinase 
pNPP  4-nitrophenyl phosphate disodium salt 
POI  protein of interest 
PTO  phosphorothioate 
RD  ribosome display 
RT  room temperature 
scFv  single-chain fragment variable 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis 
SEC  size exclusion chromatography 
Sf9  Spodoptera frugiperda (clonal isolate cell line) 
SILAC  stable isotope labelling by amino acid in cell culture 
SPR  surface plasmon resonance 
TBS  TRIS buffered saline 
TM  transmembrane helix 
TRIS  tris(hydroxymethyl)aminomethane 
X-gal  5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
XTT  2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
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2 Relevant E. coli strains 
2.1 E. coli XL1-blue 
This strain was used for cloning and expression of DARPins and DARPin-constructs, for 
cloning and expression of HER2 domains for in vitro refolding from IBs, and for preliminary 
cloning procedures of HER2 domains lateron expressed in Sf9 insect cells.  
XL1-blue provides lacIq in trans and is thus suitable for expression of DARPins coded on 
pQE30_ss (pDST67) that does not have lacIq in cis. Chemocompetent cells were prepared 
according to a modified Inoue protocol.  
Genotype: endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F’[::Tn10 proAB+ 
lacIqΔ(lacZ)M15] hsdR17(rK- mK+) 
 
2.2 E. coli DH10 EmBacY 
This strain was used for the production of bacmids through transfection with pFLmLIC 
donor plasmids carrying the coding sequences for the HER2 domains intended for Sf9 
expression. The strain is an E. coli DH10 derivative that carries the EmBacY baculoviral genome, 
an approx. 130 kb derivative of the Autographa californica nucleopolyhedrovirus (AcMNPV) 
genome. This bacmid has been genetically engineered for improved protein production and 
reduced protein degradation and contains a transposition acceptor site (mini-attTn7) for 
accepting donor DNA from pFLmLIC. The bacmid possesses the F replicon that keeps the 
plasmid copy number at 1. 
The modified viral genome carries the coding sequences for YFP (as reporter), KanR, 
GentR and CmlR. It is further deficient in the viral genes v-cath and chiA (that code for the viral 
protease V-CATH and the viral chitinase chiA, repectively). The Tn7 attachment site is located 
within a LacZα gene; insertion of Tn7 elements from pFlmLIC derivatives therefore produces a 
white phenotype when plated on agar containing X-gal and IPTG. The Tn7 transposition 
functions are provided in trans by a helper plasmid (pMON7124 with TetR) encoding for the 
required transposase in E. coli DH10 EmBacY. 
Relevant E. coli strains  263 
 
264  Appendix 5 
 
3 Curriculum vitae  
 
Personal data 
 
Name:    Jost 
First Name:   Christian 
Date of birth:   October 21st, 1982 
Place of birth:   Giessen, Germany 
Nationality:    German 
 
 
Education: 
 
09/2007 – spring 2013 Ph.D. studies in the laboratory of Prof. Dr. A. Plückthun, Institute 
    of Biochemistry, University of Zürich, Switzerland         
    (Title: “Tumor targeting with Designed Ankyrin Repeat Proteins”)  
 
10/2006 – 05/2007    Diploma thesis in the laboratory of Prof. Dr. A. Plückthun, Institute 
    of Biochemistry, University of Zürich, Switzerland 
    (Title: “Protein Engineering: Designed Ankyrin Repeat Proteins 
    directed against human epidermal growth factor receptors”) 
 
10/2004 – 09/2006  postgraduate studies of biochemistry (“Hauptstudium”) at the 
    University of Witten/Herdecke, Germany 
 
10/2002 - 08/2004  undergraduate studies of biology („Grundstudium“) at the Justus-
    Liebig-University of Giessen, Germany 
 
07/2002   „Abitur“ at the Christian-Wirth-Schule Usingen, Germany 
  
Curriculum vitae  265 
 
Practical training 
 
07/2007  participation in the two-week International Summer School   
   "Pathogen-Host-Interplay" at the Center of Infection Biology,  
   Berlin, Germany 
 
01/2006 – 04/2006 research project at the Max-Planck-Institute of Molecular Physiology, 
   Dortmund, Germany, Dr. S. Eschenburg 
   (Preparatory work for interaction studies on Cardinal and different  
   members of the Nalp-family) 
 
10/2005 – 12/2005 research project at the Institute of Virology,  
   University of Witten/Herdecke, Prof. M. Wolff 
   (Studies on modulation of PI3K-Akt-signalling in the course of VZV- 
   infection)  
 
07/2005 – 09/2005 research project in the Department of biochemistry, 
   University of Cambridge, UK, Dr. M. Carrington 
   (Characterization-studies on a VSG of T.brucei) 
 
05/2005 – 07/2005 research project at the Institute of Cell Biology, 
   University of Witten/Herdecke, Prof. H.J. Lipps 
   (Work on developmentally regulated genes during macronuclear  
   differentiation in S.lemnae) 
 
04/2005 – 05/2005 research project at the Institute of Phytochemistry, 
   University of Witten/Herdecke, Prof. U. Pfüller 
   (Purification of different viscotoxine species) 
 
03/2004 - 04/2004 research assistant at the University of Giessen, 
   Department of medical virology, Dr. C. G. Schüttler 
 
08/2002 - 09/2004 temporary job in a pet shop („aqua natura“, Leun, Germany) 
